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Abstract 
5-Methyltetrahydrofolate (5-MTHF) is involved in over 100 metabolic reactions. 
Potentially treatable cerebral folate deficiency (CFD) of 5-MTHF in cerebrospinal 
fluid (CSF) is associated in mitochondrial disease. The prevalence and significance 
of CSF 5-MTHF deficiency in mitochondrial disease was initially investigated. 
Prevalence of CSF 5-MTHF deficiency in skeletal muscle mitochondrial respiratory 
chain enzyme (RCE) defects was 15% and the minimum population prevalence of 
mitochondrial disease with CSF 5-MTHF deficiency was at least one in 30,000. This 
suggests under-diagnosis of the condition. The most common RCE defect in CSF 5-
MTHF deficient patients was isolated complex IV deficiency. Severe CSF 5-MTHF 
deficiencies (<10 nmol/L) were confined to Kearns-Sayre syndrome or FOLR1 
mutations. A novel homozygous missense mutation in FOLR1 exon 5 was observed. 
Oral folinic acid supplementation restored CSF 5-MTHF levels to within the age-
related reference range in the majority of cases. Measurement of CSF 5-MTHF and, 
where appropriate, FOLR1 mutation analysis, in suspected mitochondrial disease 
patients is recommended. The mechanisms responsible for CFD in mitochondrial 
disease are unclear. The potential role of oxidative stress as a contributing 
mechanism was also investigated. CSF conveyed antioxidant properties towards 5-
MTHF, which were overcome by hydroxyl radicals. CSF antioxidants may include 
ascorbic acid (AA). A CSF AA reference range was established and a significant 
positive correlation between CSF 5-MTHF and AA demonstrated. In SH-SY5Y 
cells, inhibition of mitochondrial complex I caused increased mitochondrial 
superoxide generation and significantly increased loss of 5-MTHF from the 
extracellular medium. Selenium has been reported to be elevated in CFD. The latter 
observation was also seen following treatment of cells with the selenium compound 
selenite; selenite has previously been implicated in ROS generation. Addition of AA 
prevented 5-MTHF degradation. Oxidative stress may be a factor in the development 
of CFD. Co-supplementation of folinic acid and AA may be of therapeutic benefit. 
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GLUT Glucose transporter 
GNMT Glycine N-methyltransferase  
GP Globus pallidus 
GPI Glycosylphosphatidylinositol 
GSH Glutathione (reduced) 
GSSG Glutathione (oxidised) 
H Histidine 
H
+
 Hydrogen 
H20 Water 
H2O2 Hydrogen peroxide 
HBSS Hank’s balanced salt solution 
HCO3 Carbonate 
Hcy  Homocysteine 
HPLC High performance liquid chromatography 
HSP Heavy strand promoter  
HVA Homovanillic acid 
I Complex I, as indicated 
I Isoleucine, as indicated 
IC Internal capsule 
ICP-MS Inductively coupled plasma mass spectrometry 
II Complex II 
III Complex III 
IV Complex IV 
K Lysine 
k Rate constant 
K
+
 Potassium 
K2HPO4 Dipotassium hydrogen phosphate 
KCN Potassium cyanide  
KH2PO4 Monopotassium dihydrogen phosphate 
KSS Kearns-Sayre syndrome 
L Leucine 
LD Leukodystrophy 
LHON Lebers Hereditary Optic Neuropathy 
LSP Light strand promoter 
Lys Lysine 
M Methionine 
m Months 
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MECP2 Gene encoding methyl CpG binding protein 2 
MELAS Mitochondrial encephalomyopathy with lactic acidosis  
and stroke-like episodes 
MEMSA Myoclonic epilepsy, myopathy, sensory ataxia 
MERFF Myoclonus epilepsy with ragged red fibres 
MIDD Maternally inherited diabetes and deafness 
MILS Maternally inherited Leigh syndrome 
min Minute(s) 
MNGIE Mitochondrial neurogastrointestinal encephalopathy 
MnSOD Manganese superoxide dismutase 
MRI Magnetic resonance imaging 
MRP Multidrug-resistance protein 
MS Methionine synthase 
mtDNA Mitochondrial deoxyribonucleic acid 
MTHFR Methylenetetrahydrofolate reductase 
N Asparagine 
Na
+
 Sodium 
NAD
+
 Nicotinamide adenine dinucleotide (oxidised) 
NADH Nicotinamide adenine dinucleotide (reduced) 
NADP
+
 Nicotinamide adenine dinucleotide phosphate (oxidised) 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced) 
NARP Neuropathy, ataxia and retinitis pigmentosa 
nDNA Nuclear deoxyribonucleic acid 
NTD Neural tube defect 
O2 Oxygen 
O2
•-
 Superoxide 
OH Origin of replication of the heavy strand 
OH
-
 Hydroxyl anion 
Ox Oxidised 
P Proline 
p. Protein 
PCFT Proton coupled folate transporter 
PCFT1 Gene encoding PCFT 
PCH Pontocerebellar hypoplasia 
PCR Polymerase chain reaction 
PEO Progressive external opthalmoplegia 
Pi Inorganic phosphate 
POLG Gene encoding polymerase gamma catalytic subunit 
Pro Proline 
PV Periventricular 
PVL Periventricular leukomalacia 
Q Glutamine 
R Arginine 
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rBAT Related to the B
0
 amino acid transporter 
RC Respiratory chain 
RCE Respiratory chain enzyme 
Red Reduced 
RFC Reduced folate carrier 
RNA Ribonucleic acid 
RNASEH2A Gene encoding ribonuclease H2A 
RNASEH2B Gene encoding ribonuclease H2B 
RNASEH2C Gene encoding ribonuclease H2C 
ROS Reactive oxygen species 
RRF Ragged red fibres 
rRNA Ribosomal ribonucleic acid 
S Serine 
SAH  S-adenosylhomocysteine 
SAM S-adenosylmethionine 
SAMHD1 Gene encoding SAM domain and HD domain-containing protein 1 
SANDO Sensory ataxia, neuropathy, dysarthria and opthalmoplegia 
SCL Selenocysteine-γ lyase 
SD Standard deviation 
SDS Sodium dodecyl sulphate  
Se Selenium or selenite, as indicated 
Sec Selenocysteine 
SEM Standard error of the mean 
SePP Selenoprotein P 
Ser Serine 
SHMT Serine hydroxymethyltransferase 
SLC Solute carrier protein 
SNHL Sensorineural hearing loss 
SOD Superoxide dismutase 
SSC Side scatter 
SUMO Small ubiquitin-like modifier 
SVCT1 Sodium dependent vitamin C transporter 1 
SVCT2 Sodium dependent vitamin C transporter 2 
T Threonine 
TBE Tris-borate-EDTA  
THF Tetrahydrofolate 
TREX1 Gene encoding three prime repair exonuclease 1 
tRNA Transfer ribonucleic acid 
TS Thymidylate synthase 
Ubi Ubiquinone 
V Complex V, as indicated 
V Valine, as indicated 
W Tryptophan 
WM White matter 
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X Stop 
Y Tyrosine 
y Years 
μ Mean 
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1. Introduction 
1.1 Mitochondria and the mitochondrial respiratory chain 
Mitochondria, originally known as bioblasts, attracted the attention of the scientific 
community in the late 19
th
 century (Altmann, 1890). Owing to their thread-like 
appearance throughout spermatogenesis, the term bioblast was replaced by 
mitochondria (mitos=thread, chondros=granule) (Benda, 1898). Mitochondria are 
thought to have evolved one to two billion years ago from aerobic α-proteobacteria 
that colonised primordial eukaryotic cells (Galluzzi et al., 2012; Margulis, 1975; 
Sagan, 1967), thus forming a symbiotic relationship which facilitated the evolution 
of eukaryotic cells by more efficient energy production via oxygen metabolism 
(Gray et al., 1999; Vafai and Mootha, 2012). Mitochondria occupy a substantial 
proportion of cytoplasmic volume with hundreds to thousands of mitochondria 
present per cell. They are responsible for countless cellular functions, including 
calcium homeostasis and apoptosis (Adachi et al., 1997; Borle, 1975; Duchen, 2000; 
Kluck et al., 1997; Lee and Thévenod, 2006). However, they are mainly renowned 
for their role in bioenergetic transduction processes whereby metabolic fuels are 
utilised in order to generate adenosine triphosphate (ATP) (Green and Blondin, 
1978; Mitchell and Moyle, 1965; Mitchell, 1961; Sherratt, 1991). For this reason, 
mitochondria are particularly extensive in high aerobic energy requiring tissues and 
organs including skeletal muscle, the heart, the liver and the brain. 
1.1.1 Structure 
A mitochondrion consists of a double phospholipid membrane structure, the outer 
membrane and the inner membrane, which divides the mitochondrion into two 
aqueous compartments, the intermembrane space and the matrix (Palade, 1956; 
Sherratt, 1991; Sjostrand, 1955). Both the outer and the inner membranes enclose the 
intermembrane space, whilst the inner membrane, folded into finger-like protruding 
cristae, solely encloses the matrix. The outer membrane contains transport porins, 
which facilitate the movement of solutes <5 kDa to freely enter into the 
intermembrane space (Ha et al., 1993). With respect to small molecules, the 
intermembrane space is chemically equivalent to the cytoplasm. In contrast, the inner 
membrane contains a number of selective transport proteins which only allow 
specific molecules to pass into the matrix (Mühlenbein et al., 2004). These include 
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enzymes for metabolic pathways, for example the Krebs cycle, ribosomal RNAs 
(rRNAs), transfer RNAs (tRNAs) and mitochondrial DNA (mtDNA). In addition, 
approximately 20% of the inner membrane is composed of cardiolipin, a 
diphosphatidylglycerol lipid, which provides a barrier against ion influx into the 
matrix (Chen and Li, 2001; Fleischer et al., 1967; Pope et al., 2008). The 
mitochondrial respiratory chain (RC), associated with cardiolipin on the inner 
membrane, is responsible for mediating the production of ATP (Mitchell and Moyle, 
1965). The cristae greatly increase the surface area of the inner membrane and are 
more abundant in high ATP demanding tissues (Forner et al., 2006; Scheffler, 2001; 
Sherratt, 1991). 
1.1.2 Oxidative phosphorylation 
The mitochondrial RC consists of a series of four multi-subunit complexes 
(complexes I-IV). The mitochondrial RC, together with complex V (ATP 
synthetase), produces ATP by the metabolic process, oxidative phosphorylation 
(Green and Zande, 1982; Nogueira et al., 2001; Smeitink et al., 2001). Substrates 
supplied to mitochondria, including pyruvate, amino acids and products of β-
oxidation of fatty acids, enter the Krebs cycle and maintain the reduced state of 
nicotinamide adenine dinucleotide (NADH/NAD
+
) and flavin adenine dinucleotide 
(FADH2/FAD) couples (Heales et al., 2002; Schapira, 2003). The transport of 
electrons from these electron donors through the mitochondrial RC is coupled to the 
pumping of protons from the matrix into the intermembrane space. This creates a 
chemiosmotic gradient described as a membrane potential estimated at 150-180 mV 
negative to the cytoplasm (Mitchell, 1961). The proton motive force drives the 
movement of protons down this gradient, driving the turbines of the F0F1-ATP 
synthetase to phosphorylate adenosine diphosphate (ADP) to ATP (Stock et al., 
2000; Walker et al., 1995). Upon synthesis, ATP is transported from the 
mitochondria into the cytoplasm of the cell via the adenine nucleotide translocase 
(ANT), expressed on the inner mitochondrial membrane (Kholodenko et al., 1987). 
Each mitochondrial RC enzyme or complex plays a specific role in electron transport 
(Figure 1). 
Complex I (NADH:ubiquinone oxidoreductase) (enzyme commission (EC) 1.6.5.3) 
consists of 44 subunits and catalyses the transfer of two electrons from NADH via 
flavin mononucleotide (FMN) and iron-sulphur prosthetic groups in order to reduce
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Figure 1 The mitochondrial respiratory chain and ROS generation. See sections 1.1.2 and 1.1.3 for detailed explanation. Ubi = 
ubiquinone; Cyt c = cytochrome c; red = reduced; ox = oxidised, I = complex I, II = complex II, III = complex III, IV = complex IV, V 
= complex V (ATP synthase), Mn-SOD = manganese superoxide dismutase, O2
 
= oxygen, O2
- = superoxide, H2O2 = hydrogen 
peroxide, Fe
2+
 = ferrous (II) iron, Fe
3+
 ferric (III) iron, •OH = hydroxyl radical, H2O = water, H
+ 
= proton, OH
- 
= hydroxyl anion, ATP 
= adenosine triophosphate, ADP = adenosine diphosphate, Pi = inorganic phosphate, NADH/NAD = nicotinamide adenine 
dinucleotide reduced/oxidised, NADPH/NADP
+
 = nicotinamide adenine dinucleotide phosphate reduced/oxidised. 
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ubiquinone to ubiquinol (Balsa et al., 2012; Friedrich and Böttcher, 2004; Hirst, 
2010). This electron transfer is coupled to the pumping of four protons across the 
inner membrane from the matrix into the intermembrane space.  
Complex II (succinate:ubiquinone oxidoreductase) (EC 1.3.5.1) comprises 4 subunits 
and catalyses the oxidation of succinate to fumarate, which takes place in the matrix. 
This reaction is part of the Krebs cycle. Electrons are transferred first to FAD, 
generating FADH2. The electrons are then transferred from FADH2 via iron-sulphur 
clusters to reduce ubiquinone to ubiquinol (Cecchini, 2003; Horsefield et al., 2004). 
Complex III (ubiquinol:cytochrome c oxidoreductase) (EC 1.10.2.2) comprises 11 
subunits and contains three haem centres, cytochrome bL, cytochrome bH and 
cytochrome c1. Complex III also contains two ubiquinone binding sites, Q0 and Qi. 
Q0 binds one molecule of ubiquinol and Qi binds one molecule of ubiquinone 
(Crofts, 2004; De Vries et al., 1982). One electron from bound ubiquinol is 
transferred to cytochrome c via an iron-sulphur cluster and cytochrome c1. 
Cytochrome c then freely diffuses away from complex III. The remaining electron 
from ubiquinol is transferred to the ubiquinone at Qi via cytochrome bL and 
cytochrome bH, thus forming a ubisemiquinone intermediate. This ‘Q’ cycle is then 
repeated with a second molecule of ubiquinol bound to Q0, with one electron being 
transferred to cytochrome c and the other electron being transferred to 
ubisemiquinone at Qi, forming ubiquinol. The reduction of ubiquinone at Qi utilises 
two protons from the mitochondrial matrix, with two protons being released into the 
intermembrane space with each reduction of ubiquinol (De Vries et al., 1982). 
Complex IV (cytochrome c oxidase) (EC 1.9.3.1) comprises 14 subunits and 
contains two copper centres, CuA and CuB, and two haem centres, haema and haema3 
(Balsa et al., 2012; Pitceathly et al., 2013). An electron from one cytochrome c is 
transferred to CuB via CuA and the two haem centres, reducing Cu
2+
 to Cu
+
. An 
electron from a second cytochrome c is transferred to haema3 via CuA and haema, 
reducing Fe
3+
 to Fe
2+
. Oxygen binds initially to haema3 and then to CuB forming a 
peroxide bridge between the two centres. A third and fourth electron from two 
further cytochrome c molecules and two protons from the matrix break the peroxide 
bridge, resulting in the formation of hydroxyl groups at the two centres, CuB and 
haema3 (Brzezinski and Gennis, 2008; Wikström, 2004). Two additional protons 
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from the matrix result in the formation of 2H20 from the hydroxyl groups at these 
centres. A total of four protons are pumped across the inner membrane from the 
matrix into the intermembrane space.  
Complex V comprises 17 subunits and contains two main domains, F0 and F1. F0 is 
the transmembrane portion of complex V and F1 is the soluble domain portion of 
complex V located on the matrix side of the inner membrane (Carbajo et al., 2007, 
2005; Collinson et al., 1994; Walker et al., 1995). The binding and subsequent 
translocation of protons from the intermembrane space via F0, causes the complex 
structure to rotate. This rotation results in a conformational change in the subunits of 
the F1 domain, which in turn, alters the binding affinity of adenine nucleotides, thus 
driving ATP synthesis (Stock et al., 2000, 1999).  
1.1.3 Generation of reactive oxygen species 
More than 90% of oxygen consumed by mitochondria undergoes a four-electron 
reduction to water via the activity of complex IV of the mitochondrial RC (Equation 
1). However, a small amount (0.1-4% of the electrons that flow through the 
mitochondrial RC) leak, which results in the generation of reactive oxygen species 
(ROS) (Boveris and Chance, 1973; Boveris et al., 1972; Loschen and Azzi, 1975). 
ROS are generated as by-products of normal physiological processes and several 
cellular ROS sources have been identified. However, it is often assumed that among 
such sources, the mitochondrial RC is the most important quantitatively (Adam-Vizi, 
2005; Sipos et al., 2003) (Figure 1).  
ROS are molecules derived from oxygen that retain the ability to readily oxidise 
other molecules. They are key determinants in cell function and whilst they play a 
key role in redox signalling from the mitochondria to the rest of the cell, their 
production can also promote mitochondrial and cellular damage (Halliwell and 
Whiteman, 2004; Musatov and Robinson, 2012). For example, extensive ROS 
production may cause nuclear and mitochondrial DNA damage, protein modification 
and lipid peroxidation. ROS are generated in all cells containing mitochondria. 
However, highly oxidative tissues including the brain, the heart and skeletal muscle 
tend to produce higher levels as a direct consequence of increased number of 
mitochondrial RCs embedded into the inner mitochondrial membrane and higher 
rates of mitochondrial RC activity (Halliwell, 1992; Tsutsui et al., 2001). 
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Equation 1 Four electron reduction of oxygen. One electron reduction of oxygen 
generates superoxide. Superoxide plus one electron and two protons generates hydrogen 
peroxide. This reaction may be catalysed by the activity of superoxide dismustase (SOD). 
Hydrogen peroxide plus one electron (for example, an electron from ferrous (II) iron) and 
one proton generates the hydroxyl radical and a molecule of water. A hydroxyl radical 
plus one electron and one proton generates a molecule of water. O2
 
= oxgen, O2
- = 
superoxide, H2O2 = hydrogen peroxide, Fe
2+
 = ferrous (II) iron, •OH = hydroxyl radical, 
H2O = water e
-
 = electron H
+
 = proton. 
Equation 2 Fenton reaction. Ferrous (II) iron is oxidised by hydrogen peroxide to 
produce ferric (III) iron, a hydroxyl radical and a hydroxyl anion. Fe
2+
 = ferrous (II) iron, 
H2O2 = hydrogen peroxide, Fe
3+
 = ferric (III) iron, OH
-
 = hydroxyl anion, •OH = hydroxyl 
radical. 
O2
- 
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The primary ROS produced by mitochondria is superoxide. Superoxide is generated 
as a result of the monoelectronic reduction of oxygen (see Equation 1) (Cadenas et 
al., 1977; Loschen and Azzi, 1975; Weisiger and Fridovich, 1973). Upon generation, 
superoxide may undergo enzymatic dismutation via the activity of manganese 
superoxide dismutase (Mn-SOD) present in the mitochondrial matrix, copper/zinc 
superoxide dismutase (Cu/Zn-SOD) present in the intermembrane space and 
cytoplasm, or extracellular (Cu/Zn) SOD (ecSOD) present in extracellular fluids, to 
produce the more stable hydrogen peroxide (see Equation 1) (Boveris et al., 1972; 
Okado-Matsumoto and Fridovich, 2001; Sturtz et al., 2001; Weisiger and Fridovich, 
1973). The importance of the SOD enzymes in the enzymatic dismutation of 
superoxide is represented by perinatal lethality in knockout animals (Lebovitz et al., 
1996; Li et al., 1995; Melov et al., 2001). Unlike superoxide, hydrogen peroxide has 
a number of fates as a result of its relative stability and membrane permeative nature, 
as detailed below. Hydrogen peroxide is transported between the mitochondrion, 
cytoplasm and the extracellular environment via aquaporins present in the 
mitochondrial and cell membranes (Bienert et al., 2007; Lee and Thévenod, 2006). 
Transport and diffusion of hydrogen peroxide can either lead to its elimination by 
intracellular and extracellular antioxidant systems including catalase (present in the 
heart and liver mitochondria) (Radi et al., 1991; Salvi et al., 2007), glutathione 
peroxidase, thioredoxin peroxidase and small non-enzymatic antioxidant molecules 
converting hydrogen peroxide to water (see Equation 1) (Aon et al., 2012; 
Kowaltowski et al., 2009; Ng et al., 2007). Conservely, hydrogen peroxide can act as 
a signalling molecule in a variety of biological networks including cell cycle, stress 
response, energy metabolism and redox balance (Czech et al., 1974; Ray et al., 2012; 
Toledano et al., 2010).  
In the absence of hydrogen peroxide removal, hydrogen peroxide can generate the 
hydroxyl radical in the presence of transition metal ions including iron and copper 
(Aust et al., 1985; Halliwell and Gutteridge, 1990). This is illustrated by the Fenton 
reaction (Equation 2, see also Equation 1) (Fenton, 1894; Thomas et al., 2009). Free 
iron and copper are mostly bound to proteins, membranes, nucleic acids and ATP. 
However, in conditions whereby transition metal ions may be released, for example 
during ischaemia or cellular acidosis, hydroxyl radicals may be consequentially 
propagated (Rustin et al., 1998; Stankiewicz et al., 2007). The hydroxyl radical is the 
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most reactive of the ROS. As a result, intracellular and extracellular antioxidant 
mechanisms are thought to have evolved in order to counteract hydroxyl radical 
generation (Venditti et al., 2013).  
Non-enzymatic small antioxidant molecules confer secondary defence against ROS. 
These include, -tocopherol (vitamin E), ascorbic acid (AA, vitamin C) and reduced 
glutathione (GSH) (Halliwell, 1996; Marquardt et al., 2013; Montecinos et al., 
2007). -Tocopherol is present in cell membranes and plasma lipoproteins, and 
functions as a chain breaking antioxidant (Gomez-Fernandez et al., 1989; Marquardt 
et al., 2013). During ROS scavenging, -tocopherol is oxidised to the tocopherol 
radical, which in turn is reduced back to -tocopherol at the membrane surface by 
AA or GSH (Halpner et al., 1998; Nakagawa et al., 1991). The relatively unreactive 
AA radical (formed from the one electron oxidation of AA) or dehydroascorbate 
(formed from the two electron oxidation of AA), or oxidised glutathione (GSSG) are 
generated as a result (Halliwell, 1996). AA is regenerated from the AA radical or 
dehydroascorbate by reduction with GSH, whilst the resultant GSSG from this 
reaction is reduced back to GSH via the NADPH dependent glutathione reductase 
system (Vethanayagam et al., 1999; Winkler, 1992, 1994). Like -tocopherol, both 
AA and GSH can effectively scavenge ROS in their reduced forms (Cuddihy et al., 
2008). 
As previously discussed, the mitochondrial RC is considered to be the most 
important source of cellular ROS generation from a quantitative perspective (Adam-
Vizi, 2005; Sipos et al., 2003). Electron leakage leading to the univalent reduction of 
oxygen forming superoxide can be localised to specific complexes. Complex I is a 
well-documented site for mitochondrial superoxide generation and produces large 
amounts by two proposed mechanisms (Barja and Herrero, 1998; Barja, 1999; 
Kushnareva et al., 2002). The first mechanism involves a reaction between reduced 
FMN with oxygen. The proportion of reduced FMN is thought to be dependent on 
the NADH/NAD
+
 ratio. Therefore, under conditions whereby the mitochondrial RC 
may be inhibited, for example owing to damage, mutation, ischaemia, loss of 
cytochrome c or by the build-up of NADH because of low ATP demand and 
consequential low respiration rate, the NADH/NAD
+
 ratio may increase leading to 
increased superoxide production (Esterházy et al., 2008; Hirst et al., 2008; Kussmaul 
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and Hirst, 2006). The second mechanism is associated with reverse electron 
transport. Reverse electron transport may occur in situations whereby electron 
donation to the ubiquinone pool coupled with a high proton motive force, forces 
electrons back into complex I (Lambert and Brand, 2004; Murphy, 2009; Treberg et 
al., 2011). This process would reduce NAD
+
 to NADH at the FMN site likely 
resulting in superoxide generation. 
In addition to complex I, complex III has also been reported to be a site of 
superoxide production (Boveris et al., 1976; Cadenas et al., 1977). The proposed 
mechanism responsible for superoxide production at this complex involves a reaction 
between oxygen and ubisemiquinone bound to the Q0 site, following supply of 
complex III with ubiquinol and Qi site inhibition. Under conditions whereby the 
stability of ubisemiquinone at the Q0 is compromised, for example due to loss of 
cytochrome c, changes in proton motive force or redox state of ubiquinone pools, 
superoxide production may be augmented (Cadenas et al., 1977; Turrens, 2003; 
Turrens et al., 1985). Complex III appears to be responsible for most of the 
superoxide produced in heart and lung mitochondria (Turrens and Boveris, 1980; 
Turrens et al., 1982), where complex I appears to be the primary source of 
superoxide in the brain (Barja and Herrero, 1998; Barja, 1999). 
The contribution of complex IV to superoxide production remains controversial. 
Mechanistic studies on enzyme catalysis mediated by complex IV have shown 
formation of reactive oxygen intermediates at the metal centres of the enzyme 
(Adam-Vizi, 2005; Srinivasan and Avadhani, 2012). However, whilst reactive 
intermediates may be produced within the enzyme, it is highly adapted to efficiently 
reduce a single oxygen molecule to two water molecules and bind partially reduced 
intermediates tightly. Therefore, the rapid kinetics of electron transfer of complex IV 
may prevent the formation of ROS. This decreases the likelihood of reactive 
intermediates being released from the enzyme. However, indirect mechanisms of 
ROS production via complex IV have been suggested. Under conditions of decreased 
flux through complex IV, for example during ischaemia, there may be an 
accumulation of reduced intermediates upstream of the mitochondrial RC. This 
accumulation may lead to loss of electrons from the mitochondrial RC leading to 
superoxide formation (Cooper and Davies, 2000; Dawson et al., 1993). In turn, loss 
of cardiolipin via ROS mediated lipid peroxidation, may lead to decreased enzyme 
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activity and cytochrome c levels leading to exacerbated upstream superoxide 
production (Chen and Lesnefsky, 2006; Paradies et al., 2000). 
Similarly, complex II can theoretically generate one-electron reductions of oxygen. 
However, whether significant amounts of superoxide are formed from this enzyme is 
questionable (Guo and Lemire, 2003; Kowaltowski et al., 2009; Liu et al., 2013b). 
Recently, it has demonstrated that when complex III is inhibited and rapid re-
oxidation of the Q pool is prevented, complex II generates superoxide in both a 
forward and reverse direction with electrons supplied from succinate and the 
ubiquinol pool, respectively (Moreno-Sánchez et al., 2013; Quinlan et al., 2012; 
Selivanov et al., 2011). Fully reduced FADH2 and semi-reduced FADH are thought 
to be the relevant producers of superoxide, releasing electrons from the 
mitochondrial RC, when the succinate binding site is not occupied with substrate 
(Quinlan et al., 2012). Whilst these studies provide a mechanism, the contribution of 
the superoxide produced at complex II to the overall total oxidant release from the 
other mitochondrial RC complexes may be relatively insignificant. 
1.2 Mammalian mitochondrial genetics  
Owing to their endosymbiotic origin, mitochondria have their own DNA. In the 
course of evolution, most genes encoding mitochondrial proteins have transferred to 
nuclear chromosomes (Smeitink et al., 2001). Therefore, the biosynthesis of 
mitochondria is under the dual control of both the mitochondrial and nuclear 
genome. Unlike nuclear DNA (nDNA), mtDNA is densely packed, made up mostly 
of coding sequence, and lacks histones and repair enzymes. As a consequence of this 
lack of protective histones and repair enzymes, mtDNA is susceptible to damage, 
which in turn, has led to a high mutation rate (Enright et al., 1992; Miyazono et al., 
2002). 
1.2.1 Structure 
Mammalian mtDNA is a 16,569 bp circular, double-stranded molecule (Figure 2) 
(Larsson, 2010). Each mitochondrion contains between two to ten copies and each 
cell contains approximately 10
3
-10
4
 identical copies, with the exception of sperm 
(~10
2
) and mature oocytes (~10
5
) (Smeitink et al., 2001). MtDNA represents 
approximately 0.5-1% of the total DNA in most cells and encodes for 37 proteins  
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Figure 2 Organisation of mammalian mtDNA. Mammalian mtDNA is a double-stranded, 16,569 bp 
circular molecule and comprises the heavy (H) and the light (L) strand. The noncoding D-loop region 
contains the promoters for the H and L strands, heavy strand promoter (HSP) and light strand 
promoter (LSP), and the origin of replication of the leading heavy strand of mtDNA (O
H
). 
Transcription from HSP produces two rRNAs (12S and 16S rRNA), 10 mRNAs (ND1, ND2, ND3, 
ND5, Cyt b, COI, COII, COIII, ND4/ND4L and ATP6/ATP8) and 14 tRNAs (F = phenylalanine, V = 
valine, L1 = leucine
UUR 
(R=A or G), I = isoleucine, M = methionone, W = tryptophan, D = aspartic 
acid, K = lysine, G = glycine, R = arginine, H = histidine, S1 = serine
UCN
, L2 = leucine
CUN
 (N=A or G 
or U or C) and T = threonine). Transcription from LSP produces one mRNA (ND6) and eight tRNAs 
(P = proline, E = glutamic acid, S2 = serine
AGU/C
, Y = tyrosine, C = cysteine, N = asparagine, A = 
alanine and Q = glutamine). ND1, ND2, ND3 ND4, ND4L, ND5 and ND6 encode subunits of 
complex I (CI), Cytb encodes a subunit of complex III (CIII), COI, COII and COIII encode subunits 
of complex IV (CIV) and ATP6 andATP8 encodes subunits of ATP synthase. Figure adapted from 
Larsson (2010). 
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contributing to the mitochondrial RC, complex V (ATP synthase), tRNAs and 
rRNAs. Of the approximate 90 proteins encoding the mitochondrial RC, mtDNA 
encodes for seven subunits of complex I, one subunit of complex III, three subunits 
of complex IV and two subunits of complex V. In addition, mtDNA also encodes for 
22 tRNAs and the 12S and 16S rRNAs that are specific for mitochondrial protein 
synthesis (Chinnery and Hudson, 2013). All the other proteins involved in the 
structure and assembly of the oxidative phosphorylation complexes are encoded by 
the nuclear genome (Leigh-Brown et al., 2010; Shoubridge, 2001). Cytosolically 
synthesised nuclear encoded proteins are transported into the mitochondria via 
protein translocators in the mitochondrial membranes and co-assembled with 
mtDNA-encoded counterparts in the inner membrane (Chacinska et al., 2010; Fox, 
2012). 
1.2.2 Maternal inheritance 
The mitochondrion is exclusively maternally inherited. During oogenesis, a small 
random subset of mitochondria are selected and amplified in a process known as the 
genetic bottleneck (Cree et al., 2008). Upon fertilisation of the ovum, all the mtDNA 
is from the maternal line. Therefore, the mode of mtDNA transmission differs from 
that of Mendelian inheritance patterns (Pasternak, 2005). Point mutations of mtDNA 
have the potential to be inherited in a matrilineal fashion. Thus a disease expressed 
in both sexes but with no evidence of paternal transmission is highly suggestive of a 
mtDNA point mutation (Schon et al., 2012). In comparison, most large-scale 
mtDNA deletions either may occur sporadically or if multiple, be caused by defects 
in nDNA encoding mitochondrial proteins (Moslemi et al., 1996; Murphy et al., 
2008). Defects in nDNA causing mitochondrial RC defects follow Mendelian rules 
of inheritance and may be autosomal dominant, recessive or X linked (Mansergh et 
al., 1999; Moslemi et al., 1996; Shoubridge, 2001). 
1.2.3 Homoplasmy, heteroplasmy and the threshold effect 
There are hundreds to thousands of mtDNA molecules per cell (polyploidy) 
(Pasternak, 2005). Normally, all mtDNA molecules are identical, a state known as 
homoplasmy (Figure 3). However, pathogenic mutations in mtDNA may be present 
in some, but not all the genomes. Therefore, when there are two or more mtDNA 
genotypes, with cells and tissues containing a mixture of wild-type and mutant 
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Figure 3 Homoplasmy, heteroplasmy and the threshold effect. The term homoplasmy is used when there is a single mtDNA genotype in 
each cell/tissue i.e. all mtDNA molecules are identical. The term heteroplasmy is used when there are two or more mtDNA genotypes 
present in cells/tissues i.e. cells and tissues containing a mixture of wild-type and mutant mtDNA. The term threshold effect is associated 
with heteroplasmy. A threshold level of mutant mtDNA needs to be reached for both the clinical expression of disease and biochemical 
defects to be observed. The above figure is a representative scenario. Threshold levels vary for different mutations and tissues. 
42 
 
mtDNA, it is known as a state of heteroplasmy (Figure 3) (Dimauro and Davidzon, 
2005; Wonnapinij et al., 2008). Whilst some pathogenic mutations are 
heteroplasmic, others may be homoplasmic, affecting all copies of the mitochondrial 
genome, including point mutations associated with Leber’s Hereditary Optic 
Neuropathy (LHON) (Gropman et al., 2004; McFarland et al., 2007).  
In the presence of heteroplasmy, a threshold level of mutation needs to be reached in 
order for both the clinical expression of the disease and biochemical defects to be 
observed (Figure 3) (Rossignol et al., 2003, 1999). Threshold levels vary between 
different mutations and tissues but are usually in the range of >70%. The threshold 
level is lower in high energy demanding tissues including the brain, heart, skeletal 
muscle, retina, renal tubules and endocrine glands (Chinnery et al., 1997; Huang et 
al., 2002). Not surprisingly, these tissues are especially vulnerable to the effects of 
pathogenic mtDNA mutations (Rahman and Hanna, 2009). 
1.2.4 Mitotic segregation 
During mitosis of a heteroplasmic cell, the proportion of mutant mtDNA passed on 
to daughter cells may change. Therefore, the mtDNA genotype may drift towards 
homoplasmy, be it wild-type or mutant. In addition, if the pathogenic threshold is 
reached in the tissue, the phenotype may also change. This phenomenon is known as 
mitotic segregation and is responsible, in part, for the age-related and tissue-related 
variability in clinical phenotype observed in mtDNA disorders (Kwong and Sohal, 
2000; Rossignol et al., 1999). Examples of mitotic segregation may include 
clearance of mutant mtDNA from the blood in Pearson syndrome (mtDNA deletion) 
or mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes 
(MELAS; point mutation m.3243 A>G) (Huang et al., 1996; Rahman et al., 2001). 
1.3 Mitochondrial disorders 
Mitochondrial disorders constitute of group of metabolic disorders that directly or 
indirectly affect the mitochondrial RC and can be caused by pathogenic mutations in 
mtDNA or nDNA (DiMauro and Schon, 2003). Many mitochondrial disorders affect 
high-energy requiring organ systems. Those affecting skeletal muscle and the brain 
are also referred to as mitochondrial encephalomyopathies (Khurana et al., 2008; 
Lim et al., 2009). Mitochondrial disorders have a birth prevalence of one in 5,000 
(Thorburn, 2004) and since the first initial mitochondrial disorder was published in 
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1959 (Ernster et al., 1959), more than 150 distinct genetic causes of mitochondrial 
disease have been identified (Vafai and Mootha, 2012).  
1.3.1 Mitochondrial respiratory-chain enzyme disorders; defects in mtDNA and 
nDNA 
Since mitochondria are under dual genetic control from both mtDNA and nDNA, 
inheritance of these disorders follows both mitochondrial and Mendelian inheritance 
patterns (DiMauro and Schon, 2003). Approximately 75-90% of mitochondrial 
disease patients have nuclear encoded genetic defects transmitted in an autosomal 
recessive or to a lesser extent autosomal dominant or X-linked manner. In contrast, 
10-25% of mitochondrial disease patients inherit their disorder via the maternal 
lineage (Naviaux, 2004). Spontaneous mutations or drug-associated mitochondrial 
defects, for example chemotherapy treatment for cancer, can also lead to severe 
mitochondrial disease (Catania et al., 2012; Murphy et al., 2008). 
Mitochondrial diseases attributable to mutations in mtDNA can be split into two 
subgroups, mutations in genes encoding mitochondrial synthesis proteins, for 
example in tRNA or rRNA, or mutations in mitochondrial RC protein-coding genes 
(Table 1) (Ding et al., 2013; Horváth et al., 2009; Taylor and Turnbull, 2005). The 
former include diseases such as MELAS and myoclonus epilepsy with ragged red 
fibres (MERRF) (Brackmann et al., 2012; Liu et al., 2013a), whilst the latter include 
LHON and neuropathy, ataxia and retinitis pigmentosa (NARP) (Duno et al., 2012; 
Gropman et al., 2004). Defects in mtDNA can be further divided into diseases 
associated with large-scale mtDNA deletions that may occur during oogenesis or 
early embryogenesis, such as Kearns-Sayre syndrome (KSS), progressive external 
opthalmoplegia (PEO) and Pearson syndrome (McShane et al., 1991; Moslemi et al., 
1996; Oldfors et al., 1990; Zeviani et al., 1988). Mitochondrial diseases attributable 
to mutations in nDNA following Mendelian inheritance can be caused by mutations 
in genes encoding protein subunits of the mitochondrial RC, accessory proteins of 
the mitochondrial RC, proteins needed for maintenance or expression of mtDNA, 
proteins required for import of solutes or proteins into mitochondria, or proteins for  
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Table 1 Examples of mitochondrial disorders caused by mutations in mtDNA. Table adapted from (Rahman and Hanna, 2009; Taylor and 
Turnbull, 2005). 
Mitochondrial 
disorder 
Clinical phenotype mtDNA gene Defect Status Inheritance 
Kearns-Sayre syndrome PEO, pigmentary retinopathy, 
cardiomyopathy 
A single large-scale 
deletion 
Several deleted 
genes 
(in most tissues)
 
Heteroplasmic Usually sporadic 
PEO Progressive External Opthalmoplegia A single large-scale 
deletion 
Several deleted 
genes 
(skeletal muscle) 
Heteroplasmic Usually sporadic 
Pearson syndrome Pancytopaenia, lactic acidosis A single large-scale 
deletion 
Several deleted 
genes 
(mostly in blood)
 
Heteroplasmic Usually sporadic 
MELAS Myopathy, Encephalopathy Lactic 
Acidosis, Stroke-like episodes 
MTTL1 
 
ND1, ND5 
tRNA (L1) 
 
Complex I  
Heteroplasmic 
 
Heteroplasmic 
Maternal 
 
Maternal 
MERRF Myoclonic Epilepsy, Ragged Red 
Fibres, myopathy 
MTTK tRNA (K) Heteroplasmic Maternal 
NARP Neuropathy, Ataxia, Retinitis 
Pigmentosa 
ATP6 ATPase 6 Heteroplasmic Maternal 
MILS Progressive brain-stem disorder 
(Maternally Inherited Leigh Syndrome) 
ATP6 ATPase 6 Heteroplasmic Maternal 
MIDD Maternally Inherited Diabetes and 
Deafness 
MTTL1 tRNA (L1) Heteroplasmic Maternal 
LHON Leber’s Hereditary Optic Neuropathy ND1 
 
ND4 
 
ND6 
Complex I  
 
Complex I  
 
Complex I  
Hetero- or homoplasmic 
 
Hetero- or homoplasmic 
 
Hetero- or homoplasmic 
Maternal 
 
Maternal 
 
Maternal 
Myopathy with diabetes Myopathy, weakness, diabetes mellitus MTTE tRNA (E) Hetero- or homoplasmic Maternal 
Sensorineural hearing loss 
(SNHL) 
Deafness RNR1 
 
MTTS1 
12S rRNA 
 
tRNA  (S1) 
Homoplasmic 
 
Hetero- or homoplasmic 
Maternal 
 
Maternal 
Exercise intolerance Fatigue, muscle weakness CYB Cytochrome b Heteroplasmic Usually sporadic 
Leigh syndrome Encephalopathy, lactic acidosis ND3 Complex I  Heteroplasmic Usually sporadic 
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Table 2 Examples of mitochondrial disorders caused by mutations in nDNA. AD = autosomal dominant, AR = autosomal recessive. Table 
adapted from (Angelini et al., 2009; Rahman and Hanna, 2009; Rahman, 2012; Zeviani and Di Donato, 2004). 
Mitochondrial 
disorder 
Clinical phenotype nDNA gene Defect Inheritance 
Leigh 
syndrome 
Encephalopathy, lactic acidosis, 
seizures 
NDUFS4  
 
NDUFS8 
 
NDUFA1  
 
SDHA  
 
SURF1 
Complex I 
 
Complex I 
 
Complex I 
 
Complex II 
 
Complex IV (biosynthesis) 
AR 
 
AR 
 
X-linked 
 
AR 
 
AR 
 
MNGIE Mitochondrial Neurogastrointestinal 
Encephalopathy 
 
TYMP Thymidine phosphorylase (mtDNA depetion/deletions)  AR 
Alpers 
syndrome 
Seizures, liver disease, dementia  POLG DNA polymerase- γ (mtDNA depletion/deletions) AR 
MEMSA Myoclonic Epilepsy, Myopathy, 
Sensory Ataxia 
 
POLG DNA polymerase- γ (mtDNA depletion/deletions) AR 
SANDO Sensory Ataxia, Neuropathy, 
Dysarthria and Opthalmoplegia 
POLG DNA polymerase- γ (mtDNA depletion/deletions) AR 
PEO Progressive External 
Opthalmoplegia 
ANT1 Adenine Nucleotide Translocase (mtDNA deletions) AD 
 
GRACILE Growth Retardation, Amino aciduria, 
Cholestasis, Iron overload, Lactic 
acidosis, Early death 
BCS1L Complex III (biosynthesis) AR 
46 
 
maintenance of mitochondrial membrane lipids and dynamics (Table 2) (Angelini et 
al., 2009). Such nuclear encoded mitochondrial diseases include Leigh syndrome and 
Alpers syndrome, respectively (Chan et al., 2005; Wedatilake et al., 2013). 
1.3.2 Clinical presentation 
Mitochondrial diseases encompass a wide range of clinical symptoms and 
presentations (Tables 1 and 2) in which the age of onset is variable (Chi et al., 2010). 
Owing to the complexity of mitochondrial genetics and biochemistry, the site of the 
mtDNA or nDNA mutation, or sporadic deletion, does not always have a clear 
correlation with the clinical phenotype, even when there is a mutation in a single 
gene (Scaglia et al., 2004). Since mitochondria are ubiquitous cellular organelles, 
every tissue in the body can be affected, which is why mitochondrial diseases are 
often multisystematic (Kierdaszuk et al., 2009; Nissenkorn et al., 1999). 
Characteristically, tissues harbouring a mtDNA defect can be affected to different 
degrees because of heteroplasmy and the threshold effect. Therefore, carriers of the 
mutation within a family may have variable symptoms or may fail to present at all 
(Rossignol et al., 1999). In general, childhood mitochondrial disease may be more 
severe than adult-onset disease and can include progressive neurological, cardiac and 
liver dysfunction. Dysfunction of these organ systems can, in turn, lead to lethargy, 
hypotonia, failure to thrive, seizures, cardiomyopathy, deafness, blindness, 
movement disorder and/or lactic acidosis. Consequently, a clinician should adopt a 
high level of suspicion when reviewing a patient with elements of a number of 
different syndromes, and referral to a tertiary centre for evaluation of a possible 
mitochondrial disease may be necessary (Chi et al., 2010; Rahman and Hanna, 
2009). In contrast, adult-onset mitochondrial diseases may present in more subtle 
ways. The disease may manifest for the first time in adulthood, or be first recognised 
in adulthood following a history of symptoms dating back to the patient’s childhood. 
Adult-onset mitochondrial disease may be a progressive multisystem disorder or take 
quite an indolent disease course (Mattman et al., 2011; Miró et al., 2000).  
Lesions in the central nervous system (CNS), peripheral nervous system and 
neuromuscular system are among the most common manifestations in mitochondrial 
disease (Chi et al., 2011; Lindner et al., 1997; Scarpelli et al., 2013). Developmental 
delay or regression, seizures and movement disorders are characteristic of a 
mitochondrial disorder in the paediatric population, whilst stroke or stroke-like 
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episodes are more common in adults (Koga et al., 2005; Lee et al., 2011). In 
addition, peripheral neuropathy is also frequently observed in mitochondrial disease 
(Stickler et al., 2006). For both the paediatric and adult population, a secondary 
deficiency of 5-methyltetrahydrofolate (5-MTHF) in cerebrospinal fluid (CSF) 
known as cerebral folate deficiency (CFD), is increasingly associated and diagnosed 
in mitochondrial disease patients (Garcia-Cazorla et al., 2008; Mangold et al., 2011; 
Pérez-Dueñas et al., 2011; Ramaekers et al., 2007c; Serrano et al., 2010). Symptoms 
related to the neuromuscular system can range from nonspecific exercise intolerance 
or exercise-induced myalgia, to muscle wasting or weakness in a predominantly 
proximal distribution (Massie et al., 2010; Schreuder et al., 2010).  
Ocular muscles have the highest density of mitochondria per cell of any type of 
muscle reflecting their high ATP demand. Therefore, opthalmological manifestations 
of mitochondrial disease are commonly observed (Grönlund et al., 2010). Common 
eye manifestations include progressive external opthalmoplegia and ptosis. The 
retinal cells may also be affected by pigmentary retinopathy, and progressive loss of 
visual acuity by optic atrophy may manifest as a result of lesions in nerve ganglion 
layer cells (Lindner et al., 1997; Sciacco et al., 2001). In addition, sensorineural 
deafness attributable to cochlear dysfunction in combination with dysfunction of 
cranial nerve VIII is associated with sensorineural hearing loss (Mansergh et al., 
1999; Mezghani et al., 2013). 
Cardiac manifestations related to mitochondrial disease include cardiac conduction 
block. In more severe cases, patients may present with cardiomyopathy, which can 
either be hypertrophic or dilated (Obara-Moszynska et al., 2013; van Beynum et al., 
2012). In addition, endocrine system and gastrointestinal system lesions including 
diabetes mellitus, delayed gastric emptying with nausea and vomiting, constipation 
and diarrhoea are also common hallmarks of mitochondrial disease (Mattman et al., 
2011; Mezghani et al., 2013; Rahman, 2013; Schaefer et al., 2013). 
1.3.3 Diagnosis 
As a consequence of the heterogeneous clinical manifestations of mitochondrial 
disease, a multidisciplinary approach to diagnosis is often required. Assessment of 
family history is of paramount importance in identifying family members with 
mitochondrial disease or susceptibility to developing a mitochondrial disorder. In 
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addition, physical and neurological examination, diagnostic laboratory tests in blood, 
skeletal muscle and CSF, and neurological imaging, are of diagnostic importance 
(Rahman and Hanna, 2009). 
If a mitochondrial disease is suspected, analysis of mtDNA and/or nDNA mutations 
in blood samples may be carried out. A positive genetic diagnosis of mitochondrial 
disease prohibits the need for further invasive investigations (Munnich et al., 1996; 
Wong, 2004). However, under circumstances whereby a genetic diagnosis has not 
been achieved, a muscle biopsy may be performed. Histochemical techniques allow 
for the detection of ragged red fibres (RRF, accumulation of mitochondria in the 
subsarcolemmal region of the muscle fibre when stained with Gomori trichrome 
stain) and histoenzymatic reactions allow for the evaluation of enzyme activities 
such as cytochrome c oxidase (COX, complex IV) (DiMauro and Hirano, 1993). The 
presence of COX-negative fibres and RRF, are highly indicative of a mitochondrial 
disorder. In addition, specific mitochondrial RC enzyme (RCE) complex assays may 
also be performed. Deficiencies in a single RCE complex are commonly associated 
with either a nuclear gene defect or a mtDNA mutation in a mtDNA protein 
encoding gene. In contrast, multiple mitochondrial RCE complex deficiencies are 
more commonplace in individuals with a mtDNA or nuclear gene defect affecting 
intramitochondrial protein synthesis, for example tRNA mutations, large-scale 
deletions, defects of aminoacyl tRNA synthestases, or translation elongation factors; 
or a mitochondrial DNA depletion syndrome (Jackson et al., 1995; Taylor et al., 
2004). A combined defect in complex II/III in the presence of normal activities of 
the individual complexes is highly suggestive of a deficiency in coenzyme Q10 
(CoQ10) since the combined complex II/III assay uses endogenous CoQ10 to 
determine enzyme activity (Ogasahara et al., 1989; Rahman et al., 2001). Additional 
genetic diagnoses may also be performed in muscle in order to search for pathogenic 
mtDNA mutations, since they are more reliably detected in this tissue as opposed to 
blood (Rahman and Hanna, 2009). Further diagnostic evaluation may be carried out 
in CSF following a lumbar puncture, with elevated lactate concentrations being 
suggestive of mitochondrial disease (Yamada et al., 2012). CSF protein may be 
elevated in KSS (Serrano et al., 2010). In addition, imaging techniques, such as brain 
magnetic resonance imaging (MRI) and computed tomography (CT) imaging, which 
may demonstrate neurological abnormalities such as leukoencephalopathy, basal 
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ganglia calcification and/or delayed myelination, may also be of diagnostic utility 
(Chi et al., 2011; Taylor et al., 2004).  
1.3.4 Treatment 
A multidisciplinary approach to the management and treatment of mitochondrial 
disease patients is required (Schon et al., 2010). Access to specialists within the 
fields of rehabilitation medicine, physiotherapy, occupational therapy, cardiology, 
endocrinology/diabetes, ophthalmology, audiology and speech therapy are of 
paramount importance when treating the associated symptoms. Symptomatic therapy 
in these clinical areas can improve quality of life and reduce morbidity in 
mitochondrial disease patients. For example, hearing aids or cochlear implants may 
maximise hearing function (Scarpelli et al., 2012; Sinnathuray et al., 2003), 
prosthetic inserts or surgical interventions in patients with ptosis may improve visual 
acuity (Rahman and Hanna, 2009) and insertion of implantable cardiac defibrillators 
may be life-saving in those patients with cardiac conduction defects, for example in 
some patients with KSS or PEO (Hara et al., 2004; Lev et al., 2004). In addition, 
treatment with low dose insulin in those patients with mitochondrial diabetes or 
anticonvulsant drugs in those with epilepsy is essential (Guillausseau et al., 2001; 
Lee et al., 2011). Importantly, managing seizures with sodium valproate should try 
to be avoided in mitochondrial disease patients, since it has been shown to inhibit 
mitochondrial oxidative phosphorylation and may cause deterioration, particularly in 
patients with POLG mutations (Rahman, 2012). 
Genetic counselling according to the Mendelian rules of inheritance in cases where a 
nDNA mutation is identified, may be appropriate. However, where a mtDNA 
mutation is identified, genetic counselling may be more difficult owing to the 
complexity of mitochondrial genetics and biochemistry (Chinnery and Hudson, 
2013; Vento and Pappa, 2013). The only definite way to avoid maternal transmission 
of a mtDNA mutation leading to the onset of a mitochondrial disease would be to 
consider ovum donation. Oocyte manipulation to replace maternal mutant mtDNA 
with donor mtDNA by transferring the pronclei from an oocyte carrying a mtDNA 
mutation into an enucleated donor egg, may eliminate mitochondrial disease from 
the progeny (Craven et al., 2010), but it is not yet licensed for clinical use. 
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Pharmacological techniques including supplementation with CoQ10 have been shown 
to be effective in individuals with a CoQ10 deficiency (Montero et al., 2013; Pfeffer 
et al., 2012). Moreover, metabolite replacement therapy including L-arginine 
therapy, since strokes may be caused by impaired vasodilation, have had a varying 
degree of efficacy in MELAS patients (Koga et al., 2005; Moran et al., 2008). In 
patients with mitochondrial neurogastrointestinal encephalopathy (MNGIE) caused 
by thymidine phosphorylase deficiency, bone marrow transplantation may be a 
favoured approach (Filosto et al., 2012; Hussein, 2013). Finally, resistance exercise 
training aimed at shifting mtDNA genotype and improving oxidative capacity may 
additionally be beneficial (Murphy et al., 2008; Taivassalo et al., 1999). 
One potentially treatable aspect of mitochondrial disease is supplementation with 
folinic acid in those patients with CFD (Garcia-Cazorla et al., 2008; Hansen and 
Blau, 2005). This will be discussed in more detail in section 1.5. 
1.4 Folate 
Folate (vitamin B9) is the generic term for a large family of essential, water-soluble 
coenzymes. Dietary sources include leafy green vegetables and fresh fruit (Jägerstad 
and Jastrebova, 2013). These coenzymes play an important role in mediating the 
transfer of one-carbon units that facilitate important cellular processes including 
nucleic acid synthesis, amino acid metabolism and remethylation of homocysteine to 
methionine (Bailey, 2010). The biological importance of folate was originally 
identified in the 1930’s when folate-containing yeast extract was used to treat 
pregnant Indian women with anaemia. Since folate is required for cellular 
replication, folate deficiency resulting in reduced red blood cell count was implicated 
as a causative factor of the anaemia observed in these women (Wills, 1991, 1931). 
In subsequent years, the requirement for folate in the diet has gained further 
recognition. For example, it has become widely accepted that adequate maternal 
consumption of folic acid before pregnancy and during the early weeks of gestation 
could prevent some, but not all, neural tube defects (NTDs) (Copp and Greene, 2000; 
Copp et al., 2013; Dunlevy et al., 2007). NTDs are severe congenital malformations 
that affect an average of one in every 1000 pregnancies (Dunlevy et al., 2007). They 
encompass varying clinical features and degrees of clinical severity. Open lesions 
that affect the brain include anencephaly and craniorachischisis, and these types of 
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lesion are invariably lethal before or at birth. In contrast, open spina bifida is 
generally compatible with postnatal survival. However, the resulting neurological 
impairment below the level of the lesion may give rise to a number of clinical 
symptoms including the inability to walk. Less severe NTDs, including closed spinal 
lesions such as spina bifida occulta, may be asymptomatic (Copp et al., 2013). The 
potential importance of dietary folate in the prevention of NTDs was initially noted 
in the 1970’s when Smithells et al. (1976) reported reduced serum concentrations of 
folic acid, riboflavin and vitamin C in mothers who were pregnant with fetuses with 
NTDs (Smithells et al., 1976). Several clinical trials evaluating the efficacy of folic 
acid supplementation in the prevention of NTDs ensued and mandatory folic acid 
food fortification of cereal and grain products with 140 µg/100 g folic acid (the fully 
oxidised, metabolically stable, synthetic form of folate) was introduced in North 
America in 1998 (Daly et al., 1998). Other countries followed suit including Canada 
and South America. Following this fortification, a decline in the prevalence of 
children born with NTD’s has been documented (Honein et al., 2001). 
The mechanisms responsible for NTD prevention and neural tube closure following 
folic acid supplementation remain relatively unknown and in some cases, 
controversial. Importantly, NTDs are not considered to be vitamin deficiency 
disorders, but are in fact associated with a range of genetic and environmental factors 
(Copp and Greene, 2010; Doudney et al., 2009). The role of folate in cell 
multiplication may in part account for closure of the neural tube by increasing cell 
proliferation. In addition, mutations in folate related genes including the 677C>T 
polymorphism in the 5,10-methylenetetrahydrofolate reductase gene (MTHFR), is 
associated with approximately a 1.8 times higher risk of NTDs (Amorim et al., 
2007). Missense mutations in genes encoding enzymes of the glycine cleavage 
system have also been associated with increased risk of NTDs and include 
aminomethyltransferase (AMT) and glycine dehydroxylase (GLDC) (Narisawa et al., 
2012). Variants in these genes affect enzyme activity and reduce flux of formate 
from the mitochondria into the cytoplasm. Formate accounts for roughly 75% of the 
one-carbon units entering one-carbon metabolism (see section 1.4.4). Treatment of 
epilepsy with anticonvulsant therapies (Lammer et al., 1987), including 
carbamezapine (Hernández-Díaz et al., 2001), has been hypothesised to have anti-
folate effects. These effects are thought to be associated with inducing teratogenic 
52 
 
mechanisms leading to NTDs. Interestingly, anticonvulsant therapy has also been 
implicated in causing secondary folate deficiency in other disorders including 
mitochondrial diseases (Opladen et al., 2010), as discussed in section 1.6.  
Taken together, further investigations are required to elucidate the underlying 
aetiology of NTDs. Specifically, studies to broaden current understanding of the 
importance of folic acid and folate metabolism in NTD prevention may lead to 
additional and potentially effective preventative strategies being implemented 
(Doudney et al., 2009). 
1.4.1 Structure 
Folate coenzymes are structurally and metabolically interconvertable. They comprise 
a pterin ring structure conjugated to a para-aminobenzoic acid moiety, which is 
further conjugated to an oligo-γ-glutamyl tail of glutamate residues of varying chain 
length (Figure 4a). However, the family members differ in the oxidation state of the 
pyrazine portion of the pterin ring, the character of the one-carbon functional groups 
at positions N5 and N10, and the number of glutamic acid moieties conjugated to 
one another via a series of γ-glutamyl links to form the oligo-γ-glutamyl tail.  
Of the folate coenzymes, 5-MTHF is the principal bioactive and transport form 
(Bailey, 2010) (Figure 4b) and is involved in over 100 metabolic reactions (Hyland 
et al., 1988; Surtees et al., 1994). 5-MTHF is characterised by a reduced pyrazine 
portion of the pterin ring to give a tetrahydro derivative and a methyl group 
conjugated at the N5 position. Like other related reduced pterin molecules including 
tetrahydrobiopterin (Blair and Pearson, 1974; Kirsch et al., 2003), 5-MTHF is 
susceptible to oxidation in the presence of molecular oxygen and oxidising species. 
5-MTHF has been shown to undergo oxidative attack at the C(4a) position with the 
hydroperoxyl radical implicated as the chain-propagating carrier. This reaction yields 
two major 5-MTHF degradation products, 4a-hydroxy-5-methyl-4a,5,6,7-
tetrahydrofolate and 5-methyl-5,6-dihydrofolate (Blair et al., 1975) (Figure 5). 
1.4.2 Absorption and transport of folate in the periphery 
Food folate is predominantly found in the 5-MTHF form. 5-MTHF can readily 
oxidise to 5-methyl-5,6-dihydrofolate in food and upon ingestion, 5-methyl-5,6-  
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Figure 4 Folate structure. a. Tetrahydrofolate and b. 5-MTHF. The folate coenzymes comprise a pterin 
ring structure conjugated to a para-aminobenzoic acid moiety, which is further conjugated to an oligo-γ-
glutamyl tail of glutamate residues of varying chain length. The family differ in the oxidation state of the 
pyrazine portion of the pterin ring, the character of the one-carbon functional groups at positions N5 and 
N10, and the number of glutamic acid moieties conjugated to one another via a series of γ-glutamyl links to 
form the oligo-γ-glutamyl tail. 
b. 
a. 
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Figure 5 Degradation of 5-MTHF. 5-MTHF is susceptible to oxidative catabolism in the presence of molecular oxygen and 
oxidising species. Figure adapted from Blair et al. (1975). 
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dihydrofolate can be rapidly degraded in the acidic conditions of the postprandial 
gastric environment (Lucock et al., 1995). In order to optimise the bioavailability of 
5-MTHF in food, AA is actively secreted into the gastric lumen (Verlinde et al., 
2008). AA reduces 5-methyl-5,6-dihydrofolate, in a two electron donation reaction, 
to 5-MTHF which is more stable in acidic environments (Lucock et al., 1995; 
Wilson and Horne, 1983). In addition, food folate is mostly bound to proteins in a 
polyglutamate form. Folate cannot be absorbed in the polyglutamate form and prior 
to absorption, is hydrolysed to the monoglutamate form via the activity of γ-glutamyl 
hydrolase in the proximal small intestine (Cole et al., 2001; Perry and Chanarin, 
1972; Reisenauer et al., 1986).  
Ingested folate and folate that is delivered via the bile duct to the duodenum during 
enterohepatic circulation (Steinberg, 1984; Steinberg et al., 1979), is absorbed in the 
proximal jejunum primarily by the reduced folate carrier (RFC) and the proton-
coupled folate transporter (PCFT) expressed on apical brush border cells (Dudeja et 
al., 2001; Hinken et al., 2011; Zhao et al., 2009a). The RFC mediates folate transport 
at neutral pH by a folate/hydroxyl anion exchange mechanism, whilst the PCFT 
mediates folate transport at low pH via a H
+
 co-transporter mechanism. However, it 
is apparent that folate transport occurs primarily via the PCFT carrier since intestinal 
folate transport is optimal at pH 5.5; the optimal transport conditions for the PCFT 
(Bailey, 2010; Urquhart et al., 2010; Zhao et al., 2009a). Whilst the RFC does play a 
role in folate transport within the small intestine, the carrier performs more effective 
specialised transport in the proximal renal tubules, in the placenta and at the blood 
brain barrier (Bailey, 2010; Patterson et al., 2008; Solanky et al., 2010). Within the 
enterocyte, food folate that does not exist as 5-MTHF, is metabolised into the 5-
MTHF form mediated by one carbon metabolism (see section 1.4.4) (Stover and 
Field, 2011). 5-MTHF is exported out of enterocytes into portal circulation by 
multidrug resistance proteins (MRP), including MRPs 1-5, expressed on the 
basolateral membrane (Chen et al., 2002; Hooijberg et al., 2003; Matherly and 
Goldman, 2003; Zhao et al., 2011). These proteins are members of the ATP-binding 
cassette (ABC) superfamily of transporters, which utilise energy from the hydrolysis 
of ATP to translocate substrates across membranes. 5-MTHF monoglutamate 
released into portal circulation can either be directly distributed to extrahepatic 
tissues or taken up by the liver. In turn, folate delivered to the liver can either be 
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converted to the polyglutamate form and incorporated into the hepatic folate pool or 
released into the enterohepatic circulation (Fernández et al., 1998; Steinberg et al., 
1979). Enterohepatic circulation is a process whereby folate is discharged into the 
bile, delivered via the bile duct to the duodenum and reabsorbed by the proximal 
jejunum before re-entering portal circulation where it can be channelled back to the 
liver or distributed to extrahepatic tissues. As much as 50% of the circulating folate 
which reaches the extrahepatic tissues would have undergone enterohepatic 
recycling in this way (Shin et al., 1995; Steinberg, 1984). 
Measurement of total folate may be defined as measuring the pterin ring of the folate 
skeleton in the tetrahydrofolate form substituted with any functional group at any 
position. Serum total folate concentrations are age and sex specific and are in the 
region of 1.1-51.0 nmol/L (0.5-22.7 µg/L), according to the reference ranges used in 
the Chemical Pathology unit at Great Ormond Street Hospital, UK (Table 3). 
Approximately 30-40% of the circulating 5-MTHF is bound to low affinity binding 
proteins including albumin, α2 macroglobulin, transferrin and the high affinity folate 
binding protein (Markkanen and Peltola, 1971; Markkanen et al., 1973, 1972). 
Diagnosis of CFD requires additional measurement of serum total folate to exclude a 
nutritional folate deficiency (Ramaekers et al., 2002). In addition, 5-MTHF and 5-
formyltetrahydrofolate in the penta- and hexaglutamate forms are stored in 
erythrocytes, incorporated into the erythrocyte during erythropoiesis (Clifford et al., 
2005; Koury and Ponka, 2004). Whilst erythrocyte folate has no known metabolic 
role, it is thought that it acts as a storage reservoir and long-term buffer for 
maintaining peripheral folate homeostasis (Choumenkovitch et al., 2001; Golbahar et 
al., 2005). Erythrocyte folate is not affected by recent dietary intake, which makes it 
a good indicator of peripheral folate status. Typical levels of total erythrocyte folate 
are in the region of 0.3-1.2 µmol/L (119-519 µg/L), according to the reference 
ranges used in the Chemical Pathology Unit at Great Ormond Street Hospital, UK 
(Table 4). In senescent erythrocytes, the folate is salvaged via the reticuloendothelial 
system and transported to the liver. Here, it is recycled and redistributed to 
extrahepatic tissues via the enterohepatic cycle (Bailey, 2010). 
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Table 3 Total serum folate reference ranges. Total serum folate reference ranges 
are age- and sex-related. Values are given in nmol/L and µg/L to accommodate how 
the concentration may be expressed in reporting. These reference ranges are used in 
in the Chemical Pathology unit at Great Ormond Street Hospital, London, UK. 
Total serum folate 
Age (years) Male (nmol/L [µg/L]) Female (nmol/L [µg/L]) 
0-1 16.2 – 50.3 [7.2 -22.4] 14.2 – 51.0 [6.3 – 22.7] 
2-3 5.6 – 33.7 [2.5 – 15.0] 3.8 – 35.3 [1.7 – 15.7] 
4-6 1.1 – 29.2 [0.5 – 13.0] 6.1 – 31.7 [2.7 – 14.1] 
7-9 5.2 – 26.7 [2.3 – 11.9] 5.4 – 30.1 [2.4 – 13.4] 
10-12 3.4 – 24.3 [1.5 – 10.8] 2.2 – 22.9 [1.0 – 10.2] 
13-18 2.7 – 19.8 [1.2 – 8.8] 2.7 – 16.2 [1.2 – 7.2] 
18+ 4.5 – 45.3 [2.0 – 20.2] 4.5 – 45.3 [2.0 – 20.2] 
 
 
Table 4 Total erythrocyte folate reference range. Values are given in nmol/L and 
µg/L to accommodate how the concentration may be expressed in reporting. This 
reference range is used in the Chemical Pathology unit at Great Ormond Street 
Hospital, London, UK.  
Total erythrocyte folate 
All ages/sex (nmol/L [µg/L]) 0.3 – 1.2 [119 – 519] 
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1.4.3 5-MTHF transport from the periphery into cerebrospinal fluid 
Circulating 5-MTHF from the periphery is transported into CSF across the choroid 
plexus (Cario et al., 2009; Grapp et al., 2012; Steinfeld et al., 2009). The choroid 
plexus is the locus of a critical interface between the blood and CSF known as the 
blood-CSF barrier (Strazielle and Ghersi-Egea, 2000). It is an endothelial-epithelial 
vascular convolute within the ventricular system of the brain weighing 
approximately 2 g and is divided into four sections, one in each lateral ventricle, one 
in the third ventricle and one in the fourth ventricle (Netsky and Shuangshoti, 1975). 
It consists of fenestrated blood vessels, epithelial cells and stroma, and depending on 
physiological or pathological conditions, the stroma can contain fibroblasts, mast 
cells, macrophages or other infiltrates (Dropp, 1976; Matyszak et al., 1992; Serot et 
al., 1994). The choroid plexus plays an important role in the production of clear and 
colourless CSF which involves a two-step process involving a number of active 
transport systems, ion and water channels (Bering, 1955; Milhorat, 1969; Speake et 
al., 2001). Plasma ions and molecules, including Na
+
, Cl
-
, K
+
, HCO3
-
, protein, amino 
acids, glucose and water, are ultrafiltrated from the fenestrated vasculature of the 
choroid plexus and are transported from the stroma into choroid plexus epithelial 
cells (Nilsson et al., 1992). Ion transporters, ion channels and co-transporters 
mediate the transport of ions and small molecules across the apical and basolateral 
membranes of the choroid plexus epithelial cells into the ventricles, whilst the 
transport of larger molecules (vitamins, hormones and peptides) is mediated by 
transcytosis, endocytosis or specific oligopeptide transporters (Grapp et al., 2013; 
Roberts et al., 2008; Spector and Johanson, 2010; Tachikawa et al., 2008). The net 
blood to CSF transport of these ions and molecules results in the formation of CSF 
(Brodbelt and Stoodley, 2007; Brown et al., 2004; Spector, 2010). Importantly, 
plasma ultrafiltrate cannot freely pass between the blood and CSF compartments 
owing to tight junctions adjoining the apical membranes of the choroid plexus 
epithelial cells. These tight junctions, known as claudins, represent the blood-CSF 
barrier (Kratzer et al., 2012; Wolburg et al., 2001). Approximately 140 ml of CSF is 
divided between the ventricular system (35 ml), spinal canal (30-70 ml) and the 
cranial subarachnoid space (35-75 ml) and the CSF, produced at ~500 ml/day, is 
consistently replenished (Brodbelt and Stoodley, 2007). CSF circulates 
rostrocaudally inside the ventricles and in cranial and spinal subarachnoid spaces 
(Tarnaris et al., 2011). Whilst CSF plays a crucial role in cushioning the brain and 
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spinal cord, of greater importance is the role of CSF in mediating metabolite, toxin 
and nutrient exchange between the CNS and the periphery, and facilitating hormonal 
and signalling mechanisms, chemical buffering and neurodevelopment (Crossgrove 
et al., 2005; Spector, 2010). 
Recently, it has been demonstrated that the transport of 5-MTHF across the choroid 
plexus is primarily mediated by the high affinity glycosylphosphatidylinositol (GPI)-
anchored folate receptor- (FR) (Cario et al., 2009; Grapp et al., 2013; Steinfeld et 
al., 2009; Wollack et al., 2008) (Figure 6). The FR is localised on the basolateral 
membrane of the choroid plexus epithelial cells and 5-MTHF uptake occurs via 
receptor-mediated endocytosis and transcytosis (Grapp et al., 2013). This is an active 
process requiring energy in the form of ATP. 5-MTHF and FR are co-transported 
via an endosomal compartment by a clathrin-independent pathway to form tubular 
early endocytic compartments. A minor proportion of internalised 5-MTHF is 
translocated to PCFT-positive vesicles and transported into the cytoplasm (Zhao et 
al., 2009b). Here, 5-MTHF is converted into the polyglutamate form via the activity 
of folyl--polyglutamate synthase (FPGS) in order to facilitate cellular retention 
(Moran and Colman, 1984; Schirch and Strong, 1989). The endosomal 
compartments are subsequently translocated to multivesicular bodies containing 
intraluminal vesicles. Multivesicular bodies are known to be sites for intracellular 
sorting of proteins between recycling, degradation and secretion pathways, and fuse 
with the apical membrane of the choroid plexus to secrete their intraluminal vesicles 
into the CSF as exosomes. Approximately 36% of all human CSF exosomes have 
been shown to contain 5-MTHF-bound FR. It has also been suggested that fusion 
of the multivesicular body to the apical membrane may also lead to 5-MTHF release 
and FR recycling between the apical membrane and the late endosomal 
compartment offering a mechanism for 5-MTHF uptake from the CSF. Once present 
in the CSF, it is thought that these exosomes deliver FR into the brain parenchyma 
(Grapp et al., 2013). Other FR-independent mechanisms of 5-MTHF transport have 
also been suggested. They include transport mediated by the RFC and ABC 
transporters (Chen et al., 2002; Leggas et al., 2004; Rao et al., 1999). These 
mechanisms may be of greater importance when 5-MTHF is present at higher 
concentrations (>100 nmol/L) (Grapp et al., 2013). Overall, the transport of 5-MTHF 
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Figure 6 Transport of 5-MTHF across choroid plexus epithelial cells. The FR is localised on the basolateral membrane of the choroid plexus epithelial cells and 5-
MTHF uptake occurs via active receptor-mediated endocytosis and transcytosis. 5-MTHF and FR are co-transported via endosomal compartments, which are 
subsequently translocated to multivesicular bodies containing intraluminal vesicles. Multivesicular bodies fuse with the apical membrane of the choroid plexus to secrete 
their intraluminal vesicles into the CSF as exosomes. Fusion of the multivesicular body to the apical membrane may also lead to 5-MTHF release and FR recycling 
between the apical membrane and the late endosomal compartment offering a mechanism for 5-MTHF uptake from the CSF. Once present in the CSF, it is thought that 
these exosomes deliver FR and 5-MTHF into the brain parenchyma. F = 5-MTHF; EEC = early endosomal compartment; MVB = multivesicular body. 
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from the periphery into CSF across the choroid plexus results in approximately a 2-4 
fold higher 5-MTHF concentration in the CSF compared to plasma (Spector and 
Lorenzo, 1975). The importance of FR in mediating 5-MTHF transport across the 
choroid plexus, is evidenced by the embryonic lethality of FR -/- knockout mice 
(Piedrahita et al., 1999; Zhu et al., 2007). In humans, mutations in the FOLR1 gene 
encoding the FR protein do not cause embryonic lethality. Patients with mutations 
in the FOLR1 gene present with undetectable CSF 5-MTHF <10 nmol/L at four to 
six months of age (Cario et al., 2009; Grapp et al., 2012; Steinfeld et al., 2009). This 
discrepancy between the mouse and human phenotype raises the possibility that an 
additional transporter, such as the folate receptor  (FR), may be responsible for 5-
MTHF transport across the choroid plexus during embryonic and fetal development, 
and expression may be downregulated following birth (Steinfeld et al., 2009). The 
function of the secreted folate receptor γ (FRγ) and folate receptor δ (FRδ) are not 
well understood (Grapp et al., 2013). In addition, it has been suggested that high 
circulating peripheral levels of 5-MTHF at birth may provide the CNS with a degree 
of protection, which could account for the delay of disease and clinical manifestation 
onset (Ramaekers and Blau, 2004). 
In addition to 5-MTHF transport across the choroid plexus into the CSF, 5-MTHF 
can also be transported across the blood-brain barrier (BBB) into the brain 
interstitium. This transport process is facilitated by the RFC (Wu and Pardridge, 
1999). However, this transport process alone would not be sufficient in achieving an 
adequate level of 5-MTHF required in the CNS (Araújo et al., 2010). 
CSF 5-MTHF concentration follows a negative age-related trend (Ormazabal et al., 
2006). The age-related CSF 5-MTHF reference ranges used in the Neurometabolic 
Unit at The National Hospital for Neurology and Neurosurgery, London, UK, are 
given in Table 5. 
1.4.4 One-carbon metabolism 
Upon transportation into the cell, the 5-MTHF monoglutamate is converted by 
methionine synthase into tetrahydrofolate (THF). Moreover, folate is modified with a 
covalently bound glutamate polypeptide. This polypeptide consists of between three 
to eight glutamate residues, with penta- and hexaglutamate being the 
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Table 5 CSF 5-MTHF reference ranges. CSF 5-MTHF follows a negative age-
related trend. Therefore, CSF 5-MTHF concentration is age-related and the below 
reference ranges are used in the Neurometabolic Unit at The National Hospital for 
Neurology and Neurosurgery, London, UK. 
CSF 5-MTHF reference ranges 
Age (years) Concentration (nmol/L) 
0 – 2 72 – 305 
2 – 5 52 – 178 
5 – 10 72 – 172 
10+ 46 – 160 
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predominant chain lengths (Brody et al., 1982). Polymerisation occurs via the 
activity of FPGS, which links each glutamate residue with -peptide bonds. The 
importance of the oligo--glutamyl tail is to generate functional coenzymes. It also 
facilitates the ability of the coenzyme to bind with high affinity to folate-dependent 
enzymes and binding proteins, and enables cellular and intracellular compartment 
retention (Moran and Colman, 1984; Schirch and Strong, 1989). 
THF polyglutamate molecules carry out their cellular functions by activating and 
carrying single carbon units at the N5 and/or N10 positions. THF carries activated 
formate as 5-formyl-THF, 10-formyl-THF or 5,10-methenyl-THF. THF also carries 
activated formaldehyde as 5,10-methylene-THF and activated methanol as 5-MTHF. 
THF polyglutamates accept and transfer these one-carbon moieties in a network of 
biosynthetic and catabolic reactions. This network is known as folate-mediated one-
carbon metabolism and the pathways associated with one-carbon metabolism 
function in three separate compartments, the cytoplasm, the mitochondria and the 
nucleus (Figure 7) (Tibbetts and Appling, 2010). Each compartment is its own 
unique entity carrying out its own specialised metabolic function. As such, folate 
coenzymes do not readily exchange between them. The mitochondrial one-carbon 
metabolism pathways generate one-carbons in the form of formate through the 
catabolism of serine, glycine and choline (Pasternack et al., 1994, 1992). The 
cytoplasmic one-carbon metabolism pathways utilise the mitochondrial-derived 
formate for nucleotide biosynthesis and for the remethylation of homocysteine to 
methionine (Lamarre et al., 2012; Stam et al., 2005). Within the nucleus, one-carbon 
metabolism pathways generate thymidylate during DNA replication and repair 
(MacFarlane et al., 2011). Whilst each compartment performs its own specialised 
metabolic function, there is interdependence between the compartments with 
ongoing shuttling of metabolic intermediates including serine, glycine and formate, 
and competition for the limiting pool of folate coenzymes (Tibbetts and Appling, 
2010).  
1.4.4.1 One-carbon metabolism in the cytoplasm 
One-carbon metabolism within the cytoplasm includes the biosynthetic pathways 
leading to the de novo synthesis of purines and thymidylate, and the remethylation of 
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Figure 7 One-carbon metabolism in the cytoplasm, mitochondrion and nucleus. DHF=dihydrofolate; THF=tetrahydrofolate; CH2-THF=5,10-
methylenetetrahydrofolate; CH
+
-THF=5,10-methenyltetrahydrofolate; 5-CHO-THF=5-formyltetrahydrofolate; 10-CHO-THF=10-formyltetrahydrofolate; CH3-
THF=5-methyltetrahydrofolate; SAM=S-adenosylmethionine; SAH=S-adenosylhomocysteine; Hcy=homocysteine; dUMP=deoxyuridine monophosphate; 
dTMP=deoxythymidine monophosphate. 1. Dihydrofolate reductase, 2. Serine hydroxymethyltransferase, 3. 5,10-methylene-THF dehydrogenase, 4. 5,10-
methenyl-THF cyclohydrolase, 5. 10-formyl-THF synthetase, 6. 5,10-methylene-THF reductase, 7. methionine synthase, 8. 10-formyl-THF dehydrogenase, 9. 
thymidylate synthase, 10. S-adenosylmethionine synthetase, 11. S-adenosylhomocysteine synthase, 12. S-adenosylhomocysteine hydrolase, 13. 5,10-methenyl-
THF synthetase, 14. Methionyl-tRNAF
MET
 formyltransferase. For detailed explanation see section 1.4.1. 
Mitochondrion 
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homocysteine to form methionine (Figure 7) (Fox and Stover, 2008; Girgis et al., 
1997). Methionine is an important precursor for the synthesis of S-
adenosylmethionine (SAM). SAM functions as a cofactor and methyl group donor 
for numerous methylation reactions (Dixon et al., 1996). These reactions include the 
methylation of DNA, RNA, neurotransmitters, phospholipids and proteins including 
histones (Mattson, 2003; Stam et al., 2005). Whilst the mitochondria serve as the 
main source of one-carbon moieties for these reactions, the cytoplasm can also 
generate one-carbon entities through the catabolism of histidine, serine and purines 
(Anguera et al., 2006; Depeint et al., 2006; Fell and Steele, 1982). 
Purine nucleotides are precursors for DNA and RNA synthesis and serve as 
coenzymes and regulatory factors (Bailey, 2010). Purines can be synthesised de novo 
via one carbon metabolism (Berg et al., 2002). The de novo pathway consists of a 
10-step enzymatic process culminating in the production of inosine monophosphate, 
the precursor of adenine and guanine nucleotides (Field et al., 2006). 10-Formyl-
THF is the cofactor required for this pathway, which is synthesised from THF and 
mitochondrial-derived formate, in an ATP-dependent reaction catalysed by 10-
formyl-THF synthetase. The formyl group of 10-formyl-THF donates a carbon to 
phosphoribosylaminoimidazole carboxamide ribonucleotide (AICAR) and 
phosphoribosylglycinamide ribonucleotide (GAR), which ultimately become the C2 
and C8 positions of the purine ring (Smith et al., 1980). 10-Formyl-THF that is not 
used to synthesise purines, is dehydrated and reduced for use in the biosynthesis of 
thymidylate and methionine. Alternatively, 10-formyl-THF can undergo irreversible, 
nicotinamide adenine dinucleotide phosphate (NADP
+
)-dependent oxidation to THF 
and CO2 via the activity of 10-formyl-THF dehydrogenase (Anguera et al., 2006). 
THF generated in this reaction can be channelled efficiently to serine 
hydroxymethyltransferase (SHMT) or 10-formyl-THF synthetase to regenerate an 
activated one-carbon. Chemotherapeutic anti-folate agents including methotrexate 
are effective in disrupting purine synthesis via the de novo pathway by targeting 
folate dependent enzymes including GAR formyltransferase (GARFT), AICAR 
formyltransferase (AICARFT) and dihydrofolate reductase (DHFR) (Allegra et al., 
1986; Baggott et al., 1994, 1986). 
10-Formyl-THF exists in cytoplasmic equilibrium with 5,10-methenyl-THF. One-
carbon units obtained from the catabolism of histidine, adenine and guanine enter the 
66 
 
cytoplasmic one-carbon pool as 5,10-methenyl-THF. During catabolism, the 
imidazole ring of histidine, adenine and guanine is converted to a formimino goup 
(Revel and Magasanik, 1958). This formimino group is transferred to THF forming 
5-formimino-THF, which is subsequently converted to 5,10-methenyl-THF by the 
cyclodeaminase activity of the protein (Depeint et al., 2006; Schalinske and Steele, 
1996). 5,10-Methenyl-THF is also synthesised from 5-formyl-THF in an ATP-
dependent reaction catalysed by 5,10-methenyl-THF synthetase. 5,10-Methenyl-THF 
synthetase is the only enzyme known to utilise 5-formyl-THF as a substrate and is 
expressed ubiquitiously. Importantly, 5-formyl-THF is not a coenzyme for one-
carbon transfer reactions but a stable storage form of excess formyl folate (Tibbetts 
and Appling, 2010). The activity of 5,10-methenyl-THF synthetase generating 5,10-
methenyl-THF from 5-formyl-THF, and SHMT generating 5-formyl-THF from 
5,10-methenyl-THF, constitutes a futile cycle. This cycle regulates the intracellular 
5-formyl-THF concentrations (Girgis et al., 1997; Stover and Schirch, 1993). 
Thymidylate and dihydrofolate (DHF) are synthesised from 5,10-methylene-THF 
and deoxyuridine monophosphate in a reaction catalysed by thymidylate synthase 
(TS) (Schiffer et al., 1995). DHF produced in this reaction is reduced back to THF 
via the activity of DHFR (Abali et al., 2008). 5,10-Methylene THF pools are derived 
from the reduction of 10-formyl-THF in sequential reactions catalysed by 5,10-
methenyl-THF cyclohydrolase and 5,10-methylene-THF dehydrogenase (Fox and 
Stover, 2008). This pool is in equilibrium with 5,10-methylene-THF derived from 
the THF-dependent conversion of serine to glycine catalysed by SHMT (Anderson et 
al., 2012; MacFarlane et al., 2008). Both pools of 5,10-methylene-THF contribute to 
the biosynthesis of thymidylate (MacFarlane et al., 2011).  
5-MTHF is the required cofactor for the Zn
2+
 and cobalamin (vitamin B12) 
dependent remethylation of homocysteine to methionine catalysed by methionine 
synthase (MS) (Dixon et al., 1996; Scott and Weir, 1998). An additional enzyme, 
betaine homocysteine methyltransferase (BHMT), also remethylates homocysteine to 
methionine in a folate-independent manner, which makes the metabolic function of 
MS partially redundant (Teng et al., 2012). However, BHMT expression is limited 
primarily to the kidney and the liver, whereas MS is ubiquitously expressed (Leclerc 
et al., 1999; Slow and Garrow, 2006). MS functions to regenerate THF, prevent 5-
MTHF accumulation, synthesise methionine and remove cellular homocysteine. 
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Elevated levels of homocysteine are a risk factor for cardiovascular disease, 
Alzheimer’s disease and NTDs (Minagawa et al., 2010; Rosenquist et al., 1996; 
Wald et al., 2002). The loss of MS activity, resulting for example from vitamin B12 
deficiency, inhibits nucleotide biosynthesis owing to the accumulation of 
cytoplasmic folate cofactors including 5-MTHF (Banerjee and Matthews, 1990; 
Yamada et al., 2000). This effect is known as the “5-MTHF trap” and occurs because 
the 5,10-methylene-THF reductase catalysed reaction is irreversible and MS is a key 
5-MTHF utilising enzyme (Fujii et al., 1982; Kaufman, 1991).  
5-MTHF is generated from 5,10-methylene-THF in a reduction reaction catalysed by 
5,10-methylene-THF reductase. Importantly, 5,10-methylene-THF reductase retains 
an allosteric binding site for SAM. Under circumstances whereby SAM 
concentrations are adequate, SAM acts as an allosteric inhibitor to ensure 5,10-
methylene-THF is spared for thymidylate biosynthesis (Jencks and Mathews, 1987; 
Matthews and Daubner, 1982). This feedback inhibition also protects against 
‘trapping’. Interestingly within the cell, 5-MTHF is bound, but not metabolised, by 
SHMT and glycine N-methyltransferase (GNMT). GNMT functions to catalyse the 
SAM dependent methylation of glycine to sarcosine, thereby governing 
transmethylation reactions by regulating and buffering the SAM/S-
adenosylhomocysteine (SAH) ratio. This is known as the cellular ‘methylation 
potential’ (Bailey, 2010; Porter et al., 1985). GNMT is itself allosterically regulated 
by 5-MTHF (Luka, 2008; Luka et al., 2007). Under conditions whereby SAM 
inhibits 5,10-methylene-THF reductase, GNMT remains active and metabolises 
excess SAM. Whereas, under conditions where SAM levels are low, 5-MTHF is 
produced by 5,10-methylene-THF reductase, thereby inhibiting GNMT activity and 
conserving methionine supply for essential methylation reactions (Wagner et al., 
1989). In addition, 5-MTHF is sequestered by SHMT and may compete with MS for 
this enzyme. SHMT acting as a 5-MTHF binding protein, conserves and limits the 
availability of 5-MTHF for homocysteine remethylation (Herbig et al., 2002; 
MacFarlane et al., 2008). 
1.4.4.2 One-carbon metabolism in the mitochondria 
One-carbon metabolism in the mitochondria includes the biosynthetic pathways 
leading to the generation of one-carbon units in the form of formate for one-carbon 
metabolism in the cytoplasm, the generation of the amino acid glycine and the 
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synthesis of formyl-methionyl-tRNA, unique for protein synthesis in mitochondria 
(Figure 7) (Tibbetts and Appling, 2010). In contrast to the cytoplasm, the 
interconversion of one-carbon substituted folate in the mitochondria is driven in the 
oxidative direction towards formate production and differs with respect to the source 
of reducing equivalents (Lamarre et al., 2012; Shane, 1989). Approximately 40% of 
the total cellular folate is found in the mitochondria (Depeint et al., 2006). 
Mitochondrial 5,10-methylene-THF synthesis is initiated via the cleavage of the C3 
of serine to glycine, catalysed by the pyridoxal-phosphate dependent SHMT 
(Pasternack et al., 1994). The C3 of serine is the primary source of folate-activated 
one-carbon units. The glycine cleavage system (GCS), a multienzyme complex that 
generates folate-activated one-carbons, catalyses the production of 5,10-methylene-
THF, CO2 and ammonia, following the reversible oxidation of glycine (Narisawa et 
al., 2012; Okamura-Ikeda et al., 2005). GCS accounts for nearly 40% of the overall 
glycine flux in humans, and the one-carbon produced contributes to the cytoplasmic 
THF-dependent biosynthesis of purines and thymidylate. Additional glycine 
production and glycine as a substrate for the GCS, is generated from oxidative 
choline catabolism (Imbard et al., 2013). This occurs through the sequential 
conversion of choline to betaine aldehyde to betaine to dimethylglycine to sarcosine 
to glycine, catalysed by choline dehydrogenase, betaine aldehyde dehydrogenase, 
betaine homocysteine methyltransferase, dimethylglycine dehydrogenase and 
sarcosine dehydrogenase, respectively (Bailey, 2010; Wittwer and Wagner, 1980). 
The generation of 10-formyl-THF from 5,10-methylene-THF requires the sequential 
conversion of 5,10-methylene-THF to 5,10-methenyl-THF, followed by the 
conversion of 5,10-methenyl-THF to 10-formyl-THF (Murta et al., 2009; Pawelek 
and MacKenzie, 1998). These reactions are catalysed by 5,10-methylene-THF 
dehydrogenase and 5,10-methenyl-THF cyclohydrolase, respectively (Cheung et al., 
1997; MacKenzie, 1997). The final step is the conversion of 10-formyl-THF to 
formate which requires 10-formyl-THF hydrolysis. Hydrolysis is mediated by the 
activity of 10-formyl-THF synthetase and a favourable ADP/ATP ratio in 
mitochondria (Christensen et al., 2013). Additionally, formyl-methionyl-tRNA is 
synthesised from 10-formyl-THF. Formyl-methionyl-tRNA is required for 
mitochondrial protein synthesis and is generated via the activity of methionyl-
tRNAF
MET
 formyltransferase (Di Pietro et al., 2002). 
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1.4.4.3 One-carbon metabolism in the nucleus 
In addition to the cytoplasm, de novo synthesis of thymidylate also occurs in the 
nucleus. Approximately 10% of cellular folate resides in the nucleus and TS, SHMT 
and DHFR have been localised to the nuclear compartment of the cell (Figure 7) 
(Anderson et al., 2012; MacFarlane et al., 2011; Samsonoff et al., 1997). These 
enzymes are substrates for UBC9-mediated modification with the small ubiquitin-
like modifier (SUMO), which targets proteins for nuclear localisation (Woeller et al., 
2007). Thymidylate synthesis in the nucleus is thought to take place directly at the 
replication fork during the S phase of the cell cycle. This would lead to reduced rates 
of uracil misincorporation (MacFarlane et al., 2011). The importance of thymidylate 
for DNA and RNA replication and repair is crucial, since the loss of TS activity due 
to gene polymorphisms or chemotherapeutic agents, results in decreased rates of 
DNA synthesis, increased rates of uracil misincorporation into DNA, chromosome 
damage, fragile site induction and apoptotic cell death (Blount et al., 1997; Hori et 
al., 1984; Kronenberg et al., 2011). 
1.5 Cerebral Folate Deficiency 
Folate deficiency can occur in both the CNS and periphery, or in the CNS alone 
(Hyland et al., 2010). Manifestation of folate deficiency may be the consequence of 
either a primary defect, for example a genetic mutation affecting synthesis, 
breakdown or transport mechanisms, or a secondary defect, a defect arising as a 
consequence of the primary cause of disease. Such primary defects that lead to a 
folate deficiency affecting both the CNS and the periphery may include primary 
inherited disorders of folate metabolism and transport, for example, mutations in the 
genes encoding 5,10-methylene tetrahydrofolate reductase, dihydrofolate reductase, 
and FRα (Banka et al., 2011; Steinfeld et al., 2009; Tsuji et al., 2011). Whereas, 
disorders such as dietary folate insufficiency, intestinal resection, cancer, use of anti-
folate drugs, for example methotrexate, hepatic failure and celiac disease, may lead 
to a more generalised secondary folate deficiency (Djukic, 2007). Folate deficiency, 
which occurs solely in the CNS compartment, is called CFD. CFD can be defined as 
any neurological syndrome associated with a low cerebrospinal fluid (CSF) 
concentration of 5-methyltetrahydrofolate (5-MTHF) in the presence of normal 
peripheral folate status (Ramaekers and Blau, 2004). As with the more generalised 
folate deficiency affecting both the periphery and CNS, manifestation of CFD may 
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also be the consequence of either a primary defect or secondary defect (see sections 
1.5.1 and 1.5.2). CFD can be classified as mild (<30% decrease below the lower 
reference range limits), moderate (30-60% decrease below the lower reference range 
limits) and severe (>60% below the lower reference range limits) (Pérez-Dueñas et 
al., 2011).  
1.5.1 Primary CFD disorders 
Defects in the transport of folate across the choroid plexus from the periphery into 
the CNS are the main cause of primary CFD. The first report of an isolated CNS 
folate deficiency was published in 1994 (Wevers et al., 1994). Whilst it was 
hypothesised that such a deficiency may be the consequence of disturbed transfer of 
folate across the choroid plexus of the blood-CSF barrier, the exact underlying 
mechanism(s) was not fully elucidated. Since this time, a number of case reports and 
cohort studies identifying patients with primary CFD have been documented in the 
literature and the underlying aetiology of disease examined (Cario et al., 2011; 
Moretti et al., 2005; Pérez-Dueñas et al., 2011; Ramaekers et al., 2013; Serrano et 
al., 2012).  
Mutations in the FOLR1 gene encoding the FRα have been associated with inherited 
primary CFD states. The first reports of mutations in the FOLR1 gene were 
published in 2009 (Cario et al., 2009; Steinfeld et al., 2009). Currently, 10 mutations 
in the coding exons of the FOLR1 gene have been reported to date, including the 
unpublished FOLR1 mutation described in Chapter 3 of this thesis (see Figure 24) 
(Grapp et al., 2012). In view of the major role of the FRα in mediating transport of 5-
MTHF from the periphery into the CSF across the choroid plexus, undetectable 
concentrations of 5-MTHF (<10 nmol/L) are usually reported in these patients 
(Ormazábal et al., 2011; Pérez-Dueñas et al., 2011; Serrano et al., 2012). 
Interestingly, a lack of correlation between clinical severity and residual function of 
the FRα in patients with FOLR1 mutations has been demonstrated, suggesting that 
additional factors and/or mechanisms may contribute to the observed clinical 
phenotype in CFD (Grapp et al., 2012; Steinfeld et al., 2009). 
In addition to FOLR1 mutations, serum blocking autoantibodies have also been 
implicated as a cause of primary CFD. In 2005, Ramaekers et al. published a cohort 
study of 28 patients with CFD (Ramaekers et al., 2005). Interestingly, serum analysis 
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revealed the presence of FRα blocking autoantibodies in 25 of the 28 patients, and 
the absence of blocking autoantibodies in none of the 28 matched controls. In 
addition, serum specimens from 41 subjects with central nervous system disease 
unrelated to CFD and from five mothers of individual patients, were negative for 
blocking autoantibodies. In the remaining three CFD patients, the underlying cause 
of disease was not identified. It was suggested that FRα blocking autoantibodies 
preferentially bind to the FRα on the epithelial cells on the basolateral membrane of 
the choroid plexus, preventing effective binding and transport of 5-MTHF from the 
periphery into the CSF to maintain CSF 5-MTHF concentrations. Ramaekers et al. 
(2005) further hypothesised that the mechanism responsible for the formation of 
these autoantibodies could be a consequence of exposure to soluble folate-binding 
proteins in human or bovine milk or sensitisation by unknown antigens with similar 
epitopes (Ramaekers et al., 2005). In support of these suggestions is the >90% amino 
acid sequence homology between the soluble-folate binding proteins in milk and the 
membrane-bound FRα and FRβ expressed on the human choroid plexus epithelium 
(Svendsen et al., 1982); FRα and FRβ cross-react with rabbit antibodies against the 
human-milk folate binding protein. A more recent study published by the same 
group demonstrated that a bovine milk free diet may downregulate autoantibody titre 
and be of therapeutic importance in CFD patients where FRα and FRβ blocking 
autoantibodies have been implicated (Ramaekers et al., 2008). 
1.5.2 Secondary CFD disorders 
Secondary CFD is associated with a wide range of conditions and in the majority of 
cases the underlying aetiology of disease is not known (Hyland et al., 2010). 
Specifically, secondary CFD in a subset of patients with mitochondrial disorders is 
becoming increasingly diagnosed in the clinic (Garcia-Cazorla et al., 2008; Mangold 
et al., 2011; Ormazábal et al., 2011; Pérez-Dueñas et al., 2011; Serrano et al., 2010). 
The association between CFD and mitochondrial disease was first described in 1983 
in KSS (Macron et al., 1983). In the same year, another case was reported 
documenting both a CFD and peripheral folate deficiency (Allen et al., 1983). More 
recently, a severe CFD was reported in a patient with an incomplete form of KSS 
(Pineda et al., 2006) and in a small cohort study of six patients with KSS published 
by the same group, five were found to have severe 5-MTHF deficiencies whilst a 
moderate deficiency was observed in the sixth (Serrano et al., 2010). Moderate CFD 
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has also been reported in a patient with mitochondrial complex I encephalomyopathy 
(Ramaekers et al., 2007a) and in a patient with Alpers disease (Hasselmann et al., 
2010). 
A number of larger cohort studies have also documented CFD in a range of 
mitochondrial disorders. A study by Garcia-Cazorla et al. (2008) analysed CSF 5-
MTHF of 28 patients with mitochondrial disease and 14 of these patients were found 
to have CFD (Garcia-Cazorla et al., 2008). Severe CFD was reported in four patients 
with KSS, whilst mild to moderate CFD was described in one patient with KSS, one 
patient with NARP, two patients with Leigh syndrome and six patients with severe 
infantile encephalomyopathies and RCE abnormalities. In another study, 36 patients 
out of 60 with a range of neurological disorders were reported with CFD and 3 of 
these cases were patients with KSS (Ormazábal et al., 2011). Perez-Duenas et al. 
(2011) analysed 584 patients with encephalopathies and 71 of these patients had 
CFD. This group reported two severe CFD in KSS, and moderate CFD in one patient 
with KSS and four patients with undefined mitochondrial disorders. Similarly, CFD 
in two patients with undefined mitochondrial disorders were also reported following 
analysis of a cohort of 103 CFD cases (Mangold et al., 2011). 
In addition to mitochondrial disorders, secondary CFD has also been reported in a 
number of other pathologies. For example, CFD has been described in Rett 
syndrome, an inherited X-linked neurodevelopmental disease of the grey matter 
leading to loss of language and motor skills (Weng et al., 2011). Rett syndrome may 
be caused by mutations in the MECP2 gene encoding methyl CpG binding protein 2 
and studies have suggested that this protein plays an important role in the formation 
of nerve synapses and gene silencing (Bird, 2008; Nguyen et al., 2012). The 
association of CFD in Rett syndrome is controversial. Decreased 5-MTHF in CSF 
was initially observed in four female patients (Ramaekers et al., 2003). Further 
investigations carried out by other groups indicated that eight out of 16 (Ormazabal 
et al., 2005), eight out of 25 (Temudo et al., 2009) and 14 out of 33 (Ramaekers et 
al., 2007b) patients, presented with decreased 5-MTHF in CSF. From the cohort of 
33 patients, 14 were found to have blocking autoantibodies against the folate 
receptors (Ramaekers et al., 2007b). In contrast, a study carried out in North 
America reported that only two patients with Rett syndrome presented with CFD out 
of a total of 76. One of these patients also presented with a peripheral folate 
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deficiency (Neul et al., 2005). The nutritional folate supplementation programme, 
which is currently in force in North America, may be attributable for the differences 
observed between these patient cohorts (Hyland et al., 2010). Similarly, the 
association between CFD and Aicardi-Goutieres syndrome has been debated. 
Aicardi-Goutieres syndrome is an autoinflammatory disorder mimicking in utero 
viral infection of the brain and may be caused by mutations in the SAMHD1 gene 
encoding SAM domain and HD domain-containing protein 1, TREX1 gene encoding 
three prime repair exonuclease 1 or ribonuclease H2 encoding genes (RNASEH2A, 
RNASEH2B, RNASEH2C) (Rice et al., 2013). Inheritance of these mutations follows 
an autosomal recessive pattern. It has been hypothesised that elevated levels of 
nucleic acid byproducts leads to an inappropriate innate immune system response, 
since CFD and elevated CSF levels of tetrahydrobiopterin and neopterin have been 
reported in three patients with the disease (Blau et al., 2003). However, CFD was not 
observed in nine patients with Aicardi-Gourtiere syndrome in North America, 
despite elevated CSF levels of tetrahydrobiopterin and neopterin being reported 
(Hyland et al., 2010). The active nutritional folate supplementation programme in 
North America may also be accountable for this observation. 
Other examples of pathologies where secondary CFD has been indicated include 
autism and autism-spectrum diseases, and neurodegenerative diseases. Four out of 28 
austic patients in one study and seven autistic patients in another study were 
diagnosed with CFD of varying degrees (Moretti et al., 2008; Ramaekers et al., 
2005). More recently, CFD has been reported in 93 patients with autism-spectrum 
disorder. In these patients a high prevalence (75.3%) of blocking autoantibodies 
against the folate receptors was reported (Frye et al., 2013). Secondary CFD has also 
been reported in neurodegenerative disorders including Alzheimer’s disease and 
Parkinson’s disease (Banka et al., 2011; dos Santos et al., 2009; Duan et al., 2002; 
Hinterberger and Fischer, 2013; Serot et al., 2001; Smach et al., 2011). It has been 
postulated that choroid plexus dysfunction, impeding the transport of 5-MTHF from 
the blood into the CSF, may be responsible for low CSF folate observed in these 
patients (Johanson et al., 2004; Rubenstein, 1998). However, a recent study reported 
CSF data that substantiated the maintenance of choroid plexus transport and 
homeostatic functions in Alzheimer’s disease patients (Spector and Johanson, 2013). 
In addition to the larger cohort studies, single case reports of patients with secondary 
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CFD have been published, including in a patient with schizophrenia and catatonia 
(Ho et al., 2010), and in a patient with severe self-injurious behaviour (Leuzzi et al., 
2012). In the former patient, elevated blocking autoantibodies against the folate 
receptors were reported. 
1.5.3 Clinical presentation 
CFD was first described in five patients with normal neurodevelopmental progress 
during the first four to six months followed by the onset of a neurological condition 
(Ramaekers et al., 2002). The initial manifestation of disease may include agitation 
and insomnia, followed by marked irritability, decelerating head growth, 
psychomotor retardation, cerebellar ataxia, dyskinesia and pyramidal signs in the 
lower limbs and seizures (Ramaekers and Blau, 2004). Autistic features may also be 
present (Frye et al., 2013; Moretti et al., 2005; Ramaekers et al., 2007a). After the 
age of 6 years, visual disorders may develop (Ramaekers et al., 2002). Despite 
normal peripheral blood and serum levels, 5-MTHF may show a steady decline. 
Brain MRI findings may be variable among patients, ranging from normal scans, to 
fronto-temporal atrophy with signs of periventricular and subcortical demyelination 
by the age of 18 months (Serrano et al., 2010).  
Whilst the described clinical picture for patients with primary CFD could be 
considered neurologically diverse, those patients presenting with a secondary CFD, 
specifically mitochondrial disorders, may display even greater clinical heterogeneity 
(Garcia-Cazorla et al., 2008). In addition, the clinical phenotypes associated with 
mitochondrial disease and CFD may overlap. Therefore, it is understandable that 
CFD may go undetected following clinical assessment and may represent an under-
recognised condition in patients such as these. For example, short stature, 
progressive muscle weakness and leukoencephalopathy, as visualised by brain MRI, 
have been reported in patients with KSS and secondary CFD (Garcia-Cazorla et al., 
2008; Ormazábal et al., 2011; Pineda et al., 2006; Serrano et al., 2010). In addition, 
hypotonia, spastic diplegia and refractory seizures have been described in a patient 
with mitochondrial complex I encephalopathy and secondary CFD (Ramaekers et al., 
2007c). In a patient with Alpers disease and secondary CFD, acute onset of status 
epilepticus and movement disorder occurred (Hasselmann et al., 2010). Interestingly 
in this patient, brain MRI at the time of disease onset showed no abnormalities. 
75 
 
However, a second brain MRI performed 3 months after disease onset demonstrated 
mild cerebral atrophy and an ischaemic lesion in the left thalamus.  
In other pathologies where secondary CFD has been implicated, similar overlapping 
clinical heterogeneity may be observed. For example, patients with Rett syndrome 
and secondary CFD have been shown to present with small hands and feet, 
deceleration of head growth, seizures and gastrointestinal disorders (Ormazabal et 
al., 2005; Ramaekers et al., 2007b; Temudo et al., 2009). In those patients with 
Aicardi-Goutieres syndrome and secondary CFD, chronic pleocytosis, postnatal 
microcephaly, developmental delay, spastic quadriplegia and refractory seizures 
have been described (Blau et al., 2003; Hyland et al., 2010). Severe psychomotor 
retardation, developmental delay and slowing of head growth were also reported in 
patients with secondary CFD associated with autism, schizophrenia and catatonia, 
and self-injurious behaviour (Ho et al., 2010; Leuzzi et al., 2012; Moretti et al., 
2008, 2005; Ramaekers et al., 2005). 
1.5.4 Diagnosis 
Once CFD is suspected in patients clinically presenting with the associated 
symptoms, confirmation of the diagnosis requires biochemical analysis of the CSF in 
conjunction with assessment of peripheral folate status in serum and red blood cells 
(Hyland et al., 2010). At the UCL Institute of Child Health and the National Hospital 
for Neurology and Neurosurgery, London, UK, techniques used for analysis of 5-
MTHF in CSF include high performance liquid chromatography (HPLC) with 
electrochemical detection (Hyland and Surtees, 1992) or fluorescence detection 
(Ormazabal et al., 2006). Additional laboratory investigations to determine the 
integrity of one-carbon metabolism (discussed in section 1.4.4) may be carried out 
and may include evaluation of methionine, homocysteine, serine and glycine 
(Hyland and Bottiglieri, 1992; Surtees et al., 1991). 
In the aforementioned laboratories, strict CSF collection protocols are adhered to. 
These protocols are consistent with other centres around the world. CSF is obtained 
from the patient by lumbar puncture, immediately snap frozen at the bedside, stored 
at -80°C and transported to the diagnostic laboratory on dry ice (Hyland et al., 2010). 
Patient information including date of birth and collection date should be provided 
since CSF 5-MTHF concentrations are age-dependent especially in the first year of 
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life (Ormazabal et al., 2006). Moreover, specific drug treatments can affect CSF 5-
MTHF values, including L-dopa and methotrexate. L-dopa is methylated by SAM in 
a catechol-O-methyltransferase dependent reaction whilst methotrexate is a DHFR 
inhibitor. Therefore, both drugs interfere with 5-MTHF metabolism. Such 
medication should be identified on the request form to avoid inappropriate diagnosis 
and treatment. Owing to the rostral-caudal gradient of CSF, 5-MTHF analysis is 
always performed in the second 0.5 ml aliquot. 
Following documentation of CFD, further laboratory investigations may be carried 
out and could include determination of FRα autoantibody status (although not widely 
available), evaluation of pterin profiles, mitochondrial RCE analyses and/or genetic 
testing for diseases associated with CFD, for example Rett syndrome or Aicardi-
Goutieres syndrome (Hyland et al., 2010; Ramaekers et al., 2007b, 2005). These 
additional exploratory investigations may provide further biochemical and/or genetic 
information, which may facilitate more appropriate treatment regimens. 
1.5.5 Treatment 
Following a positive CFD diagnosis, patients are treated with oral calcium folinate 
(folinic acid; 5-formyltetrahydrofolate) (Hansen and Blau, 2005; Hyland et al., 2010; 
Moretti et al., 2005; Ormazabal et al., 2005). Folinic acid is a reduced and 
metabolically active form of folate that is readily incorporated into one-carbon 
metabolism. Folinic acid is not susceptible to oxidation owing to the presence of the 
formyl group at position N5 stabilising the pyrazine ring of the structure (Bailey, 
2010). Folic acid is not administered for CFD since it may exacerbate the CFD 
phenotype (Hyland et al., 2010). Folic acid is the oxidised, metabolically inactive 
form of folate with a high folate receptor binding affinity. Thus, upon administration, 
folic acid competes for binding sites on the folate receptors expressed on choroid 
plexus epithelial cells of the blood-CSF barrier (Frye et al., 2013; Wu and Pardridge, 
1999). Folinic acid may be prescribed as Leucovorin, which is a mixture of the 
active L isomer and the inactive D isomer. Isovorin is a preparation of the 
biologically active L isomer only and its administration may lead to an improved 
biochemical outcome (Hyland et al., 2010). Typically, folinic acid is prescribed at 
0.5-1.0 mg/kg/day. However, in cases where there is a severe CFD, higher doses of 
2.0-3.0 mg/kg/day may be administered. It has been reported that folinic acid 
treatment could lead to side effects including gastrointestinal complications and 
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exacerbation of seizures. Therefore, patients should be monitored accordingly 
(Ramaekers and Blau, 2004).  
In general, patients diagnosed with CFD have a positive response to folinic acid 
treatment and demonstrate an improvement in biochemical and clinical phenotype. 
For example, administration of folinic acid has been shown to lead to reversal of 
white matter changes in patients with KSS (Pérez-Dueñas et al., 2011; Pineda et al., 
2006) and mitochondrial complex I deficiency (Ramaekers et al., 2007c). In 
addition, improvements in seizure frequency have been described in three patients 
with Rett syndrome (Pérez-Dueñas et al., 2011) and in three patients, two of which 
are related, with mutations in the FOLR1 gene (Cario et al., 2009; Grapp et al., 
2012). Importantly, treatment with folinic acid should commence as soon as a CFD 
state has been demonstrated, since improvement in neurological function may be 
more marked in those patients that undergo therapy before six years of age 
(Ramaekers and Blau, 2004). 
1.6 Pathogenesis of secondary CFD associated with mitochondrial disorders 
1.6.1 Pathogenic mechanisms 
In the absence of mutations in the FOLR1 gene or FR autoimmunity, the 
mechanism(s) responsible for the secondary CFD associated, in particular with a 
subset of mitochondrial disease patients, is not known. In the presence of normal 
peripheral folate levels, a disorder of folate transport across the blood-CSF barrier 
has been suspected and a number of hypotheses have previously been suggested to 
explain the defective transport, as discussed below. 
1. ATP depletion 
 
Owing to the role of mitochondria in ATP production, perhaps the most widely 
speculated pathogenic mechanism responsible for secondary CFD in a subset of 
mitochondrial disorders is an energy deficit impeding the active transport of 5-
MTHF across the choroid plexus from the periphery into the CSF (Hyland et al., 
2010; Pérez-Dueñas et al., 2011; Ramaekers et al., 2007c). In addition, since the 
activity of FPGS is ATP-dependent, failure of polyglutamation and intracellular 
retention of 5-MTHF in choroid plexus cells have also been suggested 
(Ramaekers et al., 2013a).  
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2. Choroid plexus dysfunction 
 
In patients with KSS presenting with a secondary CFD and perhaps in other 
mitochondrial disorders, it has been suggested that transport of 5-MTHF across 
the choroid plexus may be disrupted as a result of oncocytic transformation and 
accumulation of mutated mtDNA copies in choroid plexus cells (Spector and 
Johanson, 2010). Neuropathological investigations of the choroid plexus from 
two patients with KSS revealed enlarged choroid plexus epithelial cells and 
extensive cytoplasmic eosinophil granule infiltrate, when compared to normal 
controls (Tanji et al., 2000). These changes to the normal pathology associated 
with patients with KSS could disrupt the receptor-mediated endocytotic transport 
of 5-MTHF by FR and intracellular retention of 5-MTHF owing to a lack of 
polyglutamation (Grapp et al., 2013; Ramaekers et al., 2013a). 
 
3. Reactive oxygen species 
 
Seizures are a common clinical feature of patients with mitochondrial disease 
and secondary CFD (Lee et al., 2011; Opladen et al., 2010; Rahman, 2012). 
Treatment with anti-convulsant therapies including sodium valproate, 
carbamazepine and phenytoin may be prescribed in these patients (Rahman, 
2012). However, as previously discussed, sodium valproate should if possible be 
avoided in mitochondrial disease patients, since it has been shown to inhibit 
mitochondrial oxidative phosphorylation and may cause clinical worsening 
(Rahman and Hanna, 2009). Degradation of sodium valproate and 
carbamazepine by the cytochrome P450 enzyme system is associated with ROS 
generation (Opladen et al., 2010). Opladen et al. (2010) demonstrated that prior 
exposure of KB cells (a keratin-forming subline of the HeLa (Henrietta Lacks) 
tumour cell line cloned from a cervical adenocarcinoma in 1951 (Verlinde et al., 
2008)) expressing the FRα, to superoxide and hydrogen peroxide in vitro, led to 
decreased cellular 5-MTHF uptake. In addition, previous studies have also 
suggested that phenytoin may inhibit the formation of polyglutamyl folates in rat 
liver (Carl et al., 1997). Therefore, anti-convulsant therapy in mitochondrial 
disease patients with secondary CFD may increase ROS generation causing an 
inhibitory effect on cellular folate incorporation across the blood-CSF barrier 
and/or prevent polyglutamylation and subsequent cellular retention. These 
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proposed mechanisms could also account for the secondary CFD associated with 
other disorders where anti-convulsant therapy for seizure control may be required 
and where the underlying aetiology of secondary CFD is not known, for example 
Rett syndrome (Ramaekers and Blau, 2004; Ramaekers et al., 2003). 
 
Whilst these speculated mechanisms responsible for the secondary CFD associated 
with mitochondrial disease may be biologically plausible and have a contributory 
role in disease pathogenesis, there is a lack of supportive evidence for each. For 
example, there does not appear to be a relationship between the severity of RCE 
defect measured in skeletal muscle and the degree of CFD measured in CSF (Hyland 
et al., 2010). It is important to consider, however, that RCE activity measurements in 
skeletal muscle are used to represent RCE activity in the brain, since performing a 
brain biopsy is surgically more complex and involves greater risk. In addition, 
variable degrees of secondary CFD have been reported in patients with KSS. In two 
large cohort studies, there has been no difference in the concentrations of folate in 
serum and CSF when comparing children with and without anti-convulsant therapy 
(Mangold et al., 2011; Pérez-Dueñas et al., 2011). Therefore, this suggests that other 
pathogenic mechanisms may be involved, and prompts the need for further 
hypothesis-led investigations to be carried out to more extensively decipher the 
underlying aetiology of CFD associated with mitochondrial disease.  
1.6.2 Oxidative stress  
As discussed in section 1.1.3, mitochondria are considered to be the most important 
quantitative source of ROS, which are generated as by-products of oxidative 
phosphorylation at the level of the mitochondrial RC (Figure 1) (Adam-Vizi, 2005; 
Sipos et al., 2003). Mitochondrial dysfunction and impaired mitochondrial RC 
activity is associated with an increase in ROS production. Previous studies have 
demonstrated that partial inhibition of the mitochondrial RC, to a degree insufficient 
to perturb oxidative phosphorylation, can lead to an increase in ROS generation 
(Jacobson et al., 2005; Sipos et al., 2003). Under these conditions, oxidative stress 
may ensue, which represents an imbalance between ROS generation and antioxidant 
availability. Increased ROS production and oxidative stress can lead to significant 
cellular destruction including nuclear and mitochondrial DNA damage, protein 
modification and lipid peroxidation (Halliwell and Whiteman, 2004; Musatov and 
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Robinson, 2012). This, in turn, may initiate a vicious cycle leading exponentially to 
more ROS production and mitochondrial damage (Ma et al., 2009; Wang et al., 
2013). Since mitochondria are particularly numerous in the brain, owing to the high-
energy demand, the CNS may be more susceptible to oxidative stress when 
mitochondrial RC activity is compromised. In addition, the brain has a relatively 
high iron and, to a lesser extent, copper content, for example mitochondrial iron-
sulphur clusters, copper centres and haem, and a low free iron binding capacity in 
CSF (Bleijenberg et al., 1971; Bradbury, 1997; Harrison et al., 1968). Therefore, the 
production of the hydroxyl radical via the Fenton reaction may be more likely.  
Oxidative stress and increased generation of ROS have been associated with 
conditions where CFD has been implicated, including mitochondrial disease 
(Opladen et al., 2010; Pérez-Dueñas et al., 2011; Serrano et al., 2010). Oxidative 
stress has previously been proposed to contribute to CFD by causing modification of 
the FRα leading to impaired transport (Opladen et al., 2010). However, 5-MTHF, 
together with other reduced pterin molecules, is susceptible to autoxidation in the 
presence of molecular oxygen and direct oxidative attack by oxidising species, which 
leads to increased catabolism (Blair et al., 1975; Heales et al., 1988; Lam and 
Heales, 2007). Consequently, in conditions where ROS formation is increased, 
accelerated catabolism of 5-MTHF may ensue, thereby further contributing to a CFD 
state.  Since increased ROS generation is associated with impaired mitochondrial RC 
activity and loss of mitochondrial function (Jacobson et al., 2005; Sipos et al., 2003), 
oxidative stress could provide a mechanistic link between mitochondrial disorders 
and CFD.  
In addition to impaired mitochondrial RC activity and loss of mitochondrial 
function, other factors may play a contributory role in inducing oxidative stress in 
mitochondrial disorders, including selenium and AA. These factors are discussed in 
the following sections 1.6.2.1 and 1.6.2.2, respectively. 
1.6.2.1 Selenium  
The trace element selenium is an essential micronutrient required for the 
biosynthesis of selenocysteine-containing selenoproteins. Selenium exists in both 
inorganic (selenite and selenate) and organic (selenomethionine, selenocysteine, and 
Se-methylselenocysteine) (Figure 8) forms and is predominant in foods such as 
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bread, cereals, brazil nuts and dairy products (Fairweather-Tait et al., 2011; Lu et al., 
2009). Plant foods are also a major dietary source of selenium and the selenium 
content of these foods is dependent on the selenium availability in the soil in which 
they are grown. In countries such as Russia and China, there are low amounts of 
selenium in soil, which may predispose to selenium deficiency. Such a deficiency 
may lead to the onset of Keshan disease or Kashin-Beck disease. Regarding the 
former, onset of this disease is dependent on exposure to the mutated strain of 
Coxsackievirus and is characterised by a potentially fatal severe cardiomyopathy (Li 
et al., 2012). Regarding the latter, disease onset is dependent on a concomitant iodine 
deficiency and is characterised by atrophy, degeneration and necrosis of cartilage 
tissue (Ning et al., 2013). 
The mechanisms responsible for intestinal absorption of dietary selenium and the 
identity of the transporter proteins required remain uncertain. Studies have suggested 
that selenomethionine, selenocysteine and Se-methylselenocysteine may be 
transported by certain amino acid transporters, specifically the B
0
 and b
0+
rBAT 
systems; high-affinity, sodium-independent transporters of cysteine and amino acids 
(Nickel et al., 2009). In addition, the SLC26 multifunctional anion exchanger family 
are good candidates for intestinal selenate transport since inhibition of these 
exchangers reduces selenate uptake (Shennan, 1988; Wolffram et al., 1985). 
Similarly, the mechanisms responsible for the transport of selenium between the 
periphery and the CNS have yet to be fully elucidated. However, both the 
apolipoprotein E receptor 2 and the megalin receptor have been implicated in 
mediating selenium transport across BBB endothelial cells (Alvira-Botero et al., 
2010; Burk et al., 2007), and a hypothetical transport model has been proposed 
(Richardson, 2005) (Figure 9). This model suggests that selenium-containing 
selenoprotein P (SePP), which is synthesised in the liver from dietary selenium 
sources and is the most abundant selenoprotein in plasma, binds to a SePP receptor 
expressed on the BBB endothelial cell basolateral membrane. Upon binding, it is 
postulated that the complex is internalised by endocytosis and selenium cleaved via 
the activity of selenocysteine γ-lyase (SCL). Whether the SePP receptor is recycled 
or degraded is not known. The cleaved selenium may then either enter into the 
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Figure 8 Chemical structures of the selenium compounds. Structures were sourced from the National Center 
for Biotechnology Information (www.ncbi.nlm.nih.gov). 
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Figure 8 (continued) Chemical structures of the selenium compounds. Structures were sourced from the 
National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). 
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Figure 9 Proposed mechanism of transport of selenium across the blood-brain barrier. Selenoprotein P (Se), binds to a selenoprotein 
P receptor (R) (hypothesised to be apolipoprotein E receptor 2 or the megalin receptor) expressed on the blood-brain barrier endothelial 
cell basolateral membrane. Upon binding, the complex is internalised by endocytosis and selenium cleaved via the activity of 
selenocysteine γ-lyase (SCL). The cleaved selenium may then either enter into the metabolic cycle of the cell facilitating selenoprotein 
synthesis or be re-incorporated into de novo synthesis of selenoprotein P and released from the apical membrane, by an unknown 
mechanism, into the interstitial space of the brain, represented by the “?” in the figure. Selenium concentration is 30-fold lower in CSF 
than in plasma, which suggests that efflux from the CNS to the blood would occur in an energy-dependent manner. 
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metabolic cycle of the cell facilitating selenoprotein synthesis or be re-incorporated 
into de novo synthesis of SePP and released from the apical membrane, by an 
unknown mechanism, into the interstitial space of the brain. The subsequent uptake 
of SePP by brain cells and the activity of intracellular SCL could provide the cell 
with selenium for cellular metabolism and selenoprotein synthesis (Richardson, 
2005). Selenium concentration is 30-fold lower in CSF than in plasma, which 
suggests that efflux from the CNS to the blood would occur in an energy-dependent 
manner (Tondo et al., 2011, 2010). Moroever, it has been postulated that the choroid 
plexus may play a pivotal role in selenium transport from the blood to the CSF 
(Tondo et al., 2011), which is further supported by the proposed mechanism of 
Richardson (2005). CSF selenium concentration follows a negative age-related trend. 
Tondo et al. (2010) reported CSF selenium reference ranges as shown in Table 6. 
The assimilation of dietary selenium into selenoproteins occurs through a series of 
metabolic interconversions with selenide being the central metabolic intermediate of 
both the inorganic and organic selenium compounds (Figure 10) (Lu et al., 2009). 
Dietary selenomethionine and selenomethionine released from proteins is initially 
converted to selenocysteine via the activity of cystathionine-β-synthase and 
cystathionine γ-lyase through a selenocystathionine intermediate. In turn, 
selenocysteine is converted to selenide in a reaction catalysed by selenocysteine β-
lyase (Ohta and Suzuki, 2008). Dietary Se-methylselenocysteine can be converted to 
methylselenol in a cystathionine γ-lyase reaction, which can in turn be demethylated 
to produce selenide (Gabel-Jensen et al., 2010). Thioredoxin reductase and 
thioredoxin can directly reduce selenite to selenide. Alternatively, selenite can react 
with glutathione to form selenodiglutathione (Lu et al., 2009). Selenodiglutathione is 
a substrate for reduction to glutathioselenol by glutathione reductase. A reaction 
between glutathioselenol and glutathione yields selenide (Cui et al., 2008). Selenate 
is assimilated into proteins following reduction to selenide via the same thioredoxin 
reductase and thioredoxin/glutathione pathways (Björnstedt et al., 1997). However, 
the mechanism responsible for the conversion of selenate to selenite remains unclear 
but may involve the activity of thioredoxin reductase in the presence of thioredoxin 
and/or glutathione. The assimilation of selenide into selenoproteins involves the 
generation of the highly reactive selenium donor, selenophosphate, synthesized via 
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Table 6 CSF selenium reference ranges according to Tondo et al. (2010). CSF 
selenium concentration is age-related. Values are given in nmol/L and µg/L to 
accommodate how the concentration may be expressed in reporting. 
 
CSF selenium reference ranges 
Age (days (d), months (m), years (y)) Concentration (nmol/L [µg/L]) 
1 – 30 d 22.8 – 59.5 [1.8 – 4.7] 
1 m – 3y 8.6 – 38.0 [0.68 – 3.0] 
4 – 18 y 9.2 – 27.0 [0.73 – 2.13] 
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Figure 10 Selenium metabolism. The assimilation of selenium into selenoproteins. GSH = reduced glutathione, 
GSSG = oxidised glutathione. See section 1.6.2.1 for detailed explanation. 
Selenocystathionine 
Cystathionine-γ-lyase 
 
Cystathionine-γ-lyase 
GSH GSSG 
GSH 
Dimethylselenide 
Trimethylselenonium 
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the activity of selenophosphate synthetase. Selenocysteyl-tRNA
[Ser][Sec]
, which is 
incorporated into selenoproteins, is generated from selenophosphate and O-phospho-
L-seryl-tRNA
[Ser][Sec] 
in a reaction catalysed by selenocysteine synthetase (Ganichkin 
et al., 2008). Whilst selenide is the key intermediate for selenoprotein synthesis, 
selenide is also the key intermediate for selenium excretion. Methyltransferases 
sequentially add methyl groups to selenide to generate methylselenol, 
dimethylselenide and trimethylselenonium (Fernandes et al., 2012). 
Dimethylselenide is excreted in the breath and faeces, whilst trimethylselenonium is 
excreted in the urine (Ohta and Suzuki, 2008).  
The main biological function of selenoproteins is antioxidant defence 
(Moghadaszadeh and Beggs, 2006; Tinggi, 2008). Specifically, the antioxidant 
enzymes, glutathione peroxidase and thioredoxin reductase, are well-characterised 
selenoenzymes (Das and Das, 2000; Steinbrenner et al., 2006). For example, these 
selenoenzymes catalyse the reduction of hydrogen peroxide and hydroperoxides, and 
are particularly important in reducing ROS generated in mitochondria, during viral 
infections and during thyroid hormone synthesis (Fairweather-Tait et al., 2011). 
Regarding the latter, previous studies have demonstrated that selenium availability 
and maintenance are tightly regulated in the thyroid gland (Arthur et al., 1999; 
Schomburg and Köhrle, 2008). Whilst selenium plays an important biological 
function in antioxidant defence, selenium is also a CNS-sensitive toxic trace element 
when present at high physiological concentrations and patients with selenium 
toxicity in the CNS may present with a range of clinical symptoms including ataxia, 
irritability and lethargy (Tondo et al., 2011; Wilber, 1980). 
The sensitivity of the CNS to toxic levels of selenium may be a consequence of 
increased ROS production. Selenide is an auto-oxidisable molecule and may undergo 
thiol-mediated redox cycling, including with thioredoxin and glutathione systems 
which are present in CSF, leading to a rapid non-stoichiometric increase in ROS 
production (Chen et al., 2007a; Tarze et al., 2007; Wallenberg et al., 2010; Yan and 
Spallholz, 1993). In turn, NADPH may be depleted owing to continued reduction of 
thiols (Lu et al., 2009). Theoretically, high physiological selenium concentrations in 
the CNS would initiate selenide redox cycling and toxicity via increased ROS 
production, and oxidative stress would ensue. The threat of inducing such a redox 
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cycle may explain why there is no free pool of selenide in cells (Lu and Holmgren, 
2009; Lu et al., 2009). 
Interestingly, elevated CSF selenium concentrations were reported in six patients 
with KSS and secondary CFD. All patients (mean (SD) [range] age, 16 (9.4) [7 – 34] 
years) presented with CSF 5-MTHF concentrations ranging from 0.6 – 24.0 nmol/L 
(reference range 42 -81 nmol/L for patients older than 4 years) and CSF selenium 
concentrations ranging from 2.4 – 7.3 µg/L (reference range 0.73 – 2.13 µg/L for 
patients older than 4 years) (Tondo et al., 2011). The group hypothesised that owing 
to choroid plexus dysfunction in KSS, impaired transport processes may account for 
the elevated CSF selenium concentrations in these patients. However, selenium was 
not implicated as a factor responsible for CFD in these patients and the data were not 
correlated to 5-MTHF availability. In view of the potential association of selenium 
toxicity with ROS generation and the susceptibility of 5-MTHF to oxidative 
catabolism, oxidative stress in these patients may ensue leading to accelerated 
breakdown of 5-MTHF.  
1.6.2.2 Ascorbic acid 
Ascorbic acid (AA) is an essential, water-soluble vitamin (vitamin C) (Mandl et al., 
2009). Plants and most animals are able to synthesise AA from glucose. However, 
humans, guinea-pigs and a number of species of fruit-eating bats cannot synthesise 
AA owing to a lack of functional L-gulonolactone oxidase activity; the enzyme 
required for the last step in AA synthesis (Nishikimi et al., 1994). Therefore, it is a 
requirement in these species that an adequate supply of AA is taken in with the diet 
and dietary sources include many citrus fruits and leafy green vegetables. However, 
failure to consume enough AA may predispose to AA deficiency. Such a deficiency 
in humans may lead to the onset of scurvy. Scurvy is a disease that affects collagen 
stability (Barnes, 1947; Carpenter, 2012; van Robertson, 1952). AA is a required 
cofactor for a number of enzymes, including prolyl-3-hydroxylase, prolyl-4-
hydroxylase and lysyl-hydroxylase, which are important in the hydroxylation of 
proline and lysine residues of collagen (Murad et al., 1983; Tryggvason et al., 1979). 
In the absence of AA, there is a reduction in hydroxylation of these residues 
resulting in unstable collagen fibres. As a consequence, scurvy leads to brown spots 
on the skin, spongy gums and bleeding from mucous membranes and the patient may 
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be partially immobilised and suffer from fatigue (DelVecchio and Dancea, 2011; 
Olmedo et al., 2006).  
Intestinal absorption of dietary AA is mediated via the sodium-dependent vitamin C 
transporter 1 (SVCT1) expressed on the brush border surface of enterocytes, which 
transports sodium and AA in a 2:1 stoichiometry (Liang et al., 2001; Padayatty et al., 
2004; Tsukaguchi et al., 1999; Verlinde et al., 2008). Upon binding, the SVCT1 
undergoes a conformational change, releasing both sodium and AA into the cell 
(Nualart et al., 2013).  Similarly, the SVCT1 mediates absorption and re-absorption 
of AA in the kidneys and is expressed on renal tubular cells. However, the efflux of 
AA from enterocytes is not fully characterised (Padayatty et al., 2004). Proposed 
mechanisms regarding the efflux of AA from enterocytes include anion channels and 
gap-junctions (Corti et al., 2010; Khatami et al., 1986; Wilson, 2002). Once in 
circulation, the transport of AA across the choroid plexus from the blood into the 
CSF is mediated by the SVCT2 isoform expressed on the basolateral membrane 
(Harrison and May, 2009; Verlinde et al., 2008) (Figure 11). Similarly to SVCT1, 
the SVCT2 transports sodium and AA in a 2:1 stoichiometry and upon sodium and 
AA binding, undergoes a conformation change causing intracellular release 
(Tsukaguchi et al., 1999). As with intestinal AA efflux mechanisms, efflux of AA 
from choroid plexus cells into the CSF is not known (Liang et al., 2001; Padayatty et 
al., 2004). However, there is a 2-4 times higher concentration of AA in CSF 
compared to plasma suggesting that AA release into the CSF may be energy 
dependent (Spector and Johanson, 2010). Within the brain, the SVCT2 is 
ubiquitously expressed and facilitates AA uptake into cells (Caprile et al., 2009; 
Mun et al., 2006). A glutamate-AA heteroexchange system has been proposed for 
AA efflux from cells. The oxidised form of AA, dehydroascorbic acid (DHA), is 
transported across cellular membranes via the facilitative glucose transporters, 
including glucose transporter (GLUT) 1 and 3 (Figure 12) (Hosoya et al., 2008; 
Tsukaguchi et al., 1999). These transporters are ubiquitously expressed throughout 
the body and are present on both the apical and basolateral membranes of BBB cells, 
facilitating transport of DHA from the periphery into the CNS (Du et al., 2012; 
Farrell et al., 1992). Upon entry into brain parenchyma, DHA may either be reduced 
to AA by intracellular glutathione or be released in its oxidised form for reduction at 
a later stage (Lloyd et al., 1972; Washko et al., 1993). 
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Figure 11 Transport of AA across choroid plexus epithelial cells. The SVCT2 transports sodium and AA across the choroid plexus epithelial cell 
in a 2:1 stoichiometry and upon sodium and AA binding, undergoes a conformation change causing intracellular release. The mechanism(s) 
responsible for efflux of AA from choroid plexus cells into the CSF is not known. However, there is a 2-4 times higher concentration of AA in CSF 
compared to plasma suggesting that AA release into the CSF may be energy dependent. Within the brain, the SVCT2 is ubiquitously expressed and 
facilitates AA uptake into cells. In contrast, a glutamate-AA heteroexchange system has been proposed for AA efflux. SVCT2 = sodium dependent 
vitamin C transporter 2; AA = ascorbic acid, Na
+
 = sodium. 
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Figure 12 Transport of DHA across the blood brain barrier. DHA is transported across cellular membranes via the facilitative 
glucose transporters, including GLUT1 and 3. These transporters are expressed on both the apical and basolateral membranes of 
blood brain barrier cells, facilitating transport of DHA from the periphery into the CNS. GLUT = glucose transporter; DHA = 
dehydroascorbic acid. 
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AA, present in the monoanion form at physiological pH, is a ketolactone with two 
ionisable hydroxyl groups (Du et al., 2012). AA acts as a reducing agent and can 
readily undergo two consecutive, one-electron oxidations to form the AA radical and 
DHA (Figure 13) (May et al., 2003). The AA radical is relatively unreactive owing 
to resonance stabilisation of the unpaired electron and can readily oxidise to form 
DHA. However, recycling of AA by reduction of the AA free radical and DHA can 
occur (Arrigoni and De Tullio, 2002). Reduction of the AA free radical can be 
mediated by NADH-cytochrome b5 reductase, which is localised to the outer 
mitochondrial membrane, endoplasmic reticulum and plasma membrane (Ito et al., 
1981). NADH-cytochrome b5 reductase donates one electron to the AA radical, 
which in turn, draws an electron from NADH. The transmembrane AA radical 
reductase in erythrocytes can also use electrons from NADH or intracellular AA to 
regenerate extracellular AA from the AA radical generated in blood, or the AA 
radical generated by the reduction of α-tocoperoxyl radical during lipid oxidation 
(May, 1998; May et al., 2001a). Additionally, the thioredoxin reductase system can 
function as a cytosolic mechanism for AA recycling, however, thioredoxin reductase 
can also catalyse the NADPH-dependent reduction of DHA (Du et al., 2012; May et 
al., 1997; Mendiratta et al., 1998). DHA is mostly recycled by glutathione directly or 
by glutaredoxin in the cytoplasm (May et al., 2001b). 
AA has numerous biological functions. As described above, AA is an essential 
enzyme cofactor for a number of hydroxylase enzymes. These enzymes include 
prolyl-3-hydroxylase, prolyl-4-hydroxylase and lysyl-hydroxylase, required for 
collagen synthesis (Murad et al., 1983; Tryggvason et al., 1979), dopamine β-
hydroxylase, required for the synthesis of noradrenaline from dopamine and 
trimethyllysine dioxygenase and butyrobetaine dioxygenase, required for carnitine 
synthesis (Menniti et al., 1986; Rebouche, 1991). In addition, AA is also one of the 
most abundant, low molecular weight antioxidants, particularly in the CNS. Typical 
concentrations of AA in the plasma of healthy individuals are 40-60 µmol/L, where 
concentrations range from 100-400 µmol/L in CSF and 2-10 mmol/L in neurons 
(Harrison and May, 2009). AA can readily donate one electron to damaging ROS 
including hydroxyl radicals, alkoxyl radicals, peroxyl radicals, thiol radicals and 
tocopheroxyl radicals (Regoli and Winston, 1999; Winston et al., 1998). These one 
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Figure 13 Ascorbic acid metabolism. AA can readily undergo two consecutive, one-electron oxidations to form the AA radical and 
DHA. AA=ascorbic acid. DHA=dehydroascorbic acid. 
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electron donations may result in the formation of the AA radical or DHA, which in 
turn, may be recycled back to AA by the mechanisms described above. Whilst AA 
can act as an antioxidant, AA may also have pro-oxidant effects when present at low 
concentrations (Buettner and Jurkiewicz, 2010; Fisher and Naughton, 2003; Mandl 
et al., 2009) and in the presence of catalytic metals, including iron and copper. For 
example, ferric iron (Fe
3+
) may be reduced to ferrous iron (Fe
2+
) by AA, which in 
turn, may react with AA to produce hydrogen peroxide in a system termed the 
Weissberger system (Weissberger et al. 1943). As a result, subsequent cycles of the 
Fenton reaction may ensue resulting in the generation of the hydroxyl radical 
(Hamilton et al., 1964). Importantly, the pro-oxidant effects of AA are dependent on 
the availability of catalytic metals in vivo. Whilst iron is sequestered by iron binding 
proteins such as transferrin and ferritin, biological reductants such as thiols and AA, 
may release iron from these proteins for cytochrome and iron-containing enzyme 
synthesis (Boyer and McCleary, 1987; Somjai et al., 1974). Moreover, the high iron, 
and, to a lesser extent, copper content in the brain, and the low free iron binding 
capacity in CSF, as previously described in this section, may increase transition 
metal availability (Bleijenberg et al., 1971; Bradbury, 1997; Harrison et al., 1968). 
Under these conditions and in the presence of low AA concentration, the formation 
of the hydroxyl radical may be more likely, which in turn, may induce oxidative 
stress. 
Interestingly, in patients with KSS and secondary CFD, it has been predicted that 
CSF AA concentrations may be low (Spector and Johanson, 2010). This suggestion 
is supported by the combination of prominent anatomical changes, which may be 
present in the choroid plexus of patients with KSS (Tanji et al., 2000), and an energy 
deficit impeding the proposed active transport mechanism of molecules across the 
apical membrane of the choroid plexus cells (Garcia-Cazorla et al., 2008; 
Hasselmann et al., 2010; Hyland et al., 2010), such as AA. Given the biological 
function of AA as a pro-oxidant when present at low concentrations, a decrease in 
antioxidant capacity and a potential increase in hydroxyl radical generation could 
lead to exacerbation of oxidative stress and promote oxidative catabolism of 5-
MTHF. In addition, AA availability could be a factor in governing 5-MTHF 
stability. 
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1.7 Hypotheses 
1. CFD is an under-recognised condition in patients with mitochondrial disease. 
2. 5-MTHF is vulnerable to oxidative catabolism in the presence of ROS. 
3. AA protects against oxidative catabolism of 5-MTHF in the CNS. 
4. Reduced mitochondrial RCE activity and/or high selenium levels in 
mitochondrial disease induces oxidative stress which is responsible for 
secondary CFD. 
1.8 Aims 
1. To determine the prevalence and significance of CFD in mitochondrial RCE 
deficiencies. 
2. To examine the stability of 5-MTHF in CSF in the presence and absence of 
hydroxyl radicals or selenite. 
3. To examine the ability of AA to confer 5-MTHF stability. 
4. To investigate (i) mitochondrial RCE inhibition and (ii) selenite treatment on 
the stability of extracellular 5-MTHF in a cellular system. 
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Chapter 2  
Materials and Methods  
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2. Materials and Methods 
2.1 Materials 
The following were purchased from Sigma Aldrich (Poole, UK): 
Ethylenediaminetetraacetic acid (EDTA); 1,4-dithiothreitol (DTT); 1,4-
dithioerythritol (DTE); sodium octyl sulphate; L-glutathione reduced (GSH); pall 
nanosep® centrifugal device with omega membrane (10 kDa); 5-
methyltetrahydrofolate (5-MTHF) sodium salt; L-ascorbic acid (AA); sodium 
selenite; metaphosphoric acid; dehydroascorbic acid; sodium bicarbonate; sodium 
chloride; calcium chloride; magnesium sulphate; D-glucose; sodium phosphate 
monobasic; magnesium chloride; tris base; tris-HCl; sterile modified Hank’s 
balanced salt solution with sodium bicarbonate without phenol red, calcium chloride 
or magnesium sulphate (HBSS); sodium dodecyl sulphate (SDS); triton-X 100; 
sterile 4 ml/L trypan blue; β-nicotinamide adenine dinucleotide reduced (β-NADH); 
potassium cyanide (KCN); ubiquinone; cytochrome c; rotenone; ferricyanide; acetyl 
coenzyme-A (acetyl CoA); 5,5’-dithio-bis (nitrobenzoic acid) (DNTB); oxaloacetate; 
Folin-Ciocalteu phenol reagent; copper sulphate pentahydrate; tartrate; sodium 
carbonate; bovine serum albumin (BSA); ethidium bromide; iron (III) sulphate; 
hydrogen peroxide. 
The following were purchased from VWR International Ltd (Lutterworth, UK): 
Methanol HiPerSolv for HPLC; ethanol HiPerSov for HPLC; disodium hydrogen 
orthophosphate; potassium dihydrogen orthophosphate; sodium hydroxide; 
orthophosphoric acid HPLC electrochemical grade; hydrochloric acid; potassium 
dihydrogen phosphate; dipotassium hydrogen phosphate; dimethyl sulphoxide 
(DMSO); betaine hydrochloride; agarose; tris-borate-EDTA (TBE) buffer x10 
concentrate; Exonuclease I Shrimp Alkaline Phosphatase (ExoSAP) for PCR clean-
up. 
The following were purchased from Invitrogen Ltd (Paisley, UK): 
Dulbecco’s modified Eagle’s Medium/Ham’s F-12 Nutrient mixture (DMEM/F-12) 
(1:1); L-glutamine; fetal bovine serum (FBS) heat inactivated; 2.5 g/L trypsin-
EDTA; MitoSOX
TM
 Red. 
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The following were purchased from Bioline Reagents Ltd (London, UK): 
BIOTAQ DNA polymerase; x10 NH4 (ammonium) buffer; deoxynucleotide 
triphosphates (dNTPs; 2.5 mmol/L); magnesium chloride (50 mmol/L); crystal x5 
DNA loading buffer (bromophenol) blue. 
The following were purchased from Chromacol (Welwyn Garden City, UK): 
HPLC crimp top tapered vials (200 µl); HPLC aluminium crimp caps 
(rubber/PTFE). 
The following were purchased from Anachem Ltd (Luton, UK): 
PCR tube Ind At Dom Cap 0.2 ml vial. 
All other materials and reagents were analytical grade and purchased from Sigma 
Aldrich or VWR International, except where stated. 
2.2 Patient samples 
All patient samples were obtained as part of diagnostic investigations requested by 
the patient’s clinician and after informed consent. 
2.2.1 Cerebrospinal fluid 
CSF samples were taken following lumbar puncture, immediately frozen in liquid 
nitrogen at the bedside according to standard written instructions and stored at -80°C 
until analysis. A proforma for clinical information and drug history was completed 
by the clinician at the time of sampling and returned with the CSF sample. 
Redundant CSF samples remaining after diagnostic investigations had been 
performed in the Neurometabolic Unit at the National Hospital for Neurology and 
Neurosurgery, London, UK, were anonymised and used throughout this thesis. 
Disease control CSF was defined as being sourced from patients with no evidence of 
conditions relating to an inborn error of 5-MTHF metabolism or a leukodystrophy. 
CSF samples underwent a maximum of two freeze-thaw cycles and blood-stained 
samples were excluded. 
2.2.2 Skeletal muscle 
Open skeletal muscle biopsies (50-100 mg) were taken, immediately frozen in liquid 
nitrogen at the bedside according to standard written instructions and stored at -80°C 
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until analysis. A proforma for clinical information and drug history was completed 
by the clinician at the time of sampling and returned with the skeletal muscle sample. 
Diagnostic investigations were performed in the Neurometabolic Unit at the National 
Hospital for Neurology and Neurosurgery, London, UK. 
2.3 Measurement of 5-MTHF by high performance liquid chromatography  
CSF 5-MTHF reference ranges used in the Neurometabolic Unit at the National 
Hospital for Neurology and Neurosurgery, London, UK, are given in Table 5. 
2.3.1 Function 
5-MTHF was quantified using reverse-phase HPLC with fluorescence detection. 
Reverse-phase HPLC utilises a non-polar stationary phase and an aqueous mobile 
phase to separate analytes. Non-polar molecules tend to adsorb to the stationary 
phase and are retained on the HPLC column longer than polar molecules. 
Fluorescence detection uses different excitation and emission wavelengths of light, 
specific for the analyte of interest. At the excitation wavelength, the analyte adsorbs 
light and is excited, transitioning from a ground state level to a higher electronic 
state. Once the analyte has reached its highest electronic state, the analyte begins to 
lose energy. As the analyte decays to ground state levels, the analyte fluoresces and 
emits light at a longer wavelength. The emission wavelength is detected and is 
directly proportional to the quantity of analyte in the sample. The signal is amplified 
and recorded using data acquisition software (Lough and Wainer, 1996). 
2.3.2 Equipment 
PU-1580 Intelligent HPLC pump (Jasco UK Ltd., Great Dunmow, UK); AS-1555 
intelligent autosampler (Jasco); FP-920 intelligent fluorescence detector (Jasco); CO-
1560 column oven (Jasco). The mobile phase was degassed using a DG-1580-53 3 
line degasser (Jasco). The fluorescence detector was connected to a computer and 
data was recorded using EZChrom Elite data capture and analysis software (Agilent 
Technologies UK Limited, Stockport, UK). The equipment was assembled as shown 
in Figure 14. 
2.3.3 Analytical procedure 
The method was based on the diagnostic method routinely used to quantify 5-MTHF 
in CSF in the Neurometabolic Unit at the National Hospital for Neurology and 
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Neurosurgery, London, UK, adapted from the published method of (Ormazabal et 
al., 2006). Analysis of 5-MTHF in CSF was performed in the second 0.5 ml CSF 
sample. Samples underwent a maximum of two freeze-thaw cycles. Blood-stained 
samples were excluded from analysis owing to the risk of contamination by 
erythrocyte derived 5-MTHF contamination and iron release, which could propagate 
the hydroxyl radical via the Fenton reaction (Fenton, 1894; Heales et al., 1988). This 
would lead to oxidative catabolism of 5-MTHF and subsequent anomaolous results. 
The mobile phase consisted of 0.05 mol/L monopotassium phosphate, 54 µmol/L 
EDTA and 14% v/v HPLC grade methanol in ultrapure water, adjusted to pH 4.77 
with sodium hydroxide. The flow rate was set at 1.3 ml/min. Samples were thawed, 
transferred to vials and loaded into the autosampler. Each sample (50 µL) was 
injected into the flow and separated on a reverse phase 250 x 4.6 mm i.d. HiQSil 
C18W column (KYA Tech. Corp. Tokyo, Japan), maintained at 35°C. 5-MTHF was 
detected by fluorescence detection. The excitation wavelength and the emission 
wavelength were set at 290 nm and 358 nm, respectively. Samples were quantified 
against an external standard of 100 nmol/L 5-MTHF prepared in a 0.1 mg/ml DTE 
solution. A quality control was prepared by pooling CSF from previous patients with 
no evidence of an inborn error of 5-MTHF metabolism or leukodystrophy. Results of 
the internal quality control were recorded. Data obtained from samples were kept 
within ±2 standard deviations of the measured values of the current quality control. 
A calibration curve was performed to determine the linearity between the 
fluorescence spectra and standard concentration (Figure 15). Linearity was 
demonstrated between 0-100 nmol/L. Example chromatograms of a 5-MTHF 100 
nmol/L standard and 5-MTHF in CSF are presented in Figure 16.  
2.3.4 Data analysis 
5-MTHF data were visualised and quantified using EZChrom Elite data capture and 
analysis software (Agilent Technologies) using the following equation: 
Concentration (nmol/L) = 
(sample peak area/external standard peak area) x calibration standard 
concentration (nmol/L) 
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Figure 15 5-MTHF calibration curve. The linearity of 5-MTHF concentration was 
demonstrated between 0–100 nmol/L. Samples were prepared in air saturated 
conditions at ambient temperature. Samples were analysed by reverse-phase HPLC 
with fluorescence detection as described in section 2.3. All values are mean ± SEM of 
4 independent experiments, r
2
=0.99. 
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Figure 16 Sample chromatograms of 5-MTHF. a. 5-MTHF peak in a 100 nmol/L 
standard solution and b. 5-MTHF peak in CSF. 5-MTHF retention time ~16 min. 
b. 
a. 
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2.4 SH-SY5Y cell culture 
2.4.1 SH-SY5Y cell line 
The SK-N-SH cell line was originally established in 1973 from a bone-marrow 
biopsy of a four-year-old female patient with a neuroblastoma of the chest (Biedler 
et al., 1973). The cell line contained two distinct cell types, a neuroblast- like cell 
and an epithelial-like cell. The neuroblast-like cell types were subcloned sequentially 
to SH-SY, then to SH-SY5 and finally to SH-SY5Y. The SH-SY5Y cells have 
neuroblast-like morphology and retain neurite-like processes (Figure 17). The cells 
are robust and are capable of proliferating exponentially for long periods of time 
without contamination. 
The SH-SY5Y cell line has been extensively utilised as a model for neurological 
research, including studies exploring the underlying pathophysiology of Parkinson’s 
disease and Alzheimer’s disease (Cheung et al., 2009; Presgraves et al., 2004).   
2.4.2 Cell storage 
SH-SY5Y cells were obtained from the European Collection of Cell Cultures (Health 
Protection Agency, Salisbury, UK) and cultured in accordance with the supplier’s 
instructions. Cells were seeded at 1 x 10
4
 cells/cm
2
 in a 75 cm
2
 tissue culture flask in 
DMEM/F-12 supplemented with 100 ml/L fetal bovine serum (FBS) and 5 mmol/L 
L-glutamine. Cells were grown at +37°C in 5% CO2. Cell culture medium was 
replaced the day after seeding and every 48 hours thereafter. Cells were passaged at 
80-90% confluence approximately every 6 days. For cell passage, medium was 
removed from the flask and cells were washed once with 10 ml Hank’s balance salt 
solution (HBSS) at +37°C. Cells were lifted from each flask with 6 ml 2.5 g/L 
trypsin, 0.38 g/L EDTA in HBSS (trypsin-EDTA) incubated at +37°C for 3 minutes. 
Trypsin-EDTA bathed cells were diluted with 8 ml DMEM/F-12, harvested and 
centrifuged at 500x g for 5 minutes at +20°C. Supernatant was removed and cells 
resuspended in DMEM/F-12 + 100 ml/L FBS + 5 mmol/L L-glutamine. An aliquot 
of cell suspension, 10 µl, was mixed 1:1 with 4 g/L trypan blue and counted using a 
Countess Automated Cell Counter (Invitrogen Ltd). Cells of passage number 17 to 
19 were stored at a density of 1 x 10
6
 cells/ml in 300 ml/L FBS, 100 ml/L   
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Figure 17 SH-SY5Y cells. An image of SH-SY5Y cells under a light microscope. The 
cells have neuroblast-like morphology and retain neurite-like processes. 
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DMSO and 700 ml/L DMEM/F-12 as 1 ml aliquots. Cells were frozen to -80°C 
using an isopropanol freezing vessel for 24 hours and then transferred to liquid 
nitrogen for storage. 
2.4.3 Cell recovery and passage 
Cells were recovered from the liquid nitrogen and seeded at a density of 1 x 10
4
 
cells/cm
2
 in 75 cm
2
 flasks. Cells were grown in DMEM/F-12 + 100 ml/L FBS + 5 
mmol/L L-glutamine at +37°C in 5% CO2. Cell culture medium was replaced the 
day after seeding and every 48 hours thereafter. Cells were passaged at 80-90% 
confluence. For cell passage, medium was removed from the flask and cells were 
washed once with 10 ml HBSS at +37°C. Cells were lifted from each flask with 6 ml 
trypsin-EDTA incubated at +37°C for 3 minutes. Trypsin-EDTA bathed cells were 
diluted with 8 ml DMEM/F-12, harvested and centrifuged at 500x g for 5 minutes at 
+20°C. Supernatant was removed and cells resuspended in DMEM/F-12 + 100 ml/L 
FBS + 5 mmol/L L-glutamine. An aliquot of cell suspension, 10 µl, was mixed 1:1 
with 4 g/L trypan blue and counted using a Countess Automated Cell Counter 
(Invitrogen Ltd). Cells were seeded at 1 x 10
4
 cells/cm
2
 in a 75 cm
2
 tissue culture 
flask in DMEM/F-12 + 100 ml/L FBS + 5 mmol/L L-glutamine. Cells were grown at 
+37°C in 5% CO2. Cell culture medium was replaced the day after seeding and every 
48 hours thereafter. Cells were passaged as above at 80-90% confluence 
approximately every 6 days. In order to maintain experimental consistency, cells of 
passage number 19 to 24 were used throughout. 
2.4.4 Cell seeding for experiments 
For experiments, cells were seeded in 75 cm
2
 flasks at a density of 5.3 x 10
4
 
cells/cm
2
. Cells were incubated in DMEM/F-12 + 100 ml/L FBS + 5 mmol/L L-
glutamine at +37˚C in 5% CO2 and left to stabilise and attach for 24 hours prior to 
each experiment.  
2.4.5 Minimal medium harvesting for 5-MTHF quantification by HPLC 
Minimal medium consisted of 44 mmol/L sodium bicarbonate, 110 mmol/L sodium 
chloride, 1.8 mmol/L calcium chloride, 5.4 mmol/L magnesium sulphate, 0.92 
mmol/L sodium phosphate monobasic and 5 mmol/L D-glucose prepared in sterile 
cell culture grade water adjusted to pH 7.4 with CO2. Following incubation with 
cells, minimal medium aliquots of 120 µl were removed and immediately snap 
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frozen in liquid nitrogen. Samples were stored at -80°C until analysis by HPLC as 
described in section 2.3. 
2.4.6 SH-SY5Y cell harvesting for mitochondrial respiratory chain 
complex assays 
Following treatment, cells were washed once with 10 ml HBSS and lifted with 6 ml 
trypsin-EDTA at +37°C for 3 minutes. Trypsin-EDTA bathed cells were diluted with 
8 ml DMEM/F-12 + 100 ml/L FBS + 5 mmol/L L-glutamine, harvested and 
centrifuged at 500x g for 5 minutes at +4°C. The supernatant was removed and the 
cells were washed by resuspension in 10 ml HBSS at +4°C. Samples were 
centrifuged at 500x g for 5 minutes at +4°C. The supernatant was removed and the 
cells were resuspended in isolation buffer (600 l) consisting of 10 mmol/L tris (pH 
7.4), 1 mmol/L EDTA, 320 mmol/L sucrose in HPLC grade water. Each cell sample 
(200 l) was stored at -80°C in three aliquots, one for the complex of interest, one 
for citrate synthase and one for total protein. Immediately prior to analysis, each 
aliquot was thawed at +37°C and immediately snap frozen in liquid nitrogen three 
times in order to lyse the cells. Samples were analysed as described in section 2.5 
and 2.6. 
2.4.7 SH-SY5Y cell harvesting for mitochondrial superoxide estimation by 
flow cytometry 
Following treatment, cells were washed once with 10 ml HBSS and lifted with 6 ml 
trypsin-EDTA incubated at +37°C for 3 minutes. Trypsin-EDTA bathed cells were 
diluted with 8 ml DMEM/F-12 + 100 ml/L FBS + 5 mmol/L L-glutamine, harvested 
and centrifuged at 500x g for 5 minutes at +4°C. The supernatant was removed and 
the cells were washed by resuspension in 10 ml HBSS at +4°C. Samples were 
centrifuged at 500x g for 5 minutes at +4°C. The supernatant was removed and the 
cells were resuspended in 600 uL HBSS. Samples were analysed immediately by 
flow cytometric analysis as described in section 2.7.  
2.5 Mitochondrial respiratory chain enzyme assays 
Mitochondrial RCE activity reference ranges in skeletal muscle used in the 
Neurometabolic Unit at The National Hospital for Neurology and Neurosurgery, 
London, UK, are given in Table 7.  
109 
 
Table 7 Mitochondrial RCE activity (ratio to citrate synthase activity) reference 
ranges in skeletal muscle. These reference ranges are used in the 
Neurometabolic Unit at The National Hospital for Neurology and Neurosurgery, 
London, UK. 
 
  
Mitochondrial RCE activity reference ranges 
Mitochondrial RCE Activity (ratio to citrate synthase) 
Complex I 0.104-0.268 
Complex II/III 0.040-0.204 
Complex IV 0.014-0.034 
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2.5.1 Function 
A spectrophotometer is an instrument which measures the amount of light absorbed 
by a medium at a specified wavelength. According to the Beer-Lambert law, the 
amount of light absorbed by a medium is proportional to the concentration of the 
solute present. Light from a source is passed through a monochromator in order to 
produce the analytical spectrum, which in turn is passed through a wavelength 
selector. At a specific wavelength the beam passes through the sample and is 
detected on a photocell detector. The signal from the detector is amplified and 
digitally represented (Williams, 1995). 
2.5.2 Equipment 
Analysis of samples was carried out using a Uvikon XL spectrophotometer 
(Secomam, Ales, France). 
2.5.3 Procedure 
All complex and citrate synthase assays were carried out at a total protein 
concentration of 2 mg/ml (see section 2.6). 
2.5.3.1 Complex I (NADH:ubiquinone oxidoreductase) (EC 1.6.5.3)  
The complex I assay was based on the method by (Ragan et al., 1987). The method 
measures the oxidation of NADH as a decrease in absorbance at a starting 
wavelength of 340 nm, during the reduction of ubiquinone to ubiquinol by complex 
I. The proportion of NADH oxidation, which is independent of complex I, is 
determined using the specific complex I inhibitor rotenone. Sample (50 l) was 
added to a 1 ml cuvette containing a final concentration of 2.5 mg/ml BSA, 0.15 
mmol/L -NADH, 1 mmol/L KCN in 20 mmol/L potassium phosphate buffer (pH 
7.2) and 8 mmol/L magnesium chloride in HPLC grade water. 
The reaction was started following the addition of 10 l 5 mmol/L ubiquinone to the 
sample cuvette. The final concentration of ubiquinone in the cuvette was 50 M and 
the final volume in the cuvette was 1 ml. The reaction was measured at 340 nm at 
30-second intervals for 5 minutes at +30C. Rotenone (1 mmol/L; 20 l) was added 
to the sample cuvette. The final concentration of rotenone in the cuvette was 20 M. 
Measurement was continued for a further 5 minutes. Each sample cuvette was run 
against a reference cuvette. The reference cuvette contained all the components of 
111 
 
the sample cuvette except ubiquinone. A specific value for complex I was calculated 
by subtracting the change in absorbance at 340 nm following rotenone addition from 
the change in absorbance at 340 nm before rotenone inhibition. Absorbance was 
converted to molar concentration using the NADH extinction coefficient, 6.81 x 10
3
 
M
-1
 cm
-1
 (path length 1 cm, volume 1 ml), taking account of ubiquinone, using a re-
arrangement of the Beer-Lambert law: 
ΔA = c 
ε 
 
Where ΔA is the specific change in absorbance; ε = extinction coefficient; and c = 
mole/min/ml. Results are expressed as nmol/min/mg of protein or as a ratio to citrate 
synthase activity. A calibration curve was performed to determine the linearity 
between complex I activity and protein concentration. Linearity was demonstrated 
between a protein concentration range of 0-2.5 mg/ml (Figure 18). 
2.5.3.2 Complex II/III (Succinate:ubiquinone oxidoreductase, 
ubiquinol:cytochrome c oxidoreductase) (EC 1.3.5.1 + EC 1.10.2.2) 
Complex II/III activity was measured by Dr Iain Hargreaves in the Neurometabolic 
Unit laboratory at the National Hospital for Neurology and Neurosurgery, London, 
UK and patient results were analysed retrospectively, as indicated. 
The complex II/III assay was based on the method of (King, 1967). During the 
oxidation of succinate to fumarate, complex II reduces ubiquinone to ubiquinol. 
Ubiquinol is an electron donor and reduces cytochrome c. This reaction is catalysed 
by complex III. The complex II/III assay measures the succinate dependent reduction 
of cytochrome c by measuring the increase in absorbance at 550 nm. The complex 
III inhibitor, antimycin A, is used to determine the proportion of cytochrome c 
reduction which is independent of complex II/III activity. A complex II/III activity 
value is generated by subtracting the change in absorbance at 550 nm following the 
addition of antimycin A from the change in absorbance at 550 nm before antimycin 
A addition. Absorbance was converted to molar concentration using Beer-Lambert 
law (see section 2.5.3.1) and the cytochrome c extinction coefficient, 19.2 x 10
3
 M
-1
 
cm
-1
. Results are expressed as a ratio to citrate synthase activity. 
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Figure 18 Complex I calibration curve. The linearity of complex I activity was 
demonstrated between a protein concentration range of 0–2.5 mg/ml. Samples were 
prepared in air saturated conditions at ambient temperature. Samples were analysed as 
described in section 2.5.3.1. All values are mean ± SEM of 3 independent 
experiments, r
2
=0.99. 
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2.5.3.3 Complex IV (Cytochrome c oxidase) (EC 1.9.3.1) 
The complex IV assay was based on the method of (Wharton and Tzagoloff, 1967). 
The method measures the oxidation of cytochrome c catalysed by complex IV. To 
obtain reduced cytochrome c, a few ascorbic acid crystals are added to 0.8 mol/L 
oxidised cytochrome c in HPLC grade water. A PD10 desalting column equilibrated 
with 50 ml of 10 mmol/L potassium phosphate buffer (pH 7.0) in HPLC grade water 
was used to remove the ascorbic acid from the reduced cytochrome c. Reduced 
cytochrome c (50 µl) was added to 950 µl of HPLC grade water in a reference and 
sample cuvette. The sample cuvette was blanked against the reference cuvette at 550 
nm. Cytochrome c in the reference cuvette was oxidised using 10 µl of 100 mmol/L 
ferricyanide. The final concentration of ferricyanide in the cuvette was 1 mmol/L. 
The absorbance was recorded after 1 minute and used to determine the concentration 
of reduced cytochrome c. The concentration of cytochrome c was calculated using 
the Beer-Lambert law (see section 2.5.3.1). The extinction coefficient used for 
cytochrome c was 19.2 x 10
3
 M
-1
 cm
-1
 (path length 1 cm, volume 1 ml). Reduced 
cytochrome c prepared at a final concentration of 50 µmol/L was added to a sample 
and reference cuvette containing potassium phosphate buffer (pH 7.0) at a final 
concentration of 10 mmol/L in HPLC grade water. The sample cuvette was blanked 
against the reference cuvette at 550 nm. Ferricyanide (100 mmol/L; 10 µl) was 
added to the reference cuvette to oxidise cytochrome c. The final concentration of 
ferricyanide in the cuvette was 1 mmol/L. The reaction was started following the 
addition of 40 µl of sample to the sample cuvette. The change in absorbance at 550 
nm was measured over a 3 minutes at +30°C. The reaction of complex IV with 
cytochrome c follows first-order kinetics since it is dependent on the concentration 
of cytochrome c. Therefore, activity is expressed as a first order rate constant (k). 
The rate constant (k) is calculated by plotting the natural log of absorbance against 
time and determining the slope. Results are expressed as k/min/mg of protein or 
k/mol when expressed as ratio to citrate synthase activity. A calibration curve was 
performed to determine the linearity between complex IV activity and protein 
concentration. Linearity was demonstrated between a protein concentration range of 
0-2.5 mg/ml (Figure 19). 
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Figure 19 Complex IV calibration curve. The linearity of complex IV activity was 
demonstrated between a protein concentration range of 0–2.5 mg/ml. Samples were 
prepared in air saturated conditions at ambient temperature. Samples were analysed as 
described in section 2.5.3.3. All values are mean ± SEM of 3 independent 
experiments, r
2
=0.99. 
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2.5.3.4 Citrate synthase (EC 2.3.3.1) 
Citrate synthase catalyses the condensation of oxaloacetate and acetyl-coenzyme A 
to form citric acid and coenzyme A in the first step of the Krebs cycle, which takes 
place in the mitochondrial matrix. Citrate synthase activity is commonly used as a 
measure of mitochondrial enrichment (Almeida and Medina, 1998; Hargreaves et al., 
1999). The citrate synthase assay was based on the method of (Shepherd and 
Garland, 1969). The assay measures the production of coenzyme A as a result of a 
reaction between free coenzyme A with DTNB. Sample (10 µl) was added to a 
cuvette containing a final concentration of 0.1 mmol/L acetyl-coenzyme A, 0.2 
mmol/L DTNB in 100 mmol/L tris (pH 8.0), 1 g/L triton X-100 in HPLC grade 
water. The reaction was started following the addition of 10 µl of 20 mmol/L 
oxaloacetate. The final concentration of oxaloacetate in the cuvette was 0.2 mmol/L. 
The reaction was measured at 412 nm for 5 minutes at 30 second intervals at +30°C. 
The absorbance was converted to molar concentration using the Beer-Lambert law 
(see section 2.5.3.1). The extinction coefficient used for DTNB was 13.6 x 10
3
 M
-1
 
cm
-1
 (path length 1 cm, volume 1 ml). Results are expressed as nmol/min/mg of 
protein. A calibration curve was performed to determine the linearity between citrate 
synthase activity and protein concentration. Linearity was demonstrated between a 
protein concentration range of 0-2.5 mg/ml (Figure 20). 
2.5.4 Data analysis 
All data were captured and analysed using Lab Power Junior (Secomam). 
2.6 Total protein assay 
2.6.1 Function 
See section 2.5.1. 
2.6.2 Equipment 
Analysis of samples was carried out using a Uvikon XL spectrophotometer 
(Secomam, Ales, France). 
2.6.3 Procedure 
Total protein was measured using the Lowry-Peterson protein assay method (Lowry 
et al., 1951; Peterson, 1977). All samples were diluted in HPLC grade water and 
prepared in 4.5 ml cuvettes. A 5-point standard curve was prepared for each assay to  
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Figure 20 Citrate synthase calibration curve. The linearity of citrate synthase activity 
was demonstrated between a protein concentration range of 0–2.5 mg/ml. Samples 
were prepared in air saturated conditions at ambient temperature. Samples were 
analysed as described in section 2.5.3.4. All values are mean ± SEM of 3 independent 
experiments, r
2
=0.99. 
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determine the linearity between absorbance and protein concentration. Linearity was 
demonstrated between a BSA concentration range of 0-40 μg/ml, using a 200 µg/ml 
BSA stock (Figure 21). Total protein in the BSA standards ranged from 0-40 µg. 
Sample (10 µl) and HPLC grade water (990 µl) was added to each sample cuvette. A 
solution of copper-tartrate-carbonate (CTC) was prepared by adding 0.2% copper 
sulphate pentahydrate, 0.4% tartrate and 20% sodium carbonate to HPLC grade 
water. A 1:1:1:1 ratio of CTC, 10% sodium dodecyl sulphate (SDS), 0.8 mol/L 
sodium hydroxide and HPLC grade water was prepared. This was called reagent A. 
A 5:1 ratio of HPLC grade water to Folin-Ciocalteu phenol reagent was also 
prepared. This was called reagent B. Reagent A (1 ml) was added to each cuvette 
and left to incubate at room temperature for 10 minutes. Reagent B (0.5 ml) was then 
added to every cuvette and left to incubate at room temperature for 30 minutes. After 
incubation, absorbance was measured at a fixed wavelength of 750 nm. 
2.6.4 Data analysis 
All data were captured and analysed using Lab Power Junior (Secomam). Total 
protein in the unknown samples was determined from linear regression of the 
unknown sample absorbance units against the BSA standard line. 
2.7 Flow cytometry for mitochondrial superoxide estimation 
2.7.1 Function 
Flow cytometry is a technique most commonly used for cell counting and sorting. 
Flow cytometry relies on the movement of cells in suspension past a detector which 
can measure cell size, granularity and fluorescence, if fluorescent markers have been 
utilised in the experiment. Specifically, measurement of fluorescent cells is termed 
fluorescence activated cell sorting (FACS). The prepared cell sample is taken up 
from the FACS tube under pressure and transported into the flow cell. In the flow 
cell, the cell sample combines with the sheath fluid. At high pressure, the sheath 
fluid containing the cell sample is passed through a narrow chamber allowing the 
cells to pass through the light source for sensing in single file. As the cells pass 
through the light source, they scatter light. Scattered light is collected by the forward 
and side collection lenses, which provides the forward scatter (FSC) and side scatter 
data (SSC). These refer to cell size and granularity respectively and provide  
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Figure 21 BSA calibration curve. The linearity of BSA was demonstrated between a 
BSA concentration range of 0–40 ug/ml. Samples were prepared in air saturated 
conditions at ambient temperature. Samples were analysed as described in section 
2.6.3. All values are mean ± SEM of 3 independent experiments, r
2
=0.99. 
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information on cell morphology and viability. The FSC and SSC is passed on to the 
light detector which generates an electrical pulse. If cells are tagged with a 
fluorescent marker, cells emit fluorescence as they pass through the light source. The 
emitted fluorescence passes through filters depending on the excitation and emission 
wavelengths of the fluorophore and is detected by fluorescent detectors. Similarly, 
the fluorescent detector generates an electrical pulse. When the electrical pulse 
exceeds the threshold limit, the signal is amplified, recorded by the data acquisition 
software on a computer and an “event” is counted. Once a certain number of events 
have been counted, the data can be analysed (Ormerod, 2000). 
2.7.2 Equipment 
Analysis of samples was carried out using a Beckton Dickenson LSR II flow 
cytometer (BD Biosciences). 
2.7.3 Procedure 
Cells were harvested as described in section 2.4.7. Reactive oxygen species (ROS) 
were estimated using MitoSOX
TM
 Red (see section 6.5). MitoSOX
TM
 Red indicator 
is a derivative of dihydroethidium. The cationic triphenylphosphonium substituent of 
the indicator is responsible for the electrophoretically driven uptake of the probe in 
actively respiring mitochondria. Oxidation of MitoSOX
TM
 Red indicator by 
superoxide results in hydroxylation of the molecule, producing a 2-hydroxyethidium 
MitoSOX
TM
 Red derivative. This molecule exhibits a fluorescence excitation peak at 
~400 nm. No products of ethidium oxidation mediated by other ROS are excited 
within this spectrum. For MitoSOX
TM
 Red fluorescence, the argon laser (L1) was 
utilised and the excitation and emission wavelengths of the FL3 Red channel (PE-
Texas Red®), 488 nm and 615 nm respectively, were set. For each sample, cells 
were acquired by the flow cytometer and 10,000 events were counted. 
2.7.4 Data analysis 
Data were analysed using FACSDiva software (BD Biosciences). Mean fluorescence 
intensity was generated for each sample and recorded. 
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2.8 Molecular biology 
2.8.1 Polymerase chain reaction  
2.8.1.1 Function 
Polymerase chain reaction (PCR) was used to exponentially amplify specific regions 
of genomic DNA. Generally, PCR amplifies fragments of genomic DNA between 
0.1-10 kilobase pairs in size. PCR primers, complementary to the 5’ end of the 
coding strand and 3’ end of the non-coding strand, were designed specifically to the 
gene of interest. PCR consists of a series of temperature controlled cycles. Each 
cycle consists of a number of steps. 1. An initialisation step which activates the DNA 
polymerase. 2. A denaturation step which disrupts the hydrogen bonds between 
complementary bases yielding two single-stranded DNA molecules. 3. An annealing 
step which allows annealing of the PCR primers to the single-stranded DNA 
template. 4. An extension/elongation step where DNA polymerase synthesises a new 
DNA strand complementary to the DNA template strand by adding dNTPs to 
complementary bases. 5. After the last PCR cycle, a final elongation step may be 
performed to ensure any remaining single-stranded DNA is fully extended in the 
reaction tube. 6. To allow for short term storage of the PCR product, a final hold step 
may be performed where the reaction tube is kept at 15°C for a period of time 
(Mullis et al., 1986; Strachan et al., 2011). 
2.8.1.2 Equipment 
Genomic DNA concentrations were measured using a Nanodrop 1000 
Spectrophotometer (Thermo Scientific, North Carolina, USA). PCR was carried out 
using a Veriti 96-well Thermal Cycler (Applied Biosystems, Paisley, UK). 
2.8.1.3 Procedure 
Genomic DNA concentration was measured and adjusted to a concentration of 50-
200 ng/PCR reaction. Each PCR sample was prepared in a 0.2 ml PCR tube 
containing x10 NH4 buffer, DMSO, 125 mmol/L betaine, 50-200 ng DNA, 125 
µmol/L dNTP mix, 0.1 µl BIOTAQ, 2.5 mmol/L MgCl2, 5 µmol/L forward (5’) 
primer, 5 µmol/L reverse (3’) primer, made up to 20 µl in ultra-pure double distilled 
water. In place of patient DNA, negative control samples were prepared using 
surplus genomic DNA from a different patient found not to have DNA mutations in 
the gene of interest (wild-type). In a similar fashion, negative control samples were 
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prepared using ultra-pure double distilled water. In order to ensure uniformity of 
conditions in each reaction tube, a master mix containing the necessary reagents was 
prepared prior to the addition of DNA or ultra-pure double distilled water. A 
reference DNA sequence for FOLR1 was obtained from the open source 
bioinformatics genome browser database Ensembl (http://www.ensembl.org) and the 
primers for the gene were designed using the open source bioinformatics programme 
Primer3Plus (http://www.primer3plus.com). The primers used to amplify the FOLR1 
gene encoding the FRα were as follows: 
Exon 1:   Non-coding sequence 
Exon 2:  Non-coding sequence 
Exon 3:  Non-coding sequence 
Exon 4:  5’-AAGGCATTGTGGACCTATGG-3’ 
3’-CAGGATGGGTCACTCCAACT-5’ 
Exon 5:  5’-TACAAGTCCCCATCCGTCTC-3’ 
3’-TCATGGCTGCAGCATAGAAC-5’ 
Exon 6 + 7: 5’-CAGTTCTATTCGGGGCTGAGT-3’ 
3’-TCCTGGGCTTGGCTCTAGATTG-5’ 
The PCR conditions were one cycle of initial denaturation at +95C for 2 minutes, 
followed by 36 cycles of denaturation at +95C for 30 seconds, annealing at +57C 
for 30 seconds and elongation at +72C for 1 minute, followed by one cycle of final 
elongation at +72C for 3 minutes and final hold/cooling down at +15C for 5 
minutes. The PCR products were then immediately resolved by 1% agarose gel 
electrophoresis. 
2.8.2 Resolution of PCR products 
2.8.2.1 Function 
Agarose gel electrophoresis was used to separate the PCR products. Gel 
electrophoresis separates protein fragments based on their size and charge. 
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Application of an electric field moves the negatively charged molecules through the 
agarose matrix. Smaller molecules move faster and migrate further than larger 
molecules (Lee et al., 2012; Sanger and Coulson, 1978). 
2.8.2.2 Equipment 
Gel electrophoresis was carried out in a gel electrophoresis tank (BIO-RAD, 
Hertfordshire, UK) connected to a power pack (BIO-RAD). 
2.8.2.3 Procedure 
PCR products were resolved and confirmed using a 1% agarose gel. Agarose (1.6 g) 
was added to 160 ml of x1 TBE buffer and dissolved by heating on high power for 
2.5 minutes in a microwave oven. Once cooled, 7 µl of ethidium bromide (10 mg/ml) 
was added. The gel was poured into a mould, a well divider comb positioned and left 
to set. The well divider comb was removed once the gel had set. The gel was placed 
in a gel electrophoresis tank and submerged in x1 TBE buffer. PCR product (5 µl) 
was mixed with 5 µl of x5 loading buffer and 5 µl of this mix was loaded into the 
appropriate well. The tank was connected to a power pack set at 100 V and allowed 
to run for 45 minutes.  
2.8.2.4 Analysis 
After 45 minutes of gel electrophoresis had elapsed, the power pack was 
disconnected and the gel was removed from the tank. The PCR products were 
visualised under a GeneSmart and GeneView UV transilluminator (VWR) and 
digital images were captured. 
2.8.3 DNA sequencing 
2.8.3.1 Function 
Sanger sequencing is a method used to elucidate the sequence of nucleotides in a 
length of DNA. Sanger sequencing can also be referred to as dideoxy sequencing or 
chain termination. The method is based on the addition of fluorescently labelled 
dideoxynucleotides to the nucleotides in DNA. Each dideoxynucleotide, ddATP, 
ddTTP, ddCTP and ddGTP is labelled with a specific fluorescent dye. 
Dideoxynucleotides differ in comparison to nucleotides by the presence of a 
hydrogen group on the 3’ carbon instead of a hydroxyl group. When integrated into 
the DNA sequence, the dideoxynucleotides prevent the addition of further 
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nucleotides. This occurs because a phosphodiester bond cannot form between the 
dideoxynucleotide and the next incoming nucleotide. Thus, the incorporation of the 
didoxynucleotide terminates DNA chain elongation. The products of the sequencing 
reaction can be resolved by gel electrophoresis. Since the four dideoxynucleotides 
fluoresce at different wavelengths, the sequence of nucleotides can be determined.  
2.8.3.2 Procedure 
Excess primers from the PCR products were removed following the addition of 3 µl 
ExoSAP/20 µl PCR product. The removal was carried out using the Veriti 96-well 
Thermal Cycler (Applied Biosystems). The conditions were one cycle of activation 
at +37°C for 15 minutes and inactivation at +80°C for 15 mintues. PCR products and 
primers for sequencing were prepared according to the instructions provided by 
Source Bioscience (Nottingham, UK) and sent off to Source Bioscience for 
overnight Sanger sequencing analysis. 
2.8.3.3 Data analysis 
Data was analysed using Sequencher 4.9 (Gene Codes, Michigan, USA). The 
sequences were compared to that of the reference sequence obtained from the 
Ensembl database (http://www.ensembl.org).  
2.9 General data analysis  
All results are expressed as mean ± standard error of the mean (SEM) or standard 
deviation (SD). Visual inspection and cluster analysis of the data was performed. 
Obvious outliers were excluded from the overall analysis.   
2.9.1 Statistics 
All statistical analyses were carried out using Graphpad Prism 4 software (Graphpad 
Software Inc. San Diego, CA, USA) unless otherwise indicated. The Kolmogorov-
Smirnov test was used to determine whether data were normally distributed and 
Pearson correlation coefficient (r) was used for correlative analyses. Multivariate 
regression analyses were performed to investigate correlations where an age-
dependency was associated with the data (IBM SPSS Statistics, Armonk, NY, USA). 
Individual comparison of means was performed using Student’s t-test and multiple 
comparisons were made using one-way analysis of variance (one-way ANOVA). 
Independent variables found to be significant by one-way ANOVA were further 
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analysed by performing a Bonferroni multiple comparison post-hoc test. In all cases 
p<0.05 was considered significant. 
2.9.2 Calculation of first order rate constants 
For studies monitoring the decay of 5-MTHF, specifically in CSF and potassium 
phosphate buffer, the first order rate constant (k) was determined from the slope of a 
natural log (ln) of 5-MTHF concentration versus incubation time (min) plot. The 
gradient of the slope was determined by performing linear regression analysis of the 
data (Graphpad Software Inc). 
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Chapter 3 
CFD in mitochondrial respiratory 
chain enzyme deficiencies: a 
retrospective cohort study. 
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3. CFD in mitochondrial respiratory chain enzyme deficiencies: a 
retrospective cohort study. 
3.1 Introduction 
The essential water-soluble B vitamin, 5-MTHF, is the principle transport and 
bioactive form of the folate species that is involved in over 100 metabolic reactions 
(Hyland et al., 1988; Surtees et al., 1994). CFD, characterised by a low CSF 
concentration of 5-MTHF in the presence of normal peripheral folate status, is 
increasingly diagnosed in a range of neurological conditions (Garcia-Cazorla et al., 
2008; Hyland et al., 2010; Moretti et al., 2005; Pérez-Dueñas et al., 2011; Serrano et 
al., 2012). A distinct clinical phenotype for CFD has previously been described 
which is characterised by normal development until 4-6 months of age and evolving 
agitation, insomnia, psychomotor retardation, deceleration of head growth, ataxia, 
hypotonia, spasticity, dyskinesia and epilepsy (Ramaekers et al., 2002). The 
underlying aetiology of CFD may be inherited or acquired. For example, mutations 
in the FOLR1 gene encoding the FRα receptor, the protein transporter responsible for 
ATP-dependent transport of 5-MTHF from the periphery into the CSF across the 
choroid plexus cells of the blood-CSF barrier, have been reported to cause brain-
specific 5-MTHF (<10 nmol/L) deficiency leading to neurodegeneration in early 
childhood (Cario et al., 2009; Steinfeld et al., 2009). Conversely, CFD diagnosed in 
patients with neurological disorders, such as mitochondrial diseases, is not well 
understood, as discussed in sections 1.5 and 1.6.  
Mitochondrial diseases are a common group of metabolic disorders affecting 
mitochondrial RCE activity, with a combined prevalence of one in 5000 (Thorburn, 
2004). These disorders encompass a wide range of clinical symptoms and 
presentations, in which the age of onset is variable. The clinical features vary from 
single to multiple affected organs, with high-energy requiring tissues, including the 
brain and skeletal muscle, most notably impaired (Barkovich et al., 1993; Chi et al., 
2011; Jackson et al., 1995). For further discussion, see section 1.3. 
In view of the overlapping clinical heterogeneity of CFD and mitochondrial disease 
phenotypes, CFD may represent an under-recognised condition in patients with 
mitochondrial disease. As a consequence, since CFD is a potentially treatable aspect 
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of mitochondrial disease (Garcia-Cazorla et al., 2008; Hansen and Blau, 2005), 
patients may also be excluded from receiving effective treatment. 
From the available literature and current knowledge, no large-scale systematic 
analysis of CFD in mitochondrial diseases has been performed. Therefore, the 
prevalence and significance of CFD diagnosed in mitochondrial diseases remains 
unknown. Consequently, data from a large cohort of children with suspected 
mitochondrial disease, as described in section 3.4.1, were analysed retrospectively. 
3.2 Aims  
1. To analyse biochemical data from a large cohort of paediatric patients with a 
suspected mitochondrial disease in whom a skeletal muscle biopsy for 
biochemical mitochondrial RCE activity measurement and a lumbar puncture 
for CSF 5-MTHF measurement were performed. 
 
2. To perform FOLR1 mutation analysis in patients with CSF 5-MTHF <10 
nmol/L in the absence of a peripheral folate deficiency. 
 
3. To examine the potential relationship between individual mitochondrial RCE 
complex deficiencies and CSF 5-MTHF. 
 
4. To evaluate the biochemical benefit of folinic acid supplementation therapy in 
patients with severe CSF 5-MTHF deficiencies. 
 
3.3 Acknowledgement 
All data collection and analysis work, and molecular genetic analysis of the FOLR1 
gene throughout this Chapter was my own. Whilst this was not a clinical study, 
interpretation of clinical data and brain MRI/CT imaging results was facilitated by 
Dr. Shamima Rahman, Consultant Metabolic Paediatrician and Dr. W. K. Chong, 
Consultant Paediatric Neuroradiologist, at Great Ormond Street Hospital, London 
UK. CSF 5-MTHF analysis and mitochondrial respiratory chain enzyme activities 
were performed by Viruna Neergheen and Marcus Oppenheim, and Dr. Iain 
Hargreaves, respectively, in the Neurometabolic Unit at the National Hospital for 
Neurology and Neurosurgery, London, UK. Total serum folate analysis was 
performed by the Chemical Pathology Department at Great Ormond Street Hospital, 
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London, UK. Protein modelling was performed by Jose Saldanha in the Division of 
Mathematical Biology at the National Institute for Medical Research, Mill Hill, 
London, UK.  
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3.4 Methods 
3.4.1 Patients 
Paediatric patients with suspected mitochondrial disease investigated at Great 
Ormond Street Hospital, London, UK from July 2006 to November 2012 inclusive in 
whom both a skeletal muscle biopsy for biochemical mitochondrial RCE activity 
analysis and a lumbar puncture for CSF 5-MTHF analysis were performed, were 
collated from the central pathology database. 
A total of 260 paediatric patients (mean ± SD [range] age: 6.1 ± 5.2 [0.2-16.7] years; 
141M:119F) were identified and subdivided into groups as shown in Figure 22. 
Fifty-one of the 260 patients only had mitochondrial RCE activity measured. These 
patients were retrieved from the database because they had CSF neurotransmitter and 
pterin analyses performed. However, CSF 5-MTHF had not been measured in these 
cases, so they were excluded from further analyses. CSF neurotransmitter, pterin and 
5-MTHF analyses are reported together under the same diagnostic test heading 
within the central pathology database, explaining the retrieval of these cases which 
did not fit the inclusion criteria for the study. Additionally, 22 patients only had CSF 
5-MTHF measured. These patients were retrieved from the database for a number of 
reasons, including: patients who had a skeletal muscle biopsy but the sample was too 
small (<50 mg) for biochemical analysis; patients with a confirmed genetic diagnosis 
of mitochondrial disease from blood investigations, which superseded the 
requirement for skeletal muscle biopsy; and suspected mitochondrial disease patients 
who did not have a skeletal muscle biopsy for various reasons, including parental 
refusal and being considered too unwell for general anaesthesia. 
One hundred and eighty seven patients had both biochemical mitochondrial RCE 
activity and CSF 5-MTHF measured. These patients, together with those who had 
CSF 5-MTHF measured only, were further subdivided into groups (Figure 22).  
3.4.2 Patient samples 
All patient samples were tested as part of diagnostic investigations requested by the 
patient’s clinician and after informed parental consent. 
3.4.2.1 CSF 
Patient CSF samples were taken as described in section 2.2.1. 
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Figure 22 Decision tree for the distribution of patients in the cohort. The patient cohort was split into 3 subgroups (blue). Patients with low 5-
MTHF and RCE activity are represented in pink and patients with normal 5-MTHF and RCE activity in yellow. Genetically diagnosed patients are 
represented in green and undiagnosed patients in purple. RCE = respiratory chain enzyme, CSF = cerebrospinal fluid. 
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3.4.2.2 Skeletal muscle 
Patient skeletal muscle biopsies were taken as described in section 2.2.2 
3.4.3 Measurement of CSF 5-MTHF 
CSF 5-MTHF was measured by HPLC as described in section 2.3. CSF 5-MTHF 
data were analysed retrospectively. The age-related CSF 5-MTHF reference ranges 
are shown in Table 5. CFD was classified as mild (<30% below lower reference 
range limit), moderate (30-60% below lower reference range limit) and severe 
(>60% below lower reference range limit) (Pérez-Dueñas et al., 2011). 
3.4.4 Measurement of mitochondrial respiratory chain enzyme activity in 
skeletal muscle 
Mitochondrial RCE activities were measured as described in section 2.5. The 
mitochondrial RCE activity data were analysed retrospectively. Mitochondrial RCE 
activities were calculated as a ratio to citrate synthase, a mitochondrial marker 
enzyme, to compensate for mitochondrial enrichment of the muscle samples. 
Mitochondrial RCE activity (ratio to citrate synthase activity) reference ranges in 
skeletal muscle are shown in Table 7. 
3.4.5 Genetic analysis 
In patients with very low CSF 5-MTHF levels (<10 nmol/L) who did not already 
have a confirmed genetic diagnosis, Sanger sequence analysis of the FOLR1 gene 
was performed in genomic DNA isolated from blood samples. All 4 coding exons 
and exon-intron boundaries of the FOLR1 gene were amplified by polymerase chain 
reaction and sequenced using standard methods as described in section 2.8. 
3.4.6 FRα protein modelling 
A protein structure model of the novel FOLR1 homozygous missense mutation 
(c.335A>T; p.N112I) described in this Chapter (see section 3.5.1.2) and the known 
mutations in the FRα, was created based on the known crystal structure of FRα in 
complex with folic acid; protein data bank code 4LRH (Chen et al., 2013). Models 
were built using the MOE 2012.10 (2) incorporating the Amber12EHT forcefield 
running on a Linux workstation. The same program was used to visualise, analyse 
and generate images. 
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3.4.7 Additional data 
In those patients with low CSF 5-MTHF, clinical features, diagnoses (where 
available), brain MRI/CT imaging and total serum folate data were collated and 
analysed retrospectively. The genetic diagnoses of two patients with normal 
mitochondrial RCE acitivity and low CSF 5-MTHF were also identified. 
3.4.7.1 Brain MRI/CT imaging analysis 
Brain MRI/CT scans were retrospectively reviewed and findings were recorded 
qualitatively. Specific note was made of the appearances of white matter 
myelination, volume, the presence of any focal lesions or evidence of 
leukodystrophy. Quantitative MRI analysis was not performed. 
3.4.7.2 Measurement of total serum folate 
Total serum folate was measured by competitive immunoassay and analysed using 
an IMMUNLITE 2000 immunoassay system analyser, according to the 
manufacturer’s instructions (Siemens Healthcare, Surrey, UK). In patients with low 
CSF 5-MTHF (n=32), results of total serum folate concentrations were obtained, 
where available, to verify the absence of a peripheral nutritional folate deficiency 
and confirm CFD. Total serum folate data were analysed retrospectively. Owing to 
the retrospective nature of this study, the dataset for this parameter was incomplete, 
since total serum folate values were only available for patients in whom concurrent 
blood sampling had been performed at the time of lumbar puncture. The age and sex-
related total serum folate reference ranges are shown in Table 3. 
3.4.8 Data analysis 
Data analysis was carried out as described in section 2.9. 
  
133 
 
3.5 Results 
3.5.1 Patients with both biochemical mitochondrial RCE activity and CSF 5-
MTHF measured, and patients with CSF 5-MTHF measured only 
3.5.1.1 Skeletal muscle mitochondrial RCE activity and CSF 5-MTHF data 
analysis 
Both skeletal muscle mitochondrial RCE activities and CSF 5-MTHF levels had 
been determined in 187 of 260 patients with suspected paediatric mitochondrial 
disease (Figure 22). CSF 5-MTHF analysis was performed in a further 22 patients 
who did not have skeletal muscle biopsies. From these two groups of patients, a total 
of 32 patients with suspected mitochondrial disease (mean ± SD [range] age, sex 
ratio: 5.2 ± 4.2 [0.6-15.4] years; 19M:13F) had decreased CSF 5-MTHF (mean ± SD 
[range] value, 39 ± 21 [<10-71] nmol/L), a prevalence of 15% (Table 8).  
Of the subgroup of 25 CFD patients who had both skeletal muscle mitochondrial 
RCE activity and CSF 5-MTHF analysis, 8 patients (mean ± SD [range] age, sex 
ratio: 6.1 ± 4.7 [0.6-12.5] years; 3M:5F) with low CSF 5-MTHF concentrations also 
had low skeletal muscle mitochondrial RCE activity, a prevalence of 32% (Figure 
23). All 8 patients had isolated complex IV deficiency (mean ± SD [range] value, 
0.006 ± 0.002 [0.004-0.010] ratio to citrate synthase) (Table 8 and Figure 23). 
Patient 28 had isolated complex IV deficiency (activity [reference range]: 0.007 
[0.014-0.034]) and undetectable (<10 nmol/L) CSF 5-MTHF, fulfilling the criteria 
for FOLR1 mutation analysis and a genetic diagnosis was established (see section 
3.5.1.2). A genetic diagnosis was not established in the other 7 patients with both 
low skeletal muscle mitochondrial RCE activity and CFD. Genetic diagnoses were 
established for two of the remaining 17 patients in this subgroup, Patient 13 and 
Patient 25, who had normal skeletal muscle mitochondrial RCE activities (see 
section 3.5.1.2).  
Of the 187 patients who had both skeletal muscle mitochondrial RCE activity and 
CSF 5-MTHF analysis, 162 had CSF 5-MTHF concentrations within the age-related 
reference range, including 46 patients with low skeletal muscle mitochondrial RCE 
activity (mean ± SD [range] age, sex ratio: 6.7 ± 4.5 [0.9 to 16.1] years; 25M:21F). 
One hundred and sixteen patients had normal skeletal muscle mitochondrial RCE  
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Patient Age at CSF 
sampling 
(years) 
Sex Major clinical features Brain MRI/CT imaging findings CSF 
5-MTHF nmol/L 
(ref. range)/ 
Total serum 
folate nmol/L 
(ref. range) 
RCE activity (ratio to citrate 
synthase) 
CI 
(0.104-
0.268) 
CII/III 
(0.040-
0.204) 
CIV 
(0.014-
0.034) 
1 6.7 M Severe motor and cognitive delay 
Seizure disorder 
Upper airway obstruction 
Feeding difficulties  
CT normal at 4y 52 (72-172)/ - 0.160 0.190 0.022 
2 5.3 M Epilepsy (phenytoin treatment) 
Four limb motor disorder with hypotonia,  
No speech 
Minimal interaction 
MRI at 5.3y: mild generalised reduction in WM 
bulk 
59 (72-172)/ 
21.7 (1.1 – 29.2) 
0.257 0.113 0.029 
3 2.4 F Motor skills and speech regression 
Mild low frequency hearing impairment 
in the right ear 
MRI at 2.3y: hypomyelination 57 (72-305)/ - 0.117 0.119 0.024 
4 6.8 F Intractable epilepsy (levetiracetam 
treatment) 
Movement disorder 
Developmental regression and delay 
Mild nephrocalcinosis 
MRI at 2.7y: symmetrical subcortical and deep WM 
signal abnormalities;  
CT at 4y: symmetrical BG calcification, frontal 
atrophy and WM density change;  
MRI + CT at 6.9y: progressive LD with extensive 
frontal WM disease, progressive cerebellar atrophy 
and symmetrical BG calcification  
<10 (72-172)/ 
54.4 (6.1 – 31.7) 
- - - 
5 2.3 M Perimembranous ventricular septal defect 
with signs of pulmonary congestion and 
volume overload. 
MRI at 1.9y: symmetrical LD 50 (52-178)/- 0.200 0.04 0.016 
 
Table 8 Patient demographics, clinical features, brain MRI/CT imaging findings and biochemical data of patients with low CSF 5-MTHF. 
Total serum folate and CSF 5-MTHF age-related reference ranges are shown in Table 3 and Table 5, respectively. MRI = magnetic resonance 
imaging, y = years, CT = computed tomography, BG = basal ganglia, CC = corpus callosum, DM = delayed myelination, GP = globus pallidus, 
IC = internal capsule, LD = leukodystrophy, PCH = pontocerebellar hypoplasia, PV = periventricular, PVL = periventricular leukomalacia, 
WM = white matter. 
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6 5.5 M Leigh syndrome 
Developmental delay 
Gastro-oesophageal reflux disease  
 
MRI 5.5y: bilateral symmetrical abnormal signal 
within WM of cerebellar hemispheres, medulla, 
pontomedullary junction, superior cerebellar 
peduncles. 
MRI at 10.3y: as before with new bilateral lesions 
in caudate nuclei heads and progressive cerebellar 
atrophy 
44 (72-172)/ 
54.4 (1.1 – 29.2) 
0.141 0.079 0.004 
7 1.8 F Hypotonia right upper limb, lower limbs 
and trunk 
Developmental regression 
 
MRI at 1.8y: mild DM and two WM lesions (right 
posterior frontal subcortical WM and right frontal 
corona radiata) 
MRI at 2y: partial resolution of frontal WM lesions  
MRI at 3.2y: new small posterolateral temporal 
WM lesion with progressive cerebral atrophy 
52 (72-305)/ 
54.4 (14.2 – 51.0) 
0.126 0.049 0.005 
8 5.5 F Epilepsy (phenytoin treatment) 
Global developmental delay  
MRI at 10m: generalised lack of WM bulk and DM 62 (72-172)/ - 0.119 0.068 0.01 
9 6.5 F KSS 
 
CT at 4.8y and MRI at 4.9y both normal 
MRI at 6.5y: bilateral symmetrical signal 
abnormalities of cerebellar WM, dorsal brainstem, 
GP and thalamus 
MRI at 7.6y slight progression of disease especially 
in midbrain and cerebellum 
<10 (72-172)/ 
54.4 (6.1 – 31.7) 
- - - 
10 1.6 M Severe intestinal failure  
Impaired renal function 
Cardiomegaly but good cardiac function 
Hypothyroidism 
MRI at 9m: DM and lack of WM bulk  
MRI at 1.7y: bilateral symmetrical cortical injury 
with atrophy and gliosis, bilateral subcortical WM 
lesions and symmetrical cerebellar lesions 
35 (72-305)/ - 0.123 0.06 0.023 
11 14.3 M KSS MRI normal at 13.2y 54 (72-172)/ 
16.3 (2.7 – 19.8) 
- - - 
12 0.6 F Epilepsy (sodium valproate treatment) 
Global developmental delay 
 
MRI at 5.5m: mild lack of WM bulk MRI at 11m: 
new restricted diffusion in GP, thalami, brainstem 
and dentate nuclei 
 
57 (72-305)/ 
45.5 (14.2 – 51.0) 
0.240 0.079 0.005 
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13 15.4 F MEMSA MRI at 13.8y: bilateral symmetrical signal change 
within both occipital poles around calcarine sulci 
and in dentate nuclei, and right hippocampal 
sclerosis 
29 (46-160)/ - 
 
0.126 0.156 0.026 
14 1.7 F Status epilepticus  
Progressive neurological deterioration  
MRI  at 1.7y: bilateral abnormal signal in deep WM 
of both cerebral hemispheres and in cerebellar WM 
and focal abnormality of right caudate; marked 
progression 2 weeks later with diffuse cerebral and 
cerebellar  swelling and diffuse cortical and WM 
lesions, and diffuse leptomeningeal nodular process 
affecting cerebellum and brainstem 
67 (72-305)/ - 0.211 0.079 0.018 
15 9.5 M Dystonic spasms MRI normal at 9.5y 29 (72-172)/ 
54.4 (5.2 – 26.7) 
0.334 0.085 0.024 
16 2.3 F Developmental delay 
Nystagmus 
Hypotonia 
 
MRI at 1.4y: DM and decreased WM bulk 13 (52-178)/ - - - - 
17 12.5 M Renal failure MRI at 12.4y: generalised sulcal and ventricular 
prominence and prominence of cerebellar fissures 
40 (46-160)/ 
54.4 (3.4 – 24.3) 
0.134 0.041 0.01 
18 1.6 F Global developmental delay 
Movement disorder 
MRI at 11m: generalised lack of WM bulk  70 (72-305)/ - 0.225 0.068 0.004 
19 2.4 M Seizures (sodium valproate treatment) 
Developmental arrest 
Sensorineural deafness 
Poor visual attentions 
Hypothyroidism 
MRI at 3.4y: extensive reduction of cerebral WM 
bulk, with less marked reduction of brainstem and 
cerebellar bulk  
24 (52-178)/ 
54.4 (5.6 – 33.7) 
0.183 0.159 0.023 
20 0.9 M Developmental regression  
Seizures (phenytoin treatment) 
Bilateral deafness 
MRI at 9m: DM  16 (72-172)/ - 0.204 0.148 0.021 
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21 5.3 M Motor and speech regression  
Movement disorder 
MRI normal at 5.2y 58 (72-172)/ - 0.187 0.167 0.030 
22 9.6 F Optic atrophy  
Ataxia 
MRI at 3.3y: immature signal in posterior limb of 
IC and GP  
46 (72-172)/ 
51.4 (5.4 – 30.1) 
0.180 0.126 0.029 
23 1.4 M Global developmental delay 
Epilepsy (sodium valproate treatment) 
Four limb dyskinetic movement disorder 
 
CT at 13m: bilateral BG calcification with PV and 
deep WM LD and cerebellar hypoplasia 
MRI at 2.6y: PCH and generalised lack of cerebral 
volume and myelination, with bilateral symmetrical 
mature haemorrhagic infarction of BG and 
symmetrical PV and deep WM change of frontal 
lobes 
<10 (72-305)/ - - - - 
24 1.4 M Developmental delay 
Learning difficulties 
Epilepsy (sodium valproate treatment) 
 
MRI normal at 10m  
MRI at 2.6y: DM and lack of WM bulk 
MRI at 4.2y: normal appearances with myelination 
now appropriate for age 
MRI normal at 5.2y and 8.2y 
<10 (52-178)/ 
0.2 (at diagnosis) 
(16.2 – 50.3) 
- - - 
25 6.1 M KSS  
Renal tubulopathy 
Short stature 
Left sided ptosis 
MRI at 5.7y: bilateral symmetrical signal 
abnormality within GP, subthalamic nuclei and 
dorsal brainstem, with mild cerebellar hypoplasia 
MRI at 8.7y extensive signal abnormality bilaterally 
within GP and rest of BG, anterior thalami, 
midbrain, pons and medulla as well as diffuse 
symmetrical signal abnormality within deep and 
subcortical WM of cerebral hemispheres, mild 
volume loss of cerebrum and cerebellum 
MRI at 10.1y striking and extensive WM signal 
abnormality in addition to symmetrical lesions 
within thalami, BG, midbrain and dorsal pons 
<10 (72-305)/ 
54.4 (1.1 – 29.2) 
0.203 0.142 0.017 
26 2.8 F Premature infant 31 weeks gestation with 
severe failure to thrive, hypotonia and 
global developmental delay 
MRI at 3y: marked lack of WM bulk, thin CC, PVL 28 (52-178)/ 
54.4 (3.8 – 35.3) 
0.219 0.091 0.022 
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27 5.1 M Ophthalmoplegia 
Ataxia 
MRI at 4.8y: mild lack of WM bulk 66 (72-172)/ - 0.161 0.101 0.026 
28 12.1 M Intractable epilepsy (sodium valproate 
treatment) 
Profound learning difficulties 
 
MRI at 5.6y: thin CC, otherwise normal 
MRI at 11.2y global atrophy affecting cerebellum 
more severely than cerebellar hemispheres 
CT at 12y: small cerebellum and punctate BG 
calcification 
<10 (46-160)/ 
54.4 (3.4 – 24.3) 
0.248 0.181 0.007 
29 1.5 M Intractable epilepsy (sodium valproate 
treatment) 
Severe developmental delay 
MRI  at 2y: progressive cortical atrophy, thin CC  71 (72-305)/ 
54.4 (16.2 – 50.3) 
0.114 0.073 0.017 
30 2.4 M Global developmental regression 
Epilepsy (carbamezapine treatment) 
 
MRI normal at 6m 
MRI at 2y: new bilateral occipito-temporal WM and 
cortical signal abnormality 
31 (52-178)/ 
22.4 (5.6 – 33.7) 
0.201 0.122 0.028 
31 9.4 F Epilepsy (sodium valproate treatment) 
Motor and speech regression 
MRI normal at 7.7y 52 (72-172)/ 
54.4 (5.4 – 30.1) 
0.224 0.217 0.005 
32 6.5 M KSS MRI normal at 2.4y <10 (72-172)/ 
48.3 (1.1 – 29.2) 
- - - 
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Figure 23 Proportion of patients with low/normal CSF 5-MTHF concentration and 
low/normal mitochondrial RCE activity. CI=Complex I (n=6), CII/III=Complex II/III (n=2), 
CIV=Complex IV (n=29, 8), Multiple=multiple respiratory chain defects (Complex I and 
Complex IV) (n=9), N=normal (n=116, 17). 
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activities (Figure 23). Combining the 46 patients who had low skeletal muscle 
mitochondrial RCE activity and normal CSF 5-MTHF concentrations with the 8 
patients who had low skeletal muscle mitochondrial RCE activity and low CSF 5-
MTHF concentrations, the prevalence of CFD in biochemically confirmed skeletal 
muscle mitochondrial RCE defects was calculated to be 15%.  
Of the subgroup of 22 patients who only had CSF 5-MTHF measured, seven patients 
had decreased CSF 5-MTHF (mean ± SD [range] age, sex ratio: 7.3 ± 4.6 [1.2-15.4] 
years; 4M:3F), whilst the remaining 15 patients in this subgroup had CSF 5-MTHF 
concentrations within the normal age-related reference ranges. Genetic diagnoses 
were established in five of the seven patients who had low CSF 5-MTHF levels but 
did not have skeletal muscle biopsies (Patients 4, 9, 11, 24 and 32) (see section 
3.5.1.2). The remaining two patients did not have genetic diagnoses. 
3.5.1.2 Genetic diagnoses 
Of the subgroup of eight patients with low CSF 5-MTHF and complex IV 
deficiency, one patient (Patient 28) had CSF 5-MTHF <10 nmol/L. FOLR1 mutation 
analysis was performed and a genetic diagnosis was established. Patient 28 had a 
homozygous nonsense mutation in exon 7 of FOLR1 (c.610C>T; p.R204X) and his 
consanguineous parents were both heterozygous for the mutation (Figure 24 and 
Figure 25). The arginine at position 204 (R204) is highly conserved across species 
(Figure 26a).  
Of the subgroup of 17 patients with low CSF 5-MTHF and normal RCE activities, 
genetic diagnoses were established for two patients (Patients 13 and 25). Patient 13 
had MEMSA (Myoclonic Epilepsy, Myopathy, Sensory Ataxia) associated with a 
homozygous p.A467T POLG mutation, whilst Patient 25 had KSS caused by a 
single large-scale mtDNA deletion. 
Of the subgroup of seven patients with low CSF 5-MTHF but did not have muscle 
biopsies, five were found to have genetic diagnoses. Patient 4, had severe CFD (<10 
nmol/L) and FOLR1 mutation analysis in this patient revealed a novel homozygous 
missense mutation (c.335A>T; p.N112I) (Figure 24 and Figure 27). The 
consanguineous parents were both heterozygous for the mutation and the asparagine 
at position 112 is highly conserved across species (Figure 26b). Patients 9, 11, and   
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Figure 24 Genetic organisation of the FOLR1 gene. The FOLR1 gene contains 7 exons in total. Coding exons are represented in black. Mutation 
analysis of exon and exon-intron boundaries revealed mutations in Patient 4 and Patient 28, as indicated. Mutations represented above the figure have 
been previously reported (Grapp et al. 2012). Types of mutation, p.K44_P49dup = duplication, p.C65W = missense, p.C105R = missense, p.Q118X = 
nonsense, g.3576T>G = splice site, p.C169Y = missense, p.C175X = nonsense, p.N222S = missense. Amino acid abbreviations, K = lysine, P = 
proline, C = cysteine, W = tryptophan, R = arginine, Q = glutamine, X = stop, Y = tyrosine, N = asparagine, S = serine, I = isoleucine. Nucleotide bases 
abbreviations, A = adenine, T = thymine, C = cytosine, G = guanine, p = protein, g = genomic, c. = complementary. 
142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  C   T   A   C A  G  C   C  G   A  G   G  G   A  G Wild type 
Heterozygous Heterozygous 
Wild type A  C   T   A   C A  G  C   C  G   A  G   G  G   A  G 
c.610C>T 
A  C   T   A   C A  G  C   C  G   A  G   G  G   A  G Wild type 
* * 
* 
Figure 25 Family pedigree of Patient 28 and electropherograms showing sequencing results of FOLR1 exon 7. The c.610C>T is homozygous 
in Patient 28 (black square). The consanguineous parents are heterozygous for the mutation (square = father, circle = mother). 
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Figure 26  FOLR1 evolutionary conservation. The R204 (a.) and N112 (b.) residues in exons 7 and 5, respectively, are highly conserved across 
species. This suggests that the R204X stop mutation and the N112I amino acid change are likely to be pathogenic and have significant functional 
impacts. 
p.R204X 
p.N112I 
a. 
b. 
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Figure 27 Family pedigree of Patient 4 and electropherograms showing sequencing results of FOLR1 exon 5. The c.335A>T is homozygous 
in Patient 4 (black circle). The consanguineous parents are heterozygous for the mutation (square = father, circle = mother). 
Wild type 
c.335A>T 
C   T  C C C  C C  A A  C  T  T  G  G  G  G  C 
C  T  C C C  C C  A A  C T  T  G G G G  C Wild type 
Heterozygous 
C  T  C C C  C C  A A  C  T  T  G G G G C Wild type 
Heterozygous 
* 
* * 
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32 had KSS, Patient 24 had previously reported PCFT mutations (Paul et al., 2011). 
Taken together, the most profound CSF 5-MTHF deficiencies were observed in 
patients with KSS (n=4) and in those harbouring FOLR1 mutations (n=2) or PCFT 
mutations (n=1). CFD was milder (29 nmol/L) in the patient with POLG mutations. 
3.5.1.3 FRα protein modelling of the novel FOLR1 homozygous missense 
mutation (c.335A>T; p.N112I) documented in this Chapter and the 
known mutations in the FRα 
The novel FOLR1 homozygous missense mutation (c.335A>T; p.N112I) 
documented in this Chapter (see section 3.5.1.2), as well as the known missense 
mutation resulting in an amino acid change from asparagine to serine at position 222 
(p.N222S), were shown to be located in a region of the FR-α near the membrane 
(Figure 28). The remaining known mutations were shown to be located near the 
binding pocket of the FR-α (Figure 28). Nonsense mutations are not shown since 
these mutations do not result in protein expression. The g.3576T>G mutation is not 
shown since this mutation is located in an intron (Grapp et al. 2012). 
3.5.1.4 Clinical features and brain MRI/CT imaging 
All patients with low CSF 5-MTHF shared a heterogeneous clinical phenotype, with 
no single patient exhibiting all the symptoms considered distinctive for CFD 
(Ramaekers et al., 2002). Seizure disorder, movement disorder and developmental 
delay and/or regression were the most common clinical features in these patients 
(Table 8). Brain MRI/CT imaging showed no clear correlations with CFD. For 
specific diagnoses such as KSS, where there were brain MRI/CT imaging findings, 
these were consistent with those previously described in the literature for 
mitochondrial disease (Serrano et al., 2010). In other situations, the findings were 
either normal or non-specific.  
3.5.1.5 Total serum folate data 
Total serum folate concentrations were obtained for 19 of the 32 patients with 
decreased CSF 5-MTHF (Table 8). Patients 2, 11, 12 and 30 had total serum folate 
concentrations within the age and sex-specific reference ranges, whilst Patient 24 
had a total serum folate concentration below the age and sex-specific reference 
range. The remaining patients had concentrations above the respective reference 
ranges. In some of these cases, total serum folate concentrations were recorded at the 
upper limit of detection for the assay.  
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N 
terminus 
C 
terminus 
Cell membrane 
p.N11
2I 
Figure 28 Three dimensional model of the FRα protein based on the known crystal structure in 
complex with folic acid showing the novel FOLR1 homozygous missense mutation (c.335A>T; p.N112I) 
documented in this Chapter and the known mutations in the FRα. The novel mutation is represented in 
pink (arrow), whilst the known mutations are represented in green. Folic acid is in the binding pocket 
(spacefill). Grey represents carbon, blue represents nitrogen, red represents oxygen and yellow represent 
sulphur. N terminus = amine (-NH2) terminus, C terminus = carboxyl (-COOH) terminus, Asn/N = 
asparagine, Pro = proline, Lys = lysine, Cys = cysteine. 
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3.5.1.6 Effect of anti-epileptic drugs on the levels of CSF 5-MTHF in children 
receiving treatment 
Antiepileptic drugs (AEDs), notably sodium valproate, carbamezapine and 
phenytoin, have been reported to impair the active transport of 5-MTHF across the 
blood-CSF barrier from the periphery into the CSF (Opladen et al., 2010). From the 
group of 32 patients with suspected mitochondrial disease who had low CSF 5-
MTHF concentration, 12 had received AEDs. However, there was no difference in 
CSF 5-MTHF levels between the 12 patients treated with AEDs and the 20 patients 
not on AEDs (Figure 29). The impact of specific AEDs on CSF 5-MTHF availability 
was not determined owing to small sample size for individual AEDs. 
3.5.2 No correlation between CSF 5-MTHF and mitochondrial RCE activity 
in skeletal muscle 
To study the relationship between skeletal muscle mitochondrial RCE activity and 
CSF 5-MTHF concentration, a potential correlation between skeletal muscle 
mitochondrial RCE activity and corresponding CSF 5-MTHF concentrations in 
patients with an isolated RCE defect, was tested. No correlation was observed 
between isolated complex I deficiency (n=6) or isolated complex IV deficiency 
(n=37) and CSF 5-MTHF concentration (Figure 30a and Figure 30b). Sample size 
was too small (n=2) to test for correlation between isolated complex II/III deficiency 
and CSF 5-MTHF concentration. 
3.5.3 Biochemical response to folinic acid supplementation in patients with 
low CSF 5-MTHF 
Serial lumbar puncture and CSF 5-MTHF analysis was performed in four patients 
who were treated with folinic acid supplementation (Patients 4, 9, 25 and 28). 
Patients 9, 25 and 28 demonstrated a good biochemical response to treatment with 
increase of CSF 5-MTHF to within the respective age-related reference range 
(Figure 31a). However, after 11.6 months of therapy, CSF 5-MTHF was not yet 
restored to within the age-related reference range in Patient 4 (Figure 31a). Disease 
progression was observed in Patient 32. This patient presented with Pearson 
syndrome (transfusion dependent sideroblastic anaemia and neutropaenia) at 2.4 
years. Initial lumbar puncture at 2.4 years demonstrated a normal CSF 5-MTHF 
concentration of 142 nmol/L (52-178). The patient’s clinical phenotype progressed 
from Pearson syndrome to KSS and repeat lumbar puncture at 6.5 years revealed a 
CSF 5-MTHF concentration of <10 nmol/L (72-172) (Figure 31b).  
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Figure 29  Individual comparison of mean CSF 5-MTHF concentrations between 
patients not receiving/receiving anti-convulsant therapy. No significant difference 
between the two groups was observed, determined by Student’s t-test. 
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Figure 30 No correlation between CSF 5-MTHF and skeletal muscle RCE activity. A 
correlation could not be demonstrated for a. Complex I deficient patients (r=-0.24; p=0.65; 
n=6), or b. complex IV deficient patients (r=-0.03; p=0.89; n=29). 
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Figure 31 Biochemical responses of patients with low CSF 5-MTHF on folinic acid 
supplementation who had serial lumbar punctures. a. The shaded areas represent the age related 
reference range for 5-MTHF at the time of sampling; 72-172 nmol/L (5-10 years), 46- 160 nmol/L 
(10 years-adult). Individual 5-MTHF values (nmol/L) are in brackets. Oral folinic acid 
supplementation dose (mg/kg/day) at each subsequent CSF 5-MTHF measurement; Patient 4 = 1.2, 
5.0 + 6.25 (intravenously); Patient 9 = 0.9, 1.4; Patient 25 = 1.1, 1.5; Patient 28 = 1.7. b. Decrease in 
CSF 5-MTHF concentration in Patient 32 who initially presented with Pearson syndrome and whose 
disease progressed to KSS. The shaded areas represent the age-related reference range for 5-MTHF at 
the time of sampling; 52-178 nmol/L (2-5 years), 72-172 nmol/L (5-10 years). Individual 5-MTHF 
values (nmol/L) are in brackets. Patient 32 is now receiving folinic acid supplementation at a dose of 
1.0 mg/kg/day. 
a. 
b. 
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3.6 Discussion 
In this Chapter, data from a large cohort of paediatric patients with a suspected 
mitochondrial disease, in whom both a skeletal muscle biopsy for mitochondrial 
RCE analysis and CSF 5-MTHF analysis was performed, were collated from the 
central pathology database at Great Ormond Street Hospital, London, UK. Although 
CFD was first noted in a patient with KSS in 1983 (Allen et al., 1983), from the 
available literature and current knowledge, this is the first study to systematically 
document prevalence of CSF 5-MTHF deficiency in a large cohort of patients with 
suspected or proven mitochondrial disease investigated in a single centre. In this 
cohort, the prevalence of CSF 5-MTHF deficiency in suspected mitochondrial 
disease patients was 15%. In addition, the prevalence of CSF 5-MTHF deficiency 
was also 15% in those patients who had biochemically confirmed skeletal muscle 
mitochondrial RCE deficiency. From this data it can be extrapolated that, based on a 
birth prevalence for mitochondrial disease of one in 5000 (Thorburn, 2004), the 
minimum population prevalence of mitochondrial disease with CSF 5-MTHF 
deficiency is approximately one in 30,000, suggesting that CSF 5-MTHF deficiency 
in mitochondrial disease is not as rare as initially anticipated. 
Severity of CSF 5-MTHF deficiency was variable in the cohort, but the most 
profound CSF 5-MTHF deficiencies were seen in patients with KSS caused by 
single large-scale mtDNA deletions (Patients 9, 11, 25 and 32), those with mutations 
in the FOLR1 gene encoding FRα (Patients 4 and 28), and in Patient 24 who had a 
mutation in the PCFT gene. KSS manifests as external ophthalmoplegia, pigmentary 
retinopathy, ataxia and aberrant cardiac conduction (Oldfors et al., 1990; Rahman 
and Hanna, 2009; Zeviani et al., 1988). Oncocytic transformation, comprising 
cellular enlargement and granular eosinophilic cytoplasm, of choroid plexus cells has 
been observed in KSS, possibly because of accumulation of mutated mtDNA in 
these cells leading to decreased ATP production (Spector and Johanson, 2010; Tanji 
et al., 2000). Choroid plexus cells are involved in the production of CSF at the 
blood-CSF barrier (Bering, 1955; Milhorat, 1969; Speake et al., 2001). Therefore, 
choroid plexus dysfunction may explain the severe CFD observed in KSS patients. 
Similarly, impaired folate transport across choroid plexus cells may also represent 
the cause of the severe CFD observed with FOLR1 mutations (Cario et al., 2009; 
Steinfeld et al., 2009), since FRα is responsible for active transport of 5-MTHF 
across choroid plexus cells from the peripheral circulation into CSF (Grapp et al., 
152 
 
2013). In this cohort, two patients with severe CSF 5-MTHF deficiency (<10 
nmol/L) had FOLR1 mutations: a novel homozygous missense mutation in exon 5 
(c.335A>T; p.N112I), and a homozygous nonsense mutation in exon 7 (c.610C>T; 
p.R204X), which was previously reported to be pathogenic (Dill et al., 2011; Grapp 
et al., 2012). Both sets of healthy consanguineous parents were found to be carriers 
for the respective mutations. Regarding the former novel FOLR1 mutation, the 
asparagine at position 112 was found to be conserved throughout evolution and both 
consanguineous parents were heterozygous for the mutation, suggesting that this 
missense mutation is pathogenic and responsible for the severe CSF 5-MTHF 
deficiency observed  in this patient. The clinical heterogeneity of patients with CFD 
and the lack of aetiological diagnosis in the majority of cases, suggests that FOLR1 
sequence analysis should be performed in all patients with CSF 5-MTHF values <10 
nmol/L in the absence of peripheral folate deficiency. 
Patient 24 has previously been reported in the literature to have compound 
heterozygous mutations in the PCFT1 gene (Paul et al., 2011). Briefly, a mutation in 
exon 2 (c.1004C>A; p.A335D) was inherited from the heterozygous father whilst the 
heterozygous mother contributed an allele with deletion of two nucleotides in exon 1 
that caused a frameshift starting at position N68 with early termination of translation 
(c.204-205delCC). PCFT is responsible for intestinal absorption of 5-MTHF from 
the diet and transport of 5-MTHF from the blood into the CSF (Urquhart et al., 2010; 
Zhao et al., 2009a). Therefore, mutations in the PCFT1 gene cause hereditary folate 
malabsorption leading to global 5-MTHF deficiency (Shin et al., 2011). These 
patients present with CSF 5-MTHF concentrations <10 nmol/L and low peripheral 
folate levels, as demonstrated in Patient 24. Global 5-MTHF deficiency should be 
considered as an indicator of a potential mutation in the PCFT1 gene and PCFT1 
mutation analysis should be carried out in patients with similar biochemical 
presentations. In view of the global 5-MTHF deficiency and according to the 
definition (Ramaekers and Blau, 2004), patients with mutations in this gene are not 
wholly considered to have CFD. 
Deficiency of complex IV was the most common mitochondrial RCE defect in 
patients with CSF 5-MTHF deficiency in the cohort. This is in contrast to the 
findings of other groups who have reported abnormalities in other mitochondrial 
RCE complexes in CFD patients (Garcia-Cazorla et al., 2008; Pineda et al., 2006; 
Ramaekers et al., 2007c). This could partly be explained by a CFD diagnosis 
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superseding the need for a skeletal muscle biopsy and subsequent biochemical 
mitochondrial RCE analysis. Seven out of the eight patients with complex IV 
deficiency had mild-moderate CSF 5-MTHF deficiency, suggesting the deficiency is 
secondary to the complex IV defect, with the exception of patient 28 who had severe 
CSF 5-MTHF deficiency and a homozygous FOLR1 mutation. From the available 
literature and current knowledge, this is the first time mitochondrial RCE activity 
has been measured and isolated complex IV deficiency documented in a patient with 
a confirmed FOLR1 gene mutation. It is unclear whether the complex IV deficiency 
is secondary to the FOLR1 mutations in this patient, or whether he may have a 
second recessive disorder, since the coexistence of two recessive disorders is not 
uncommon in consanguineous pedigrees (Bittles et al., 1991; Hamamy, 2012). 
Taken together, mitochondrial RCE defects in patients with CFD cannot be predicted 
from CSF 5-MTHF data and vice versa, highlighting the importance of performing 
both a skeletal muscle biopsy and lumbar puncture in patients with suspected 
mitochondrial disease. This may be especially appropriate in patients with CSF 5-
MTHF <10 nmol/L who have suspected or confirmed FOLR1 mutations. These 
suggestions are supported by the lack of correlation between CSF 5-MTHF values 
and the degree of mitochondrial RCE deficiency measured in skeletal muscle, 
although relatively low n numbers were used for analysis. Nevertheless, in view of 
this lack of correlation, other mechanisms arising from loss of mitochondrial 
function need to be considered, for example oxidative stress leading to increased 5-
MTHF catabolism, which is investigated in the following Chapters (Aylett et al., 
2013). 
In two patients, genetically confirmed mitochondrial disease was associated with 
CSF 5-MTHF deficiency but normal mitochondrial RCE activity. In one case 
(Patient 25), this could be explained by the mtDNA deletion being heteroplasmic 
and therefore, the patient had enough wild type mtDNA to compensate. The other 
case (Patient 13), had POLG mutations with a predominantly CNS phenotype and 
very low levels of multiple mtDNA deletions in skeletal muscle. 
FRα protein modelling of the novel FOLR1 homozygous missense mutation 
(c.335A>T; p.N112I) documented in this Chapter and the known mutation resulting 
in an amino acid change from asparagine to serine at position 222 (Grapp et al., 
2012), showed that these changes were located in two separate regions of the FRα 
near to the membrane. This could suggest that the interaction between the receptor 
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and the membrane may be affected. For example, the receptor may not be anchored 
to the membrane sufficiently or receptor-mediated endocytosis (see section 1.4.3) 
may not function properly. The remaining known mutations were shown to be 
located near to the binding pocket of the FRα. This could suggest that folate binding 
to the receptor could be affected. For example, folate may not bind to the binding 
pocket at all (loss of the formation of a ligand/receptor complex) or folate may bind 
weakly within the binding pocket but not sufficiently enough to activate the receptor. 
The clinical heterogeneity associated with CSF 5-MTHF deficiency, including that 
associated with proven mitochondrial diseases (Garcia-Cazorla et al., 2008; 
Hasselmann et al., 2010; Pineda et al., 2006; Serrano et al., 2010), is demonstrated in 
Table 8. Seizure disorder, movement disorder and developmental delay and/or 
regression were the most common clinical features. However, no patient exhibited 
all the symptoms considered distinctive for CFD (Ramaekers et al., 2002), 
suggesting that it is important to measure CSF 5-MTHF in all patients at risk of 
CFD, rather than relying on clinical manifestations. With regard to the neuroimaging 
data, an apparent association between the degree of CSF 5-MTHF and the severity of 
lesions was observed. Patients who presented with normal scans had CSF 5-MTHF 
deficiencies within the mild-moderate range, whereas, patients with severe CSF 5-
MTHF deficiencies were typically more affected than others. In general, the majority 
of patients presented with delayed myelination and/or leukodystrophy, which were 
more evident at different stages of disease progression. 
Total serum folate was documented for 19 out of 32 patients with decreased CSF 5-
MTHF concentrations (Table 8). CFD could be could be confirmed in four patients 
who had total serum folate concentrations within the age and sex-specific reference 
ranges, indicating the absence of a periphery nutritional folate deficiency 
(Ramaekers and Blau, 2004; Ramaekers et al., 2002). However, a peripheral 
nutritional folate deficiency was noted in Patient 24 who had PCFT mutations, 
which confirmed global folate deficiency characteristic of patients with PCFT 
mutations (Paul et al., 2011; Shin et al., 2011). Total serum folate concentrations in 
the remaining patients were above the age and sex-specific reference ranges and, in 
some cases, at the upper limit of detection for the assay. Whilst CFD could also be 
confirmed in these patients, possible explanations for these high peripheral folate 
levels could include: parental administration of vitamin supplements, or empirical 
treatment with folinic acid treatment by a clinician owing to the patient’s potential 
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risk of developing CFD and/or the patient’s clinical presentation. It is critically 
important for concurrent blood samples and lumbar punctures to be taken and 
subsequent analysis of 5-MTHF in these samples, in order to diagnostically confirm 
CFD. In those patients where a total serum folate measurement was absent, only a 
CSF 5-MTHF deficiency may be inferred. 
Seizures are a common clinical feature in patients with CFD and mitochondrial 
disease (Lee et al., 2011; Rahman, 2012). Treatment with AEDs including sodium 
valproate, carbamazepine and phenytoin has been reported to reduce FOLR1-
mediated uptake of 5-MTHF from the periphery into CSF in cell model systems 
(Opladen et al., 2010). In this cohort, 38% of patients were treated with AEDs. 
However, no difference in CSF 5-MTHF concentration was observed between 
patients not receiving and receiving AEDs, indicating that these findings do not 
necessarily support the work of Opladen et al. (2010). However, this could be 
accounted for by the lack of data regarding the impact of specific AEDs on CSF 5-
MTHF availability since the sample size for individual AEDs was too small. It also 
cannot be ruled out that anticonvulsant treatment may have contributed to the 
decreased CSF 5-MTHF concentrations in this group of patients. 
Recognition and prompt diagnosis of CFD is of paramount importance since CFD is 
treatable in patients with a primary deficiency (Cario et al., 2009; Grapp et al., 2012; 
Steinfeld et al., 2009) and is one potentially treatable aspect of disease in patients 
with mitochondrial disorders (Garcia-Cazorla et al., 2008; Grapp et al., 2012; 
Moretti et al., 2005; Pérez-Dueñas et al., 2011). Positive clinical response to folinic 
acid treatment has previously been reported in the literature (Hasselmann et al., 
2010; Pérez-Dueñas et al., 2010; Pineda et al., 2006; Serrano et al., 2012). However, 
from the available literature and current knowledge, this is the first report of serial 
CSF 5-MTHF measurements demonstrating biochemical improvement in CSF 5-
MTHF status in multiple patients with KSS or FOLR1 gene mutations receiving 
folinic acid supplementation. Therapeutic benefit of folinic acid and restoration of 
CSF 5-MTHF values to within the age-related reference range was demonstrated in 
both KSS (n=2) and in one patient with a FOLR1 mutation (n=1). Specifically for 
KSS, empirical treatment with folinic acid to all paediatric patients with single large 
mtDNA deletions may be beneficial. This recommendation is supported by the 
observation that the onset of CFD may be associated with disease progression from 
Pearson syndrome to KSS as demonstrated by the serial CSF 5-MTHF 
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concentrations in Patient 32. From the available literature and current knowledge, 
this is the first report documenting progressive loss of CSF 5-MTHF. CSF 5-MTHF 
levels have not yet been restored to within the age-related reference range in Patient 
4 despite ongoing folinic acid supplementation. The folinic acid dosing regimen in 
this patient is currently being escalated. Biochemical improvement in patients with a 
CSF 5-MTHF deficiency following folinic acid supplementation further illustrates 
the importance of performing lumbar punctures and measuring CSF 5-MTHF. 
Whilst it is essential to explore all therapeutic options for patients on an 
individualised basis, it is critically important to identify those patients with a 
treatable element to their disease. 
3.7 Conclusion 
In conclusion, from the cohort described here, a minimum population prevalence of 
mitochondrial disease with CSF 5-MTHF deficiency is approximately one in 30,000, 
suggesting that CSF 5-MTHF deficiency may be more common in patients with 
RCE defects than was initially appreciated. A lack of aetiological diagnosis was 
observed in the majority of cases. Profound CSF 5-MTHF deficiencies may be 
associated with defects in 5-MTHF transport across the blood-CSF barrier, including 
KSS and in patients with a FOLR1 mutation or PCFT1 mutation. Concerning 
patients with a FOLR1 mutation, the data suggests that FOLR1 mutation analysis 
should be a priority in patients with CSF 5-MTHF <10 nmol/L in the absence of 
peripheral folate deficiency. Importantly, in patients with mitochondrial RCE 
abnormalities, the degree of CSF 5-MTHF deficiency cannot be predicted and vice 
versa. This emphasises the importance of performing a skeletal muscle biopsy and 
lumbar puncture, and carrying out the appropriate analyses in those patients 
suspected of having a mitochondrial disease. Patients with decreased CSF 5-MTHF 
concentrations had heterogeneous clinical presentation, including brain MRI/CT 
imaging, suggesting that CSF 5-MTHF analysis may be of critical importance as 
opposed to relying on clinical manifestations. To confirm CFD, it is critically 
important to take a concurrent blood sample for total serum folate analysis at the 
time of lumbar puncture. In this cohort, anti-convulsant therapy was not associated 
with severity of CSF 5-MTHF deficiency. The biochemical improvement of CSF 5-
MTHF deficient patients receiving folinic acid supplementation further highlights 
the importance of identifying these patients and commencing a treatment regimen as 
early as possible.  
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4. The effect of hydroxyl radicals or selenite on 5-MTHF stability in 
CSF and the ability of AA to confer protection of 5-MTHF. 
4.1 Introduction 
The study described in Chapter 3 suggests that CSF 5-MTHF deficiency may 
represent an under-recognised, potentially treatable condition in patients with 
mitochondrial disease. A lack of aetiological diagnosis was observed in the majority 
of cases and mitochondrial RCE defects in patients with decreased CSF 5-MTHF 
could not be predicted from the CSF 5-MTHF data. This work highlights the 
importance of elucidating the molecular mechanisms responsible for CFD associated 
with mitochondrial disease in order to gain an understanding of disease 
pathogenesis. As discussed in section 1.6, the mechanisms responsible for secondary 
CFD associated with a subset of patients with mitochondrial disease, are not known. 
Several groups have postulated that CFD in mitochondrial disease may be explained 
by defective transport of 5-MTHF across the epithelial cells of the choroid plexus 
from the periphery into CSF (Hyland et al., 2010; Opladen et al., 2010; Pérez-
Dueñas et al., 2011; Tanji et al., 2000). However, there is a lack of sufficient 
evidence supporting these mechanisms, suggesting that other mechanisms may be 
accountable. 
5-MTHF is susceptible to oxidative catabolism in the presence of oxidising species 
(see section 1.4.1) (Blair et al., 1975; Heales et al., 1988; Lam and Heales, 2007). 
Consequently, in situations where ROS formation is increased, accelerated 
catabolism of 5-MTHF may ensue, thereby contributing to a CFD state. The 
mitochondrial RC is considered to be the most important quantitative source of 
cellular ROS (Boveris and Chance, 1973; Boveris et al., 1972; Loschen and Azzi, 
1975) and dysfunction of the mitochondrial RC is associated with an increase in 
ROS production (see sections 1.1.3 and 1.6.2) (Jacobson et al., 2005; Sipos et al., 
2003). Thus, induction of oxidative stress, represented by an imbalance between 
ROS generation and antioxidant availability, could provide a mechanistic link 
between mitochondrial disorders and CFD.  
In addition to dysfunction of the mitochondrial RC, abnormal biochemical 
parameters may also lead to increased ROS generation. Specifically, in six KSS 
patients with secondary CFD, elevated CSF selenium concentrations were reported 
(Tondo et al., 2011). However, selenium was not implicated as a factor responsible 
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for CFD in these patients and the data were not correlated to 5-MTHF availability in 
this study. Selenium toxicity has previously been associated with increased ROS 
generation, as a consequence of redox-cycling of selenide with reduced thiols, for 
example GSH (see section 1.6.2.1) (Chen et al., 2007b; Tarze et al., 2007; Yan and 
Spallholz, 1993). Therefore, elevated CSF selenium concentrations could promote 
ROS production and accelerate breakdown of 5-MTHF. 
As well as the generation of ROS, antioxidant availability is an additional factor 
governing induction of oxidative stress. In a paper by Spector and Johanson (2010), 
AA was predicted to be low in concentration in the CSF of patients with CFD. In the 
context of CFD, it is of interest to note that AA is also actively transported from the 
periphery into CSF across the choroid plexus (Harrison and May, 2009; Verlinde et 
al., 2008) and is prone to oxidation due to its antioxidant properties (see section 
1.6.2.2) (Regoli and Winston, 1999; Winston et al., 1998). However, regarding the 
latter, at low concentrations, AA may function in a pro-oxidant manner (see section 
1.6.2.2) (Buettner and Jurkiewicz, 2010; Fisher and Naughton, 2003). Therefore, a 
decrease in AA availability and a potential increase in ROS generation could 
exacerbate oxidative stress and promote oxidative catabolism of 5-MTHF. Thus, AA 
may represent a factor governing 5-MTHF stability. 
In the absence of a peripheral folate deficiency, diagnosis of CFD relies on the 
measurement of 5-MTHF in the CSF compartment of the CNS (Ormazabal et al., 
2006; Ramaekers and Blau, 2004). Therefore, building upon what is currently known 
from the literature, the susceptibility of 5-MTHF to oxidative catabolism in disease 
control CSF was examined in this Chapter. In addition, the antioxidant capacity of 
AA to confer protection of 5-MTHF was assessed. 
4.2 Aims 
1. To determine the stability of endogenous 5-MTHF in disease control CSF in 
the absence and presence of hydroxyl radicals propagated by the Fenton 
reaction. 
 
2. To determine the effect of sodium selenite, in the absence and presence of 
GSH, on endogenous 5-MTHF stability in disease control CSF. 
 
3. To examine the ability of AA to confer protection of 5-MTHF. 
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4.4 Materials and Methods 
4.4.1 Materials 
Purchasing details of all materials used throughout this Chapter are described in 
section 2.1, unless otherwise stated. 
4.4.2 Patient CSF samples 
Patient CSF samples were collected as described in section 2.2.  
4.4.3 Treatment and buffer solutions 
Hydroxyl radical generating system 
Hydroxyl radicals were propagated by the Fenton reaction as previously described 
(Heales et al., 1988). Stock solutions of 1 mmol/L EDTA, 1 mmol/L iron (II) 
sulphate and 5 mmol/L hydrogen peroxide, were prepared fresh for each experiment 
in either potassium phosphate buffer (pH 7.4) or HPLC grade water as indicated in 
section 4.5. Hydroxyl radicals were used to study CSF 5-MTHF stability because the 
brain has a relatively high iron and, to a lesser extent, copper content, for example 
mitochondrial iron-sulphur clusters, copper centres and haem, and a low free iron 
binding capacity in CSF (Bleijenberg et al., 1971; Bradbury, 1997; Harrison et al., 
1968). Therefore, the production of the hydroxyl radical via the Fenton reaction may 
be more likely.  
Sodium selenite 
Selenite stock solutions as indicated in section 4.5 were prepared fresh for each 
experiment in HPLC grade water. Selenite was the selenium compound of choice 
since selenite is routinely used throughout the literature to study thiol-mediated 
redox cycling of selenium (Selenius et al., 2008; Wallenberg et al., 2010) and is the 
most commonly used dietary form (Kim et al., 2007). 
GSH 
GSH stock solutions as indicated in section 4.5 were prepared fresh for each 
experiment in HPLC grade water. 
5-MTHF 
5-MTHF stock solutions as indicated in section 4.5 were prepared fresh for each 
experiment in potassium phosphate buffer (pH 7.4). 
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AA 
An AA stock solution as indicated in section 4.5 was prepared fresh for each 
experiment in potassium phosphate buffer (pH 7.4). 
Potassium phosphate buffer 
Potassium phosphate buffer (0.1 M) was prepared by dissolving monopotassium 
dihydrogen phosphate (KH2PO4) and dipotassium hydrogen phosphate (K2HPO4) in 
HPLC grade water. One part KH2PO4 was added to two parts K2HPO4. The solution 
was mixed and incubated at 30°C for one hour and adjusted to pH 7.4 with either 
KH2PO4 or K2HPO4. 
4.4.4 Measurement of 5-MTHF 
5-MTHF was measured by HPLC as described in section 2.3. 
4.4.5 Data analysis 
Data analyses were carried out as described in section 2.9. Figure 32 is an example 
of a plot from which the first order rate constant (k) was calculated from the gradient 
of the slope. The gradient of the slope was determined by performing linear 
regression analysis of the data (Graphpad Software Inc). Natural log (ln) of 5-MTHF 
concentration (nmol/L) versus incubation time (min) plots were constructed for each 
experiment where k was calculated. 
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Figure 32 An example plot from which the rate constant (k) was 
calculated from the gradient of the slope. The gradient of the slope 
was calculated by performing linear regression analysis of the data 
(Graphpad Softward Inc.).  
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4.5 Experimental protocol 
4.5.1 5-MTHF stability in CSF 
Pooled disease control patient CSF (n=8) was incubated at +37°C for 30 minute 
timed intervals, from 0-150 minutes. At each 30 minute time interval, samples (120 
µL) were immediately snap frozen in liquid nitrogen and stored at -80°C until 
analysis of 5-MTHF by HPLC as described in section 2.3. For comparison, the 
stability of 5-MTHF in potassium phosphate buffer was determined. Samples were 
prepared by adding 500 uL of 1 μmol/L 5-MTHF (final concentration: 500 nmol/L) 
or 150 μL of 1 μmol/L 5-MTHF (final concentration: 150 nmol/L) made up in 0.1 M 
potassium phosphate buffer (pH 7.4), to 500 μL or 850 μL of 0.1 M potassium 
phosphate buffer, respectively. Samples were mixed and incubated at +37°C for 30 
minute timed intervals, from 0-150 minutes. At each 30 minute time interval, 
samples (120 µL) were immediately snap frozen in liquid nitrogen and stored at  
-80°C until analysis of 5-MTHF by HPLC as described in section 2.3. 
4.5.2 5-MTHF stability in CSF in the presence of a hydroxyl radical generating 
system 
Hydroxyl radicals were propagated by the Fenton reaction (Equation 3). The reaction 
differs from the original Fenton reaction (see Equation 2) (Fenton, 1894), in that 
EDTA is also added to the reaction mix. EDTA increases the amount of iron in 
solution by preventing the formation of Fe(OH)3 and iron oxide precipitates 
(Pogozelski et al., 1995).  
 
Equation 3: Fe
2+
 (ferrous) + H2O2 + EDTA  Fe
3+
 (ferric) + OH
-
 + •OH 
 
Samples were prepared by adding 50 µL of 1 mM EDTA (final concentration in 
reaction 50 µmol/L) and 50 µL of 1 mM iron (II) sulphate (final concentration in 
reaction 50 µmol/L) made up in ultrapure water, to 10 µL of 5 mmol/L hydrogen 
peroxide (final concentration in reaction 50 µmol/L) and 890 µL pooled disease 
control patient CSF (n=8). Samples were mixed and incubated at +37 °C for 30 
minute timed intervals, from 0-150 minutes. At each 30 minute time interval, 
samples (120 µL) were immediately snap frozen in liquid nitrogen and stored at -
80°C until analysis of 5-MTHF by HPLC as described in section 2.3. For 
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comparison, the stability of 5-MTHF in potassium phosphate buffer in the presence 
of hydroxyl radicals was determined. Samples were prepared by adding 500 µL of 1 
μmol/L 5-MTHF (final concentration: 500 nmol/L) or 150 μL of 1 μmol/L 5-MTHF 
(final concentration: 150 nmol/L), 50 µL of 1 mmol/L EDTA (final concentration in 
reaction 50 µmol/L) and 50 µL of 1 mmol/L iron (II) sulphate (final concentration in 
reaction 50 µmol/L) made up in 0.1 M of potassium phosphate buffer (pH 7.4), to 10 
uL of 5 mmol/L hydrogen peroxide (final concentration in reaction 50 µmol/L) and 
390 µL or 740 µL of 0.1 M potassium phosphate buffer, respectively. Samples were 
mixed and incubated at +37 °C for 30 minute timed intervals, from 0-150 minutes. 
At each 30 minute time interval, samples (120 µL) were immediately snap frozen in 
liquid nitrogen and stored at -80°C until analysis of 5-MTHF by HPLC as described 
in section 2.3. 
4.5.3 5-MTHF stability in CSF in the presence of selenite 
Samples were prepared by adding 10 L of 24 g/L selenite (final concentration: 2 
g/L) or 10 L of 240 g/L selenite (final concentration: 20 g/L) made up in 
ultrapure water, to 110 L of pooled disease control patient CSF (n=8). Control 
samples were prepared in the absence of selenite. Samples were mixed, incubated at 
+37°C for 150 minutes (the conditions 5-MTHF is known to be stable for in CSF as 
determined by experiment 4.5.1), immediately snap frozen in liquid nitrogen and 
stored at -80°C until analysis of 5-MTHF by HPLC as described in section 2.3. 
4.5.4 5-MTHF stability in CSF in the presence of GSH and selenite 
Samples were prepared by adding 5 L of 48 g/L selenite (final concentration: 2 
g/L), 5 L of 120 g/L selenite (final concentration: 5 g/L), 5 L of 240 g/L 
selenite (final concentration: 10 g/L), 5 L of 360 g/L selenite (final 
concentration: 15 g/L) or 5 L of 480 g/L selenite (final concentration: 20 g/L) 
made up in ultrapure water, to 5 L of 7.2 M GSH (final concentration 300 
nmol/L) made up in ultrapure water and 110 L of pooled control patient CSF. 
Control samples were prepared in the absence of GSH and selenite. Samples were 
mixed, incubated at +37°C for 150 minutes (the conditions 5-MTHF is known to be 
stable for in CSF as determined by experiment 4.5.1), immediately snap frozen in 
liquid nitrogen and stored at -80°C until analysis of 5-MTHF by HPLC as described 
in section 2.3. 
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4.5.5 5-MTHF stability in CSF in the presence of GSH and selenite (40:1) 
Samples were prepared by adding 5 L of 24.0 mol/L GSH (final concentration: 
1.0 mol/L) and 5 L of 48 g/L selenite (final concentration: 2 g/L) or 5 L of 
62.4 mol/L GSH (final concentration: 2.6 µmol/L) and 5 L of 120 g/L selenite 
(final concentration: 5 g/L) or 5 L of 122.4 mol/L GSH (final concentration: 5.1 
µmol/L) and 5 L of 240 g/L selenite (final concentration: 10 g/L), made up in 
ultrapure water, to 110 L of pooled disease control CSF. Control samples were 
prepared in the absence of GSH and selenite. Samples were mixed, incubated at 
+37°C for 150 minutes (the conditions 5-MTHF is known to be stable for in CSF as 
determined by experiment 4.5.1), immediately snap frozen in liquid nitrogen and 
stored at -80°C until analysis of 5-MTHF by HPLC as described in section 2.3. 
4.5.6 5-MTHF stability in (i) filtered CSF and (ii) filtered CSF in the presence 
of GSH and selenite (40:1) 
(i) Pooled control patient CSF (n=12) was aliquoted into 10 kDa pore size 
filter centrifugal eppendorf tubes. Molecules >10 kDa in size would be 
filtered out of the CSF. Control samples remained unfiltered. Samples 
were centrifuged for 10 minutes at 14000 rpm. Samples were pooled and 
incubated at +37°C for 30 minute timed intervals, from 0-150 minutes. At 
each 30 minute time interval, samples (120 L) were immediately snap 
frozen in liquid nitrogen and stored at -80°C until analysis of 5-MTHF by 
HPLC as described in section 2.3. 
(ii) Pooled disease control patient CSF (n=12) was aliquoted into 10 kDa 
pore size filter centrifugal eppendorf tubes, centrifuged for 10 min at 
14000 rpm and pooled. Samples where then prepared and analysed as 
described in section 4.5.5. 
4.5.7 5-MTHF stability in potassium phosphate buffer and AA 
Samples were prepared by adding 150 µL of 1 µmol/L 5-MTHF (final concentration: 
150 nmol/L) and 150 µL of 1 mmol/L AA (final concentration: 150 µmol/L) made 
up in 0.1 M potassium phosphate buffer (pH 7.4), to 700 µL of 0.1 M potassium 
phosphate buffer. Control samples were prepared in the absence of AA. Samples 
were mixed and incubated at +37°C for 30 minute timed intervals, from 0-150 
minutes. At each 30 minute time interval, samples (120 µL) were immediately snap 
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frozen in liquid nitrogen and stored at -80°C until analysis of 5-MTHF by HPLC as 
described in section 2.3. 
4.5.8 5-MTHF stability in potassium phosphate buffer in the presence of a 
hydroxyl radical generating system and AA 
Hydroxyl radicals were propagated by the Fenton reaction (Equation 3). Samples 
were prepared by adding 150 μL of 1 μmol/L 5-MTHF (final concentration: 150 
nmol/L), 150 µL of 1 mmol/L AA (final concentration: 150 µmol/L), 50 µL of 1 
mmol/L EDTA (final concentration in reaction 50 µmol/L) and 50 µL of 1 mmol/L 
iron (II) sulphate (final concentration in reaction 50 µmol/L) made up in 0.1 M of 
potassium phosphate buffer (pH 7.4), to 10 uL of 5 mmol/L hydrogen peroxide (final 
concentration in reaction 50 µmol/L) and 590 µL of 0.1 M potassium phosphate 
buffer, respectively. Samples were mixed and incubated at +37 °C for 30 minute 
timed intervals, from 0-150 minutes. At each 30 minute time interval, samples (120 
µL) were immediately snap frozen in liquid nitrogen and stored at -80°C until 
analysis of 5-MTHF by HPLC as described in section 2.3. 
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4.6 Results 
4.6.1 5-MTHF is stable in CSF 
Reduced pterin molecules, including 5-MTHF, are labile molecules and are 
susceptible to autoxidation and oxidative attack in the presence of molecular oxygen 
and oxidising species, respectively (Blair et al., 1975; Heales et al., 1988). In order 
to determine whether 5-MTHF exhibits similar molecular properties in physiological 
fluids, the stability of 5-MTHF in CSF was initially determined in pooled disease 
control patient CSF samples. An endogenous 5-MTHF concentration of 94.4 ± 7.5 
nmol/L was recorded at 0 minute. Over the 150 minute incubation period, no 
significant loss of 5-MTHF was observed compared to 0 minute and 5-MTHF 
remained relatively stable (Figure 33; Table 9). In contrast, 5-MTHF degraded in 
potassium phosphate buffer over time. Stability was first determined at an initial 5-
MTHF concentration of 500 nmol/L, a concentration within the linearity of the 5-
MTHF assay as shown in section 2.3 and comparable to concentrations used in 
previous studies (Opladen et al., 2006; Ormazabal et al., 2006). A 5-MTHF 
concentration of 340.1 ± 10.0 nmol/L was recorded at 0 minute. Over time, 5-MTHF 
progressively decreased in concentration (Figure 34a). An overall significant loss of 
46% was observed at 150 minutes, compared to 0 minute (p<0.01). In a parallel 
experiment, the stability of 5-MTHF in potassium phosphate buffer at a more 
physiological CSF concentration of 150 nmol/L was assessed. This 5-MTHF 
concentration is within the CSF reference range across all ages (72-305 nmol/L [0-2 
years], 52-178 nmol/L [2-5 years], 72-172 nmol/L [5-10 years], 46-160 nmol/L [10 
years-adult]). A 5-MTHF concentration of 121.8 ± 3.8 nmol/L was recorded at 0 
minute. Over time, 5-MTHF progressively decreased in concentration (Figure 34b). 
At 150 minutes, an overall significant loss of 25% was observed, compared to 0 
minute (p<0.05). The decay of 5-MTHF in buffer was found to obey first order 
kinetics over the 150 minute time period analysed (Table 9). 
4.6.2 5-MTHF rapidly degrades in CSF in the presence of a hydroxyl radical 
generating system 
In view of the relative stability of 5-MTHF in CSF (as determined in section 4.6.1), 
the stability of CSF 5-MTHF in the presence of hydroxyl radicals  
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Figure 33 5-MTHF stability in CSF. Samples were incubated in air saturated 
conditions at 37C. All values are mean ± SEM of 6 independent experiments.  
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Table 9 Calculated first or pseudo first (*) order rate constant for 5-MTHF 
degradation in CSF only, potassium phosphate buffer only, CSF or potassium 
phosphate buffer and hydroxyl radicals, potassium phosphate buffer and AA (150 
µmol/L) and potassium phosphate buffer and hydroxyl radicals and AA (150 
µmol/L). All values are mean ± SEM of 6 independent experiments. •OH = hydroxyl 
radicals, ND = not detectable. 
 
 
 
 
 
 
 
 
 
  
Conditions 
 
Rate constant 
(k/min) 
CSF 
 
ND 
Potassium phosphate buffer (5-MTHF 500 nmol/L) 
 
0.004 ± 0.0006 
Potassium phosphate buffer (5-MTHF 150 nmol/L) 
 
0.001 ± 0.0002 
CSF + •OH * 
 
0.02 ± 0.002 
Potassium phosphate buffer + •OH (5-MTHF 500 nmol/L) * 
 
0.04 ± 0.005 
Potassium phosphate buffer + •OH (5-MTHF 150 nmol/L) * 
 
0.07 ± 0.005 
Potassium phosphate buffer + AA (5-MTHF 150 nmol/L) 
 
ND 
Potassium phosphate buffer + •OH + AA (5-MTHF 150 nmol/L) * 
 
0.05 ± 0.005 
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Figure 34 5-MTHF stability in potassium phosphate buffer. a. 5-MTHF stability at 
an initial concentration of 500 nmol/L and b. at an initial concentration of 150 nmol/L. 
Samples were incubated in air saturated conditions at 37C. All values are mean ± 
SEM of 6 independent experiments. * p<0.05, ** p<0.01 difference in comparison to 
0 min by one-way ANOVA followed by Bonferroni’s multiple comparison test.  
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propagated by the Fenton reaction (Equation 3) was evaluated. A 5-MTHF 
concentration of 117.7 ± 2.2 nmol/L was recorded at 0 minute. 5-MTHF was shown 
to rapidly decay (Figure 35). An overall significant loss of 98% was observed at 150 
minutes, compared to 0 minutes (p<0.001). 5-MTHF in CSF in the presence of 
hydroxyl radicals, decayed at a faster rate compared to CSF alone (Table 9). 
Similarly, 5-MTHF rapidly decayed in potassium phosphate buffer following the 
introduction of a hydroxyl radical generating system. Stability was first determined 
at an initial 5-MTHF concentration of 500 nmol/L. A 5-MTHF concentration of 
301.4 ± 7.0 nmol/L was recorded at 0 minute. Over time, 5-MTHF rapidly decayed 
(Figure 36a). An overall significant loss of 100% was observed at 120 minutes, 
compared to 0 minute (p<0.001). In a parallel experiment, the stability of 5-MTHF 
in potassium phosphate buffer at a more physiological CSF concentration of 150 
nmol/L in the presence of hydroxyl radicals was assessed. A 5-MTHF concentration 
of 137.7 ± 5.0 nmol/L was recorded at 0 minute. Similarly, 5-MTHF rapidly decayed 
over time (Figure 36b). A significant 100% loss of 5-MTHF was observed at 90 
minutes, compared to 0 minutes (p<0.001). 5-MTHF, in the presence of hydroxyl 
radicals in CSF and in potassium phosphate buffer, decayed according to pseudo 
first order kinetics at a faster rate compared to potassium phosphate buffer alone 
(Table 9). 
4.6.3 5-MTHF is stable in CSF in the presence of selenite 
The effect of selenite on the stability of 5-MTHF in CSF was further determined. A 
5-MTHF concentration in pooled disease control CSF of 90.3 ± 1.1 nmol/L was 
recorded at 0 minute. In the presence of 2 µg/L selenite [a concentration within the 
CSF selenium reference range across all ages (1.8-4.7 µg/L (1–30 days), 0.68-3.00 
µg/L (1 month – 3 years) 0.73-2.13 µg/L (4 – 18 years) (Tondo et al., 2010)] and 20 
µg/L selenite [a selenium concentration associated with induction of ROS production 
(Maraldi et al., 2011)] no significant loss of 5-MTHF was observed after 150 
minutes incubation, compared to control (Figure 37).  
4.6.4 5-MTHF is stable in CSF in the presence of GSH and selenite  
In view of the relative stability of 5-MTHF in CSF in section 4.6.3, the stability of 5-
MTHF in the presence of selenite at various concentrations and GSH at a 
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Figure 35 5-MTHF stability in CSF in the presence of a hydroxyl radical generating 
system. Samples were incubated in air saturated conditions at 37C. All values are 
mean ± SEM of 6 independent experiments. *** p<0.001 difference in comparison to 
0 min by one-way ANOVA followed by Bonferroni’s multiple comparison test. 
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Figure 36 5-MTHF stability in potassium phosphate buffer in the presence of a 
hydroxyl radical generating system. a. Stability of 5-MTHF at an initial concentration 
of 500 nmol/L and b. at an initial concentration of 150 nmol/L. Samples were 
incubated in air saturated conditions at 37C. All values are mean ± SEM of 6 
independent experiments. *** p<0.001 difference in comparison to 0 min by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. 
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Figure 37 Concentration of CSF 5-MTHF remaining following incubation with 
selenite for 150 minutes. Samples were incubated in air saturated conditions at 37C. 
All values are mean ± SEM of 4 independent experiments.  
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physiological CSF concentration of 300 nmol/L (Samuelsson et al., 2011), was 
determined. A 5-MTHF concentration in CSF of 101.1 ± 5.4 nmol/L was recorded at 
0 minute. In the presence of GSH and selenite (2, 5, 10, 15 and 20 µg/L), 
concentrations within the CSF selenium reference range across all ages (1.8-4.7 µg/L 
(1–30 days), 0.68-3.00 µg/L (1 month – 3 years) 0.73-2.13 µg/L (4 – 18 years) 
(Tondo et al., 2010) and associated with induction of ROS production (Maraldi et 
al., 2011), no significant loss of 5-MTHF after 150 minutes incubation was 
observed, compared to control (Figure 38). 
4.6.5 5-MTHF is stable in CSF in the presence of GSH and selenite (40:1) 
Redox cycling of selenite with reduced GSH resulting in ROS production has been 
shown to be optimal at a GSH to selenite ratio of 40:1 (Yan and Spallholz, 1993). 
Since 5-MTHF in CSF remained relatively stable in section 4.6.4, the stability of 5-
MTHF in the presence of a GSH to selenite ratio of 40:1 was examined. A 5-MTHF 
concentration of 76.4 ± 4.0 nmol/L was recorded at 0 minute. No significant loss of 
5-MTHF was observed after 150 minutes incubation in the presence of GSH to 
sodium selenite ratios of 40:1; 1.0 µmol/L: 2 µg/L (25.6 nmol/L), 2.6 µmol/L: 5 
µg/L (64.1 nmol/L) and 5.1 µmol/L: 10 µg/L (128.2 nmol/L) (Figure 39). The 
selenite concentrations used were either within the CSF selenium reference range, 2 
µg/L (see section 4.6.3) (Tondo et al., 2010) or concentrations associated with 
induction of ROS production, 5 µg/L and 10 µg/L (Maraldi et al., 2011). 
4.6.6 5-MTHF is stable in filtered CSF and in filtered CSF in the presence of 
GSH and selenite (40:1) 
The relative stability of 5-MTHF in CSF observed in sections 4.6.3, 4.6.4 and 4.6.5, 
could be due to the presence of endogenous enzymatic antioxidant mechanisms 
reducing ROS to unreactive products, for example extracellular SOD (ecSOD). 
EcSOD catalyses the production of the more stable intermediate hydrogen peroxide 
from superoxide (Stewart et al., 2002; Weisiger and Fridovich, 1973). EcSOD is a 
32.5 kDa protein. Therefore, prior to each experiment, CSF was filtered through 10 
kDa pore size filters in order to eliminate endogenous molecules >10 kDa in size, 
including ecSOD. 
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Figure 38 Concentration of CSF 5-MTHF remaining following incubation with 
selenite and GSH (300 nmol/L) for 150 minutes. Samples were incubated in air 
saturated conditions at 37C. All values are mean ± SEM of 4 independent 
experiments.  
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Figure 39 Concentration of CSF 5-MTHF remaining following incubation with 
GSH and selenite at a ratio of 40:1, as indicated, for 150 minutes. Samples were 
incubated in air saturated conditions at 37C. All values are mean ± SEM of 4 
independent experiments. Se – selenite. 
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Initially, the stability of 5-MTHF in filtered CSF was determined. A 5-MTHF 
concentration of 98.5 ± 15.8 nmol/L was recorded at 0 minute. Over time, 5-MTHF 
remained relatively stable and no significant loss of 5-MTHF was observed, 
compared to 0 minute (Figure 40a). 
In view of the relative stability of 5-MTHF in filtered CSF, the stability of 5-MTHF 
in filtered CSF in the presence of a GSH to selenite ratio of 40:1 was examined. A 5-
MTHF concentration of 74.4 ± 1.4 nmol/L was recorded at 0 minute. No significant 
loss of 5-MTHF after 150 minutes incubation was observed compared to control in 
the presence of GSH to selenite ratios of 40:1; 1.0 µmol/L: 2 µg/L (25.6 nmol/L), 2.6 
µmol/L: 5 µg/L (64.1 nmol/L) and 5.1 µmol/L: 10 µg/L (128.2 nmol/L)  (Figure 
40b).  
4.6.7 AA confers protection of 5-MTHF in potassium phosphate buffer 
The ability of AA at a physiological CSF concentration of 150 µmol/L (Brau et al., 
1984) to confer protection of 5-MTHF at an initial concentration of 150 nmol/L in 
potassium phosphate buffer, was further determined. A 5-MTHF concentration of 
116.6 ± 7.9 nmol/L was recorded at 0 minute. Over time, 5-MTHF remained 
relatively stable in buffer and was no significant loss of 5-MTHF was observed, 
compared to 0 minute (Figure 41; Table 9).  
4.6.8 5-MTHF rapidly degrades in potassium phosphate buffer in the 
presence of a hydroxyl radical generating system and AA 
In view of the protective effect of AA on 5-MTHF stability in section 4.6.7, the 
effect of AA (150 µmol/L) on 5-MTHF stability at an initial concentration of 150 
nmol/L in the presence of hydroxyl radicals in potassium phosphate buffer, was 
assessed. A 5-MTHF concentration of 144.9 ± 4.3 nmol/L was recorded at 0 minute. 
Over time, 5-MTHF rapidly decayed (Figure 42). An overall significant loss of 
100% was observed at 90 minutes, compared to 0 minute (p<0.001). 5-MTHF, in the 
presence of hydroxyl radicals and AA in potassium phosphate buffer, decayed at a 
faster rate compared to potassium phosphate buffer alone (Table 9). 
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Figure 40 5-MTHF stability in filtered CSF (a) and concentration of 5-MTHF 
remaining in filtered CSF following incubation with GSH and selenite at a ratio of 
40:1, as indicated (b), for 150 minutes. Samples were incubated in air saturated 
conditions at 37C. All values are mean ± SEM of 4 independent experiments. Se – 
selenite. 
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Figure 41 5-MTHF stability at an initial concentration of 150 nmol/L in potassium 
phosphate buffer in the presence of AA (150 µmol/L). Samples were incubated in air 
saturated conditions at 37C. All values are mean ± SEM of 6 independent 
experiments.  
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Figure 42 5-MTHF stability at an initial concentration of 150 nmol/L in potassium 
phosphate buffer in the presence of a hydroxyl radical generating system and AA 
(150 µmol/L). Samples were incubated in air saturated conditions at 37C. All values 
are mean ± SEM of 6 independent experiments. *** p<0.001 difference in comparison 
to 0 min by one-way ANOVA followed by Bonferroni’s Multiple comparison test. 
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4.7 Discussion 
An initial loss of 5-MTHF was observed between sample preparation and 0 minute 
for all studies carried out in potassium phosphate buffer owing to the susceptibility 
of 5-MTHF to autoxidation in the presence of molecular oxygen (Blair et al., 1975) 
and lack of antioxidants present. Since 5-MTHF is prone to oxidation (Blair et al., 
1975), for diagnostic work, 5-MTHF calibrants are made up in the presence of an 
antioxidant, such as DTE, in order to prevent degradation. This is in accordance with 
the standard operating procedure used in the Clinical Pathology Accredited 
Neurometabolic Unit at the National Hospital for Neurology and Neurosurgery, 
London, UK, as detailed in section 2.3. For the studies reported here relating to the 
evaluation of 5-MTHF stability in the presence of oxidants, no such antioxidant was 
initially present. Consequently, a degree of loss of 5-MTHF would be expected to 
occur prior to quantification of 5-MTHF at the initial time point. The degree of loss 
appears to be comparable between experiments and so the effect of oxidants and/or 
antioxidants is being tested against a relatively consistent background. The data also 
reinforce the requirement for the immediate addition of antioxidants when preparing 
calibrants for quantitative analysis. 
Initially, the stability of endogenous 5-MTHF in CSF was assessed. In contrast to 5-
MTHF in potassium phosphate buffer at both initial concentrations of 500 nmol/L 
and 150 nmol/L, endogenous 5-MTHF in CSF was relatively stable. This apparent 
stability suggests the presence of protective factors, including non-enzymatic and 
enzymatic antioxidants (Alho et al., 1998; Boveris et al., 1972; Ng et al., 2007), 
counteracting 5-MTHF decay. However, introduction of a hydroxyl radical 
generating system to CSF resulted in loss of 5-MTHF. This finding implies that any 
protective factors present in CSF may be overwhelmed by ROS generation leading 
to loss of 5-MTHF from CSF. Similarly, 5-MTHF (500 nmol/L and 150 nmol/L) 
degradation in the presence of hydroxyl radicals was also observed in potassium 
phosphate buffer.  
The rate constants were also calculated for these experiments. A large k value 
(Connors, 1990) indicates that the reaction is fast in the forward direction, whereas, a 
small k value indicates that the reaction is slow in the forward direction . Owing to 
the observed stability of 5-MTHF in CSF as a consequence of the presence of 
putative protective factors counteracting 5-MTHF decay, an undetectable rate of 
decay was recorded. However, in agreement with previous observations (Blair et al., 
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1975), 5-MTHF was found to decay according to first order kinetics in buffer; the 
rate of reaction was proportional to the concentration of reactant i.e. 5-MTHF. This 
definition of first order kinetics can be applied to the difference in rate constant 
values observed between 5-MTHF decay in buffer at an initial concentration of 500 
nmol/L and 150 nmol/L. The rate is approximately four times faster in the 500 
nmol/L decay experiment compared to the 150 nmol/L decay experiment, which is 
associated with an approximate four times increase in concentration of 5-MTHF in 
the system. In experiments where hydroxyl radicals were propagated, the reaction is 
pseudo first order. When there are two reactants in a system, the reaction follows 
second order kinetics (Connors, 1990). However, owing to hydroxyl radicals being 
present in large excess within the system (Equation 4), it is not a ‘true’ reactant. The 
hydroxyl radicals ‘flood’ the system and the concentration of hydroxyl radicals is 
absorbed by the rate constant. Consequently, the observed reaction rate depends on 
the concentration of 5-MTHF only. This is called a pseudo first order reaction 
(Connors 1990). 
Equation 4: [5-MTHF] + [•OH (excess)]  [Product] 
An expected slower rate of CSF 5-MTHF decay in the presence of hydroxyl radicals 
was observed in comparison to that of 5-MTHF in buffer at both concentrations 
assessed, owing to the presence of endogenous protective antioxidant molecules and 
enzyme systems in CSF (Alho et al., 1998; Kolmakova et al., 2010). However, in 
contrast to the rates of decay observed for 5-MTHF in buffer alone, 5-MTHF at an 
initial concentration of 150 nmol/L decayed at a faster rate in the presence of 
hydroxyl radicals compared to 5-MTHF at an initial concentration of 500 nmol/L. 
This reversal can be explained by the large excess of hydroxyl radicals present in the 
system leading to an increased rate of 5-MTHF decay. 
Elevated selenium concentrations have been reported in CSF of patients with KSS 
(Tondo et al., 2011) and high physiological selenium concentrations have been 
shown to undergo redox cycling with reduced thiols, including GSH which is also 
present in CSF, to propagate ROS (Chen et al., 2007b; Lu et al., 2009; Tarze et al., 
2007; Yan and Spallholz, 1993). This reaction has been shown to be optimal at a 
GSH to selenite ratio of 40:1 (Yan and Spallholz, 1993). In view of the susceptibility 
of 5-MTHF in CSF to oxidative catabolism by ROS, the effect of selenite in the 
absence of GSH (due to endogenous GSH in CSF) (Samuelsson et al., 2011) and 
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presence of GSH was determined.  Interestingly, CSF 5-MTHF stability was 
unaffected following the addition of selenite only, GSH plus selenite and GSH plus 
selenite at a ratio of 40:1. It was postulated that owing to the physiological nature of 
CSF, the observed 5-MTHF stability may be attributable to the activity of 
endogenous non-enzymatic and enzymatic antioxidant mechanisms including 
ecSOD (Adachi et al., 2001; Stewart et al., 2002). However, upon CSF filtration 
through a 10 kDa pore size filter to remove 32.5 kDa ecSOD and addition of GSH 
and selenite at a ratio of 40:1, 5-MTHF remained stable. It is important to note that 
other large antioxidant proteins with a molecular mass >10 kDa, may also be filtered 
out of the CSF. These proteins may include catalase (59.8 kDa), glutathione 
peroxidase (GPx3 (extracellular), 25.6 kDa), thioredoxin (Trx1 (secreted cytosolic 
form), 12.0 kDa) and thioredoxin peroxidase (Prx4 (secreted endoplasmic reticulum 
form), 30.5 kDa) (Bendich and Deckelbaum, 2010; Moriarty-Craige and Jones, 
2004; Rubartelli et al., 1992) (http://www.uniprot.org/). However, other small 
molecule antioxidants with a molecular mass <10 kDa may pass through the 10 kDa 
size filter pores and remain in the CSF. These proteins may include AA (176 Da), 
GSH (307 Da), α-tocopherol (431 Da), uric acid (168 Da), ubiquinol (865 Da) and 
melatonin (232 Da) (Alho et al., 1998; Kolmakova et al., 2010; Marquardt et al., 
2013; Montecinos et al., 2007) (http://www.uniprot.org/). Therefore, the presence of 
these small molecular weight (<10 kDa) antioxidant molecules may explain the 
observed 5-MTHF stability in this system.  
Alternatively, other possible explanations may also be possible. For example, it has 
been documented that the reaction between selenite and GSH occurs favourably in 
acidic conditions to generate hydrogen selenide. In the presence of molecular 
oxygen, hydrogen selenide is susceptible to autoxidation and ROS are generated as a 
by-product. However, at a more neutral pH, the reaction yields elemental selenium 
(Lu et al., 2009). Since the pH of CSF is 7.33 (Widmaier and Raff, 2006), this 
environment would favour the production of elemental selenium, not hydrogen 
selenide and the associated generation of ROS, which could be an additional factor 
responsible for the observed stability of 5-MTHF in the aforementioned 
experimental systems. Interestingly, oxidation of GSH catalysed by selenite and 
subsequent ROS propagation has previously been demonstrated in the presence 
HTB123/DU4475 cells, a human mammary tumour cell line (Yan and Spallholz, 
1993). The presence of a cellular environment may facilitate the formation of 
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selenium metabolites, following the addition of selenite, that more easily oxidise 
with GSH to produce ROS. Therefore, use of a cellular system may be of importance 
when studying the stability of 5-MTHF in the presence of high physiological 
concentrations of selenium. In order to explore this, the stability of extracellular 5-
MTHF in the presence of selenite treated SH-SY5Y cells will be examined in 
Chapter 6. 
AA is a major antioxidant in the CNS that is prone to oxidation owing to its 
antioxidant capabilities (Barabás et al., 1995; Rice, 1999; Winston et al., 1998). It 
has been predicted that AA is low in concentration in the CSF of patients with CFD 
(Spector and Johanson, 2010). Therefore, the ability of AA to confer protection of 5-
MTHF was evaluated. The potential importance of AA to confer protection of 5-
MTHF was illustrated by the marked reduction in 5-MTHF catabolism observed in 
potassium phosphate buffer incubations performed in the presence of an AA 
concentration comparable to that observed in CSF (Brau et al., 1984). Similarly to 5-
MTHF in CSF, an undetectable rate of decay was recorded. AA is one of a number 
of antioxidants present in CSF and, among an array of other protective factors some 
of which are listed above (Alho et al., 1998; Kolmakova et al., 2010), its presence 
could explain the apparent stability of 5-MTHF observed in CSF and in the selenite, 
and GSH plus selenite, CSF systems. However, the ability of AA to confer 
protection towards 5-MTHF in potassium phosphate buffer was overwhelmed 
following the addition of a hydroxyl radical generating system. Since hydroxyl 
radicals are present in excess in the system, this finding suggests that either a higher 
concentration of AA or lower concentration of hydroxyl radicals is required to 
achieve redox homeostasis and subsequent 5-MTHF stability.  
AA is considered to be a double-edged sword. Whilst AA is an antioxidant, at low 
physiological CSF concentrations (~ <100 µmol/L) (Brau et al., 1984), AA has pro-
oxidant capabilities (Buettner and Jurkiewicz, 2010; Fisher and Naughton, 2003). 
Therefore, AA may exacerbate ROS generation in the system. Specifically, Fe
3+
 
generated in the Fenton reaction can be reduced to Fe
2+
 by AA and/or directly react 
with AA to produce hydrogen peroxide in the Weissberger system (Weissberger et 
al., 1943). This system dictates that the generation of Fe
2+
 and/or hydrogen peroxide 
may facilitate further generation of hydroxyl radicals by subsequent Fenton cycles, 
leading to accelerated 5-MTHF degradation (Fisher and Naughton, 2003; Hamilton 
et al., 1964). However, the rate of 5-MTHF degradation in the hydroxyl radicals and 
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AA system was marginally slower than that of hydroxyl radicals alone, suggesting 
that ROS generation is not exacerbated in the presence of AA via the mechanisms 
described above. Instead, the slower rate of 5-MTHF degradation in the hydroxyl 
radicals and AA system compared to hydroxyl radicals alone, may be attributable to 
the presence of AA in the system eliciting antioxidant protection. This study also 
indicates that AA at a physiological CSF concentration of 150 µmol/L has 
antioxidant capabilities. 
4.8 Conclusion 
In conclusion, the stability of 5-MTHF in CSF is dependent on the availability of 
antioxidants to counteract oxidative catabolism mediated by ROS. Whilst protective 
antioxidant molecules, including AA, are present in CSF, introduction of a hydroxyl 
radical generating system overwhelms such protective mechanisms. The rapid 
deleterious effect of hydroxyl radicals on 5-MTHF stability in CSF is reflected by an 
increase in rate of 5-MTHF decay. For comparative purposes, 5-MTHF stability 
studies were also carried out in potassium phosphate buffer and similar observations 
were documented. It is important to note that whilst these studies clearly 
demonstrate the susceptibility of 5-MTHF to oxidative attack by hydroxyl radicals in 
CSF, they were carried out in a non-cellular environment, ex vivo. In addition, whilst 
there is a high iron content in the brain and CSF has a low free iron binding capacity, 
the contribution of Fenton chemistry in promoting neurotoxicity in vivo remains 
unclear (Bleijenberg et al., 1971; Bradbury, 1997; Harrison et al., 1968; Stankiewicz 
et al., 2007). The deleterious effect of ROS generated as a consequence of selenite 
metabolism has yet to be documented. This may be attributed to a number of factors 
including the presence of antioxidant mechanisms that exist in CSF, the neutral pH 
of CSF and the lack of an appropriate cellular system to facilitate selenium 
metabolism. Moreover, in view of AA, which is present in CSF, conferring stability 
of 5-MTHF, AA may be a biologically relevant endogenous protective factor, in 
vivo. 
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5. Development and utilisation of a method to quantify CSF AA and 
the potential relationship between AA and 5-MTHF in CSF  
5.1 Introduction 
As determined in Chapter 4, 5-MTHF is relatively stable in CSF. This apparent 
stability suggests that protective factors present in CSF may counteract decay of 5-
MTHF. However, introduction of a hydroxyl radical generating system led to a 
significant loss of 5-MTHF from CSF, indicating that any protective mechanisms 
present may be overwhelmed.  
As discussed in section 4.7, CSF is known to contain an array of non-enzymatic and 
enzymatic antioxidant molecules (Alho et al., 1998; Kolmakova et al., 2010), which 
may confer protection of 5-MTHF. Such molecules in CSF include the essential 
water-soluble antioxidant, ascorbic acid (AA) (Barabás et al., 1995; Caprile et al., 
2009; Rice, 1999). Like 5-MTHF, AA is actively transported from the periphery into 
CSF, is prone to oxidation owing to its antioxidant capabilities and has been 
predicted to be low in concentration in CSF of patients with CFD (Harrison and 
May, 2009; Spector and Johanson, 2010; Weissberger et al., 1943). The biological 
role, transport and biochemistry of AA are discussed in detail in section 1.6.2.2. In 
Chapter 4, AA was demonstrated to counteract decay of 5-MTHF in potassium 
phosphate buffer at a concentration comparable to that observed in CSF. This 
observation suggests that AA, among other antioxidant molecules, may be an 
endogenous protective factor governing 5-MTHF availability and may be of 
biological relevance in CFD states. 
In order to evaluate the importance of AA on 5-MTHF availability in CSF, a method 
to measure AA in CSF was developed and the potential relationship between CSF 
AA and 5-MTHF was examined in this Chapter. 
The work presented in this Chapter was extended to examine the potential 
relationships between AA or 5-MTHF and the CSF neurotransmitter metabolites, 
homovanillic acid (HVA) or 5-hydroxyindoleacetic acid (5-HIAA). This extension 
was carried out because HVA and 5-HIAA had previously been measured in the 
CSF samples used in this Chapter for diagnostic purposes and previous studies have 
demonstrated relationships between 5-MTHF and HVA or 5-HIAA in CSF 
(Ormazabal et al., 2006; Surtees et al., 1994; Verbeek et al., 2008). Additionally, AA 
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is a cofactor for dopamine-β-hydroxylase, the enzyme which catalyses the 
production of noradrenaline from dopamine (Menniti et al., 1986) and has been 
implicated in influencing tyrosine hydroxylase and tryptophan hydroxylase activities 
(Stone and Townsley, 1973). 
5.2 Aims 
1. To develop and utilise a method for AA measurement in CSF.  
2. To develop an in-house reference range for assessment of AA in disease control 
CSF samples.  
3. To determine whether a potential relationship may exist between AA and 5-
MTHF in CSF.  
4. To determine whether potential relationships may exist between AA or 5-MTHF 
and HVA or 5-HIAA in CSF. 
5. To examine AA concentration in CSF from patients with a documented CSF 5-
MTHF deficiency. 
5.3 Acknowledgement 
Part of the work presented in this Chapter has been published (Aylett et al., 2013). I 
can confirm that all of the work documented was my own with the exception of CSF 
5-MTHF measurements and CSF neurotransmitter metabolite measurements, HVA 
and 5-HIAA, which were performed by Viruna Neergheen and Marcus Oppenheim, 
and Dr. Simon Pope, respectively, in the Neurometabolic Unit at the National 
Hospital for Neurology and Neurosurgery, London, UK. 
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5.4 Materials and Methods 
5.4.1 Materials 
Purchasing details of all materials used throughout this Chapter are described in 
section 2.1, unless otherwise stated. 
5.4.2 Patient CSF samples 
Patient CSF samples were collected as described in section 2.2.  
5.4.3 Development of a HPLC with electrochemical detection method to 
quantify AA in CSF 
In order to fulfil the aims of this Chapter, a method to detect and quantify AA in 
CSF was required. Methods used to measure AA in CSF have previously included 
colorimetric determination (Hashmi et al., 1973) and spectrophotometric ultraviolet 
scanning (Cupello et al., 2002). However, the most common direct method for AA 
quantification in CSF, as well as in other biological samples including plasma, is 
reverse-phase HPLC coupled with electrochemical detection (ECD) (Khan et al., 
2011; Li and Franke, 2009; Nagy and Degrell, 1989). This technique offers 
sufficient sensitivity and high throughput, and is also used to measure other redox 
active molecules in biological fluids, including the CSF neurotransmitter 
metabolites, homovanillic acid (HVA, dopamine metabolite) and 5-
hydroxyindoleacetic acid (5-HIAA, serotonin metabolite) (Hyland, 1993; Hyland et 
al., 1993). The reverse-phase HPLC-ECD method of Nagy and Degrell (1989) was 
developed and utilised for measurement of AA in CSF in this Chapter. 
5.4.3.1 Function 
Reverse-phase HPLC utilises a non-polar stationary phase and an aqueous mobile 
phase to separate analytes. Non-polar molecules tend to adsorb to the stationary 
phase and are retained on the HPLC column longer than polar molecules. 
Coulometric ECD is used for the detection of electroactive species in sample eluent, 
separated by the HPLC system. The HPLC eluent flows sequentially through two 
porous graphite working electrodes. The first electrode (E1) is the screening 
electrode, which screens out easily oxidisable compounds in order to reduce noise 
and produce a cleaner chromatogram. The second electrode (E2) is the detector 
electrode, which is set to give the maximum oxidation for the compound of interest. 
Coulometric ECD allows for 100% of the species of interest to be oxidised. As a 
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result, the observed current signal is directly proportional to the concentration of the 
analyte of interest in the sample (Flanagan et al., 2005). 
5.4.3.2 Equipment 
PU-1580 intelligent HPLC pump (Jasco); AS-1555 intelligent autosampler (Jasco); 
Coulochem II electrochemical detector module (model 5200A) and 5010 analytical 
cell (ESA Analytical Ltd, Aylesbury, UK). The mobile phase was degassed using a 
DG-1580-53 3-line degasser (Jasco). The electrochemical detector module was 
connected to a computer and data recorded using Jasco Borwin data capture and 
analysis software (Jasco). The equipment was set up as shown in Figure 14. 
5.4.3.3 External AA standard sample preparation 
AA is susceptible to autoxidation (Weissberger et al., 1943) and is unstable in 
aqueous solutions containing transition metal ions, including copper (II) and iron 
(III) ions. However, in aqueous solutions containing metaphosphoric acid and 
EDTA, AA stabilises. This is because metaphosphoric acid and EDTA lower the pH 
of the solution and chelate metal ions in order to inhibit the copper (II)/iron (III)-
catalysed oxidation of AA (Lyman et al., 1937; Wechtersbach and Cigić, 2007). 
Therefore, to prevent AA oxidation and anomalous data, all external AA standard 
samples were prepared in an acidic solution of 0.2 mmol/L metaphosphoric acid and 
5 mmol/L EDTA made up in HPLC grade water (Nagy and Degrell, 1989).  
5.4.3.4 Analytical procedure 
The mobile phase consisted of 0.1 mmol/L disodium hydrogenphosphate, 0.07 
mmol/L EDTA, 0.15 mmol/L sodium octyl sulphate and 50 ml/L methanol made up 
in ultrapure water, adjusted to pH 3.1 using orthophosphoric acid. The flow rate was 
0.5 ml/min. Samples were transferred to vials and loaded into the autosampler. Each 
sample (50 μL) was injected into the flow and separated on a C18 reverse phase 
Spherisorb ODS-2, 5 μm, 250 x 4.6 mm column (Waters, Elstree, UK), maintained 
at 28°C. E1 was set to +50 mV to oxidise analytes of low oxidation potential. The 
optimum voltage E2 was determined by voltammogram by measuring the peak area 
of 150 µmol/L AA at varying E2 potentials from +50 mV to +800 mV (Figure 43). 
An E2 potential of +650 mV, where the voltammogram plateaued indicating optimal   
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Figure 43 AA voltammogram. AA standards (150 µmol/L) were prepared in an 
aqueous solution of 0.2 mmol/L metaphosphoric acid and 5 mmol/L EDTA in air 
saturated conditions at ambient temperature. Samples were analysed at increasing 
E2 voltage by HPLC-ECD as described in section 5.4.3. 
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AA quantification, was chosen for determination of AA. External AA standard 
samples were prepared at a concentration of 150 µmol/L, a concentration 
comparable to that of AA in CSF. An example chromatogram of an AA 150 µmol/L 
standard is shown in Figure 44. A quality control was prepared by pooling disease 
control CSF. Results of the internal quality control were recorded. Data obtained 
from samples were kept within ±2 standard deviations of the measured values of the 
current quality control. A calibration curve was performed to determine the linearity 
between current amplitude and standard concentration. Linearity was demonstrated 
for AA between 0–80 mol/L (Figure 45). 
5.4.3.5 Measurement of AA in CSF 
Analysis of AA in CSF was performed in the first 0.5 ml CSF sample, since there is 
a sufficient volume of CSF remaining after diagnostic neurotransmitter analysis in 
the vial. Samples underwent a maximum of two freeze-thaw cycles. Blood-stained 
samples were excluded from analysis owing to the risk of AA oxidation in the 
presence of erythrocyte derived iron release, which could propagate the hydroxyl 
radical via the Fenton reaction (see Equation 2) (Fenton, 1894; Heales et al., 1988). 
According to the method of Nagy and Degrell (1989), CSF for AA measurement 
required very little prior sample preparation. Therefore, neat CSF was injected into 
the HPLC mobile phase flow. AA in CSF was measured using the analytical 
procedure outlined in section 5.4.3.4. An example chromatogram of AA in CSF is 
shown in Figure 46. 
5.4.3.6 Data analysis 
AA chromatograms were visualised and quantified using Jasco Borwin data capture 
and analysis software (Jasco) using the following equation: 
Concentration (µmol/L) = 
(sample peak area/external standard peak area) x calibration standard 
concentration (µmol/L) 
5.4.3.7 Recovery of AA performed in CSF 
Recovery experiments were performed to assess the performance of the method by 
spiking pooled disease control CSF (100 µl) with 10 µl 550 µmol/L AA (final 
concentration 50 µmol/L) and measuring the concentration of AA recovered. A 
mean recovery of 96 ± 2.3% was achieved for AA. 
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Figure 45 AA calibration curve. The linearity of AA concentration was demonstrated 
between 0–80 mol/L. Samples were prepared in an aqueous solution of 0.2 mmol/L 
metaphosphoric acid and 5 mmol/L EDTA in air saturated conditions at ambient 
temperature. Samples were analysed by HPLC as described in section 5.4.3. All values 
are mean ± SEM of 4 independent experiments. r
2
 = 0.94. 
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5.4.3.8 AA stability in CSF 
AA stability in CSF was determined in pooled disease control CSF samples. Pooled 
disease control patient CSF (n=12) was incubated at 37°C for 30 minute time 
intervals, from 0-150 minutes. AA was analysed in CSF samples (120 µL) by HPLC 
as described in section 5.4.3.4. Over the period of time studied, no significant loss of 
AA was observed. AA concentrations at 0 min and 150 min were 233.5 ± 22.4 
µmol/L and 214 ± 18.4 µmol/L, respectively (p>0.05) (Figure 47). 
5.4.3.9 AA availability in filtered CSF 
Pooled control patient CSF (n=12) was aliquoted into 10 kDa pore size filter 
centrifugal eppendorf tubes. Molecules greater than 10 kDa in size would be filtered 
out of the CSF. Control samples remained unfiltered. Samples were centrifuged for 
10 minutes at 14000 rpm. Samples were pooled and incubated at +37°C for 150 
minutes (the length of time 5-MTHF is stable for in CSF as determined by 
experiment 4.5.1). AA was analysed in CSF samples (120 L) by HPLC as 
described in section 5.4.3.4. At 150 minutes, no significant loss of AA was observed 
in either filtered or unfiltered CSF samples. An AA concentration in filtered CSF of 
120.9 ± 7.1 µmol/L was recorded at 150 minutes, whilst a CSF AA concentration of 
121.1 ± 5.9 µmol/L was recorded at 150 minutes in unfiltered CSF (Figure 48). 
5.4.3.10 Reproducibility of the assay 
Data from standard samples were analysed to calculate the intra- and inter-assay 
variation of the method. The intra-batch accuracy had a coefficient of variance of 
1.0% and the inter-day accuracy had a coefficient of variance of 12.6%. 
5.4.4 Measurement of CSF 5-MTHF 
CSF 5-MTHF was measured by HPLC as described in section 2.3. CSF 5-MTHF 
data were analysed retrospectively. The age-related CSF 5-MTHF reference ranges 
are shown in Table 5.  
5.4.5 Measurement of CSF HVA and 5-HIAA 
CSF HVA and 5-HIAA were measured by HPLC as described below. CSF HVA and 
5-HIAA data were analysed retrospectively. The age-related CSF HVA and 5-HIAA 
reference ranges are shown in Table 10.  
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Figure 47 AA stability in CSF. Samples were incubated in air saturated conditions at 
37°C. All values are mean ± SEM of 4 independent experiments. 
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Figure 48 AA availability in filtered CSF following 150 minute incubation. Samples 
were incubated in air saturated conditions at 37C for 150 minutes. All values are 
mean ± SEM of 4 independent experiments.  
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Table 10 CSF HVA and 5-HIAA reference ranges. CSF HVA and 5-HIAA follow 
negative age-related trends. Therefore, CSF HVA and 5-HIAA concentrations are 
age-related and the below reference ranges are used in the Neurometabolic Unit at 
The National Hospital for Neurology and Neurosurgery, London, UK. 
 
 
 
 
 
 
 
 
 
 
 
 
  
CSF HVA and 5-HIAA reference ranges 
Age (years) Concentration (nmol/L) 
HVA 5-HIAA 
0 – 0.33 324 – 1098 199 – 608  
0.34 – 0.66 362 – 955  63 – 503  
0.67 – 1.0 176 – 851  68 – 451  
1.1 – 5.0 154 – 867  89 – 367  
5.1 – adult  71 – 565  58 – 220  
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5.4.5.1 Function 
HPLC-ECD function is described in detail in section 5.4.3.1. 
5.4.5.2 Equipment 
The HPLC-ECD equipment used is described in section 5.4.3.2. The ECD detector 
was connected to a computer and data was recorded using Azur version 4.6 
chromatography data capture and analysis software (Datalys, St Martin D-Heres, 
France). The equipment was assembled as shown in Figure 14. 
5.4.5.3 Analytical procedure 
The method was based on the diagnostic method routinely used to quantify HVA 
and 5-HIAA in CSF in the Neurometabolic Unit at the National Hospital for 
Neurology and Neurosurgery, London, UK, adapted from previously published 
methods (Hyland, 1993; Hyland et al., 1993). Analysis of HVA and 5-HIAA in CSF 
was performed in the first 0.5 ml CSF sample. Samples underwent a maximum of 
two freeze-thaw cycles. Blood-stained samples were excluded from analysis owing 
to the risk of contamination by erythrocyte derived iron release which could degrade 
HVA and 5-HIAA (Fenton, 1894; Heales et al., 1988). This would lead to oxidative 
catabolism of HVA and 5-HIAA, and subsequent anomaolous results. The mobile 
phase consisted of 0.05 mol/L monopotassium phosphate, 1 mol/L 1-
octanesulphonic acid, 0.05 mol/L EDTA and 18% v/v HPLC grade methanol in 
ultrapure water, adjusted to pH 2.74 with hydrochloric acid. The flow rate was set at 
1.3 ml/min. Samples were thawed, transferred to vials and loaded into the 
autosampler. Each sample (50 µL) was injected into the flow and separated on a 
reverse phase 250 x 4.6 mm i.d. HiQSil C18W column (KYA Tech. Corp.), 
maintained at 35°C. HVA and 5-HIAA were detected by electrochemical detection. 
The screening electrode (E1) was set to +50 mV to oxidise analytes of low oxidation 
potential. The detector electrode (E2) was set at +450 mV in order to maximally 
oxidise HVA and 5-HIAA for quantification in the sample. Samples were quantified 
against an external standard of 500 nmol/L HVA or 5-HIAA prepared in HPLC 
grade water with two drops of 12.2 mol/L hydrochloric acid. A quality control was 
prepared by pooling CSF from previous patients with no evidence of an inborn error 
of monoamine metabolism. Results of the internal quality control were recorded. 
Data obtained from samples were kept within ±2 standard deviations of the 
measured values of the current quality control.  
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5.4.5.4 Data analysis 
HVA or 5-HIAA data were visualised and quantified using Azur version 4.6 
chromatography data capture and analysis software (Datalys), using the following 
equation: 
Concentration (nmol/L) = 
(sample peak area/external standard peak area) x calibration standard 
concentration (nmol/L) 
5.4.6 CSF samples for in-house AA reference range and to test for 
correlations between AA, 5-MTHF, HVA and 5-HIAA in CSF 
AA values were established for a total of 105 patients (mean ± SD [range] age, sex 
ratio: 5.7 ± 8.0 [1 day-19.7 years] years; 68M:37F) whose CSF was investigated in 
the Neurometabolic Unit laboratory at the National Hospital for Neurology and 
Neurosurgery, London, UK, from September to November 2012, inclusive. 
5.4.7 CSF samples from patients with CSF 5-MTHF deficiency 
AA values were established for a total of 21 patients (mean ± SD [range] age, sex 
ratio: 12.6 ± 8.8 [0.7 – 53.8] years; 12M:8F) with low CSF 5-MTHF, whose CSF 
was investigated in the Neurometabolic Unit at the National Hospital for Neurology 
and Neurosurgery, London, UK, from November 2012 to January 2013, inclusive. 
Minimal clinical features and diagnoses (where available) were collated for these 
patients. 
5.4.8 Data analysis 
Data analyses were carried out as described in section 2.9. 
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5.5 Results  
5.5.1 In-house AA reference range in CSF 
AA is an abundant antioxidant in the CNS with a CSF concentration within the 
µmol/L range (Rice, 1999). An in-house reference range for AA in CSF was 
determined by measuring AA in disease control CSF samples (n=105). The data was 
shown to follow a normal distribution (Figure 49). The mean and SD were 
calculated. Data points greater than mean ± 2 SD were defined as outliers and 
excluded from overall statistical analyses (n=6). Reference ranges are calculated as 
±2 SD either side of the mean (Marshall and Bangert, 2008). An AA reference range 
in CSF was calculated to be 103–303 µmol/L (n=99) (Table 11). This range 
encompasses individual CSF AA concentrations reported in the literature (Brau et 
al., 1984; Rice, 1999; Spector, 1981). 
5.5.2 Age has no effect on the AA reference range in CSF 
Since age-dependency can have a significant impact on the upper and lower 
reference range limits, especially in the first year of life, the effect of age on the AA 
reference range in CSF was determined (Ormazabal et al., 2006). No significant 
effect of age upon AA concentration could be demonstrated and a non-significant 
correlation was observed between CSF AA concentration and age (r=-0.043, p=0.67, 
n=99) (Figure 50). Therefore, the reference range for AA in CSF was considered age 
independent. 
5.5.3 Correlation between AA and 5-MTHF in CSF, but not with AA and HVA 
or 5-HIAA 
5-MTHF, HVA and 5-HIAA concentrations were determined in the same CSF 
samples utilised to determine the reference range for AA in CSF (n=105). The data 
were analysed and outliers for both parameters tested (n=9, n=8, n=7, for 5-MTHF, 
HVA and 5-HIAA correlations with AA, respectively) were excluded. The reference 
ranges for 5-MTHF, HVA and 5-HIAA in CSF are age dependent. However, since 
AA concentration in CSF is not dependent on age, the age dependency of 5-MTHF, 
HVA and 5-HIAA in CSF does not affect the overall analysis and the Pearson 
correlation test was performed (see section 2.9). A significant positive correlation 
was observed between AA and 5-MTHF (r=0.284, p=0.002, n=96) (Figure 51a). 
However, non-significant correlations were observed between AA and HVA 
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Figure 49 Normal distribution plot of CSF AA concentration from a reference 
population. Data was shown to follow a normal distribution (p<0.05, n=105). Samples 
were prepared in air saturated conditions at ambient temperature. µ=mean, 
SD=standard deviation. 
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AA reference range in CSF 
 
n number  
 
AA concentration (µmol/L) 
 
Minimum value (mean – 2 SD) 
 
Median 
 
Maximum value (mean + 2 SD) 
 
Mean ± SD 
 
 
99 
 
 
 
103 
 
196 
 
303 
 
203 ± 50 
Table 11 AA reference range in CSF. Data relating to the determination of a 
reference range for AA in CSF. For determination of the CSF AA reference range, the 
data were analysed and obvious outliers (n=6) were excluded. 
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Figure 50 Effect of age on AA concentration in CSF from a reference population. 
Correlation of CSF AA and age (r=-0.043, p=0.67, n=99). Samples were prepared in 
air saturated conditions at ambient temperature. Correlation determined by the Pearson 
test. 
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Figure 51 Correlation of AA with 5-MTHF, HVA and 5-HIAA in CSF. a. Correlation of 
AA and 5-MTHF (r=0.284; p=0.002, n=96) b. Correlation of AA and HVA in CSF 
(r=0.111, p=0.27, n=97) c. Correlation of AA and 5-HIAA in CSF (r=0.173, p=0.08, 
n=98). Samples were prepared in air saturated conditions at ambient temperature. 
Correlations determined by the Pearson test. 
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(r=0.111, p=0.27, n=97) (Figure 51b), and AA and 5-HIAA (r=0.173, p=0.08, n=98) 
(Figure 51c). 
5.5.4 Correlation between 5-MTHF and 5-HIAA in CSF, but not with 5-MTHF 
and HVA  
5-MTHF, HVA and 5-HIAA concentrations were determined in the same CSF 
samples utilised to determine the reference range for AA in CSF (n=105). The data 
were analysed and outliers for both HVA and 5-HIAA tested (n=5, n=4, for HVA 
and 5-HIAA correlations with 5-MTHF, respectively) were excluded. Since 5-
MTHF, HVA and 5-HIAA concentrations in CSF are age dependent, multivariate 
analysis of the data was performed, which removes the effect of age on the 
parameters when testing for correlations (see section 2.9).  A non-significant 
correlation was observed between 5-MTHF and HVA (r=0.187, p=0.11, n=100) 
(Figure 52a). However, a significant positive correlation was observed between 5-
MTHF and 5-HIAA (r=0.234, p=0.03, n=101) (Figure 52b). 
5.5.5 CSF AA concentration is low in a proportion of patients with low CSF 5-
MTHF 
To further evaluate the relationship between AA and 5-MTHF in CSF, CSF AA 
concentration was measured in CSF of patients with low CSF 5-MTHF (n=21) 
(Table 12). Using the in-house CSF AA reference range established in this Chapter, 
8 individuals (38%, Patients 1-8 inclusive) with low CSF 5-MTHF, also had 
evidence of a CSF AA deficiency (Figure 53; Table 13). 
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Figure 52 Correlation of 5-MTHF with HVA and 5-HIAA in CSF. a. 
Correlation of 5-MTHF and HVA (r=0.187, p=0.11, n=100) b. Correlation of 5-
MTHF and 5-HIAA in CSF (r=0.234, p=0.03, n=101). Samples were prepared in 
air saturated conditions at ambient temperature. Correlations determined by 
multivariate analysis. 
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CSF AA measurement in patients with a documented CSF 5-MTHF 
deficiency 
Sample parameters 
 
Minimum value 
 
Median 
 
Maximum value 
 
Mean ± SD 
 
AA (µmol/L) 
 
13 
 
131 
 
300 
 
134 ± 84 
5-MTHF (nmol/L) 
 
8 
 
43 
 
67 
 
41 ± 4 
Table 12 CSF AA analysis in patients with low CSF 5-MTHF. Data relating to the 
determination of CSF AA and 5-MTHF in patients with low CSF 5-MTHF. 
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Figure 53 Distribution of CSF AA concentrations in 21 patients with low CSF 
5-MTHF. The age-independent AA reference range utilised was 103 – 303 
µmol/L. The dotted line represents the lower CSF AA reference range value of 
103 µmol/L. 
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Patient 
 
Age at 
CSF 
sampling 
(years) 
 
 
Sex 
 
Major clinical features 
 
CSF 5-MTHF 
nmol/L (reference range) 
 
CSF AA(µmol/L) 
1 
 
41.5 M Generalised muscle twitches 
 
22 (46-160) 96 
2 
 
9.7 F Chorea and involuntary movements, myopathic 
 
62 (72-172) 90 
3 
 
2.6 F Movement disorder, seizures 
 
48 (52-178) 45 
4 
 
53.8 M Seizures, progressive dystonia, ataxia 35 (46-160) 17 
5 
 
3.7 M Developmental delay, impaired vision 
 
44 (52-178) 12 
6 
 
1.5 M Developmental delay, seizures, folate malabsorption  
 
<10 (72-305) 40 
7 
 
1.7 F Neuroregression 52 (72-305) 42 
Table 13 Patients with low CSF 5-MTHF and corresponding CSF AA status. CSF 5-MTHF reference ranges are dependent on age 
and the reference range used are according to the reference ranges used in the Neurometabolic Unit at the National Hospital for 
Neurology and Neurosurgery, London, UK (see Table 5). The age-independent AA reference range utilised was 103-303 µmol/L, as 
described in this Chapter. Concentrations of CSF 5-MTHF or AA below the lower reference range limit are highlighted in bold. 
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8 
 
0.7 F Seizures, developmental delay 
 
63 (72-172) 86 
9 
 
14.6 F Paroxysmal dystonia (exercise-induced) 
 
26 (46-160) 131 
10 
 
2.9 M Dihydropteridine reductase deficiency 
 
8 (52-178) 131 
11 
 
6.4 M Ptosis, loss of motor skills 
 
43 (72-172) 293 
12 
 
15.8 M Muscle wasting 
 
24 (46-160) 139 
13 
 
1.8 M Developmental delay, visual impairment, seizures 
 
67 (72-305) 172 
14 
 
15.9 M Dystonia, myoclonic jerks 
 
39 (46-160) 224 
15 
 
11.9 F Developmental delay 
 
42 (46-160) 196 
16 
 
6.7 F Previous low CSF 5-MTHF deficiency – now on 
treatment 
 
26 (72-172) 241 
17 
 
6.8 F Developmental delay, seizures, choreo-athetosis, 
Missense FOLR1 mutation in exon 5  
[c.335A>T; p.N112I] 
(Patient 4 in Chapter 3) 
<10 (72-172) 189 
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18 
 
41.6 M Progressive generalised dystonia, tremor 
 
45 (46-160) 154 
19 
 
5.2 F Encephalitis  
 
66 (72-172) 108 
20 
 
9.7 M Seizures, severe behavioural problems, psychosis 
 
58 (72-172) 114 
21 
 
9.8 M Spastic diplegia 
 
61 (72-172) 300 
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5.6 Discussion 
In Chapter 4, AA was shown to confer protection of 5-MTHF and as a consequence 
of the relative stability of 5-MTHF in CSF, AA was implicated as a biologically 
relevant protective factor of 5-MTHF in the CNS. In view of these observations and 
since CFD is diagnosed in the absence of a peripheral folate deficiency in the CSF 
compartment of the CNS (Ramaekers and Blau, 2004), the relationship between AA 
and 5-MTHF in CSF was examined in this Chapter. In order to facilitate this 
investigation, development and utilisation of a reliable HPLC-ECD method for 
analysis of AA concentration in CSF was carried out (Nagy and Degrell, 1989). 
Optimisation, linearity, recovery, stability and reproducibility of the method were 
demonstrated. An in-house, age independent reference range for AA in CSF was also 
determined.  
A significant positive correlation was demonstrated between AA and 5-MTHF in 
CSF. Since AA, like 5-MTHF, is an essential water-soluble vitamin that is actively 
transported into the CNS from the periphery (Harrison and May, 2009; Hyland et al., 
2010; Rice, 1999), such a correlation may be a reflection that both AA and 5-MTHF 
status is dependent upon dietary intake and active transport into the CSF 
compartment (Grapp et al., 2013; Liang et al., 2001). However, this correlation could 
also indicate an antioxidant protective role of AA towards 5-MTHF. This suggestion 
is supported by the observation of enhanced serum 5-MTHF in individuals also 
taking AA (Verlinde et al., 2008). The significant positive correlation between these 
two water-soluble vitamins also adds credence to the hypothesis that AA may be one 
of a number of biologically relevant factors needed to conserve 5-MTHF 
concentrations within the normal physiological range in CSF. There were no clear 
correlations observed between AA and HVA or 5-HIAA suggesting that AA 
concentration may not directly impact upon the availability of these neurotransmitter 
metabolites in CSF. 
The relationships between 5-MTHF and HVA or 5-HIAA were also examined. A 
significant positive correlation was observed between 5-MTHF and 5-HIAA. 
However, a non-significant correlation was observed between 5-MTHF and HVA, 
which suggests that 5-MTHF may not affect HVA concentration in CSF. These data 
are in accordance with a previous study (Verbeek et al., 2008), and partly in 
accordance with another study which concluded that children with decreased CSF 5-
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MTHF concentrations also had concomitant decreased concentrations of 5-HIAA 
and HVA (Surtees et al., 1994). Non-significant correlations between CSF 5-MTHF 
and 5-HIAA and HVA have also been reported, which similarly, are partly in 
accordance with the data described here (Ormazabal et al., 2006). The correlation 
between 5-MTHF and 5-HIAA observed here cannot readily be explained. It has 
been suggested that 5-MTHF may regenerate tetrahydrobiopterin from quinoid 
dihydrobiopterin through 5,10-methylenetetrahydrofolate reductase (MTHFR) 
(Kaufman, 1991; Matthews and Kaufman, 1980). Since tetrahydrobiopterin is a 
cofactor for tryptophan hydroxylase, regeneration of tetrahydrobiopterin by 5-MTHF 
would link 5-MTHF to serotonin synthesis, and in turn, production of the metabolite 
5-HIAA (Figure 54) (Clot et al., 2009). Another possible explanation for this 
correlation could be through neurotransmitter synaptic vesicle loading or release 
(Serrano et al., 2010; Surtees et al., 1994). Vesicular loading or release of 
neurotransmitters depends upon energy metabolism and ATP production (Bai et al., 
2001). Since 5-MTHF is involved in de novo purine and thymidylate synthesis 
(MacFarlane et al., 2011; Samsonoff et al., 1997), decreased levels of 5-MTHF may 
disturb mtDNA synthesis and subsequently lead to mitochondrial dysfunction.  
When considering the cohort of 21 patients with a CSF 5-MTHF deficiency in this 
Chapter, 38% were shown to also have evidence of an AA deficiency (Patients 1-8). 
However, there was no obvious link between AA concentration and the degree of 
CSF 5-MTHF deficiency observed in these patients. Although this was not a clinical 
evaluation study and only minimal clinical details were available, the clinical data 
reflect the known heterogeneity of patients presenting with a CSF 5-MTHF 
deficiency. It is of interest to note that AA deficiency could be demonstrated in a 
patient with folate malabsoption (Patient 6) but not in Patient 17 (Patient 4 in 
Chapter 3) who had a novel missense FOLR1 mutation in exon 5 [c.335A>T; 
p.N112I]. Whilst AA deficiency was not universal amongst the cohort of patients 
described, this finding may indicate that for a significant subset of individuals with a 
CSF 5-MTHF deficiency, the biochemical interaction between these two water-
soluble vitamins deserves further evaluation. In view of the positive correlation 
between CSF AA and 5-MTHF demonstrated in this Chapter, it could be 
hypothesised that the deficiency of CSF AA documented in Patients 1-8 may be a 
factor determining CSF 5-MTHF availability. 
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Figure 54 Synthesis and catabolism of dopamine and serotonin. Dopamine and serotonin are formed from the amino acids tyrosine and tryptophan, 
respectively. Tetrahydrobiopterin (BH4) is formed in a three-step pathway from GTP and is regenerated from quinoid dihydrobiopterin by 
dihydropteridine reductase with 5-MTHF as a cofactor. Tetrahydrobiopterin is the cofactor for tyrosine hydroxylase, tryptophan hydroxylase and 
phenylalanine hydroxylase, together with oxygen. Aromatic L-amino acid decarboxylase and pyridoxal 5′-phosphate are required for the conversion of L-
Dopa to dopamine and 5-hydroxytryptophan to serotonin. Dopamine and serotonin are rapidly metabolised to form HVA and 5-HIAA, respectively, and 
these metabolites are measured in CSF to provide an indication of the overall turnover of these neurotransmitters. Noradrenaline may be formed from 
dopamine via the activity of dopamine-β-hydroxylase. Figure adapted from Clot et al. (2009).  
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Interestingly, a CSF 5-MTHF deficiency was observed in one patient with 
dihydropteridine reductase deficiency (Patient 10). Previous studies have also 
reported similar findings (Irons et al., 1987; Kaufman, 1991; Smith et al., 1985). The 
deficiency in CSF 5-MTHF in this patient may be attributed to quinoid 
dihydrobiopterin interfering with folate metabolism. Dihydropteridine reductase and 
5,10-methylenetetrahydrofolate reductase catalyse the production of 
tetrahydrobiopterin from quinoid dihydrobioptein (Matthews and Kaufman, 1980). 
5,10-Methylenetetrahydrofolate reductase uses 5-MTHF as a coenzyme for the 
reaction, which results in the production of 5,10-methylenetetrahydrofolate (Bailey, 
2010). In the absence of dihydropteridine reductase, quinoid dihydrobiopterin 
accumulates and 5-MTHF levels may be depleted owing the activity of 5,10-
methylenetetrahydrofolate reductase (Kaufman, 1991). Alternatively or in addition, 
dihydrofolate reductase may also catalyse the production of tetrahydrobiopterin from 
quinoid dihydrobiopterin (Crabtree and Channon, 2011). In this reaction, 
dihydrofolate reductase uses tetrahydrofolate as a coenzyme, which results in the 
production of dihydrofolate. Similarly, in the absence of dihydropteridine reductase, 
quinoid dihydrobiopterin accumulates and tetrahydrofolate levels may be depleted 
owing the activity of dihydrofolate reductase, which in turn, impedes one-carbon 
metabolism (Stahl, 2007). In general, the role of 5-MTHF in regenerating 
tetrahydrobiopterin from quinoid dihydrobiopterin, catalysed by 5,10-
methylenetetrahydrofolate reductase, provides an escape from the “methyl trap” (see 
section 1.4.4.1) (Kaufman, 1991). 
5.7 Conclusion 
In conclusion, AA may be a significant antioxidant protective factor that determines 
the availability of 5-MTHF in CSF. AA deficiency was not universal among the 
CFD patients studied, but it was only possible to examine a relatively small number 
of patients during this study. This finding may suggest that for a significant subset of 
individuals with CFD, the biochemical interaction between these two vitamins 
deserves further evaluation. CSF AA deficiency may be a factor governing 5-MTHF 
availability in those patients with a documented CSF 5-MTHF deficiency. 
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The impact of mitochondrial 
respiratory chain enzyme inhibition 
in SH-SY5Y cells or selenite 
treatment of SH-SY5Y cells on the 
stability of 5-MTHF in extracellular 
minimal medium 
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6. The impact of mitochondrial respiratory chain enzyme inhibition 
in SH-SY5Y cells or selenite treatment of SH-SY5Y cells on the 
stability of 5-MTHF in extracellular minimal medium 
6.1  Introduction  
As shown in Chapter 3, low CSF 5-MTHF is associated in a number of patients with 
mitochondrial RCE defects. Complex I and complex IV deficiency were the most 
frequently observed skeletal muscle mitochondrial RCE defects in this Chapter. The 
mitochondrial RC is considered to be a major quantitative source of intracellular 
ROS production (see section 1.1.3) (Boveris and Chance, 1973; Boveris et al., 1972; 
Loschen and Azzi, 1975). In conditions associated with mitochondrial dysfunction, 
including mitochondrial RCE defects, an increase in electron leakage from the 
mitochondrial RC and ROS generation may be plausible. Previous studies have 
demonstrated that partial inhibition of the mitochondrial RC, to a degree insufficient 
to perturb oxidative phosphorylation, can lead to an increase in ROS production 
(Jacobson et al., 2005; Sipos et al., 2003). Studies documented in Chapter 4 
demonstrated the susceptibility of 5-MTHF to oxidative catabolism in the presence 
of hydroxyl radicals. Therefore, increased ROS production as a consequence of 
mitochondrial RC dysfunction could provide a mechanistic link between 
mitochondrial disorders and CFD. 
Additionally in Chapter 4, the effect of selenite, GSH and selenite, and GSH and 
selenite at a ratio of 40:1 on the stability of endogenous 5-MTHF in CSF was 
examined. As discussed in section 1.6.2.1, elevated CSF selenium concentrations 
have been documented in six patients with KSS (Tondo et al., 2011) but selenium 
was not implicated as a factor responsible for CFD in these patients and the data 
were not correlated to 5-MTHF availability. Metabolism of selenium may result in 
increased ROS production as a consequence of selenide redox cycling with reduced 
thiols, for example GSH (Chen et al., 2007a; Tarze et al., 2007; Yan and Spallholz, 
1993). In Chapter 4 the stability of 5-MTHF in CSF was unaffected following the 
addition of selenite, GSH plus selenite and GSH plus selenite at a ratio of 40:1. 
Since CSF contains endogenous antioxidants (Alho et al., 1998; Kolmakova et al., 
2010), this system may not have represented an effective model to study the 
potential impact of selenite on the stability of 5-MTHF. It was suggested in section 
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4.7 that the presence of a cellular environment may facilitate selenium metabolism 
and redox cycling with reduce thiols in order to propagate ROS (Yan and Spallholz, 
1993). 
In this Chapter, the effect of partial inhibition of mitochondrial complex I or 
complex IV, or selenite treatment of SH-SY5Y cells (see section 2.4.1) on 
extracellular 5-MTHF stability was determined. In view of the ability of AA to 
confer protection of 5-MTHF, as demonstrated in Chapters 4 and 5, co-incubation of 
AA with 5-MTHF was carried out in studies where loss of 5-MTHF was observed. 
6.2 Aims 
1. To examine the effect of partial inhibition of the mitochondrial RC at the level 
of complex I or complex IV on the stability of 5-MTHF in the extracellular 
minimal medium.  
 
2. To examine the effect of selenite treatment of SH-SY5Y cells on the stability of 
5-MTHF in the extracellular minimal medium. 
 
3. To examine the ability of AA to confer protection of 5-MTHF. 
6.3 Acknowledgement 
Part of the work presented in this Chapter has been published (Aylett et al., 2013). I 
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6.4 Materials and Methods 
6.4.1 Materials 
Purchasing details of all materials used throughout this Chapter are described in 
section 2.1, unless otherwise stated. 
6.4.2 Treatment solutions and cell culture medium 
5-MTHF 
5-MTHF stock solutions as indicated in section 6.5 were prepared fresh for each 
experiment in minimal medium (pH 7.4). 
Rotenone 
Rotenone stock solutions as indicated in section 6.5 were prepared fresh for each 
experiment in HPLC grade ethanol. Rotenone is commonly used in studies to inhibit 
mitochondrial complex I activity (Shaikh and Nicholson, 2009). It is an irreversible, 
competitive inhibitor that binds to the ubiquinone binding site of complex I (Adam-
Vizi, 2005). 
AA 
An AA stock solution as indicated in section 6.5 was prepared fresh for each 
experiment in minimal medium (pH 7.4). 
MitoSOX
TM
 Red 
MitoSOX
TM
 Red was prepared according to the manufacturer’s instructions 
(Invitrogen Ltd). Briefly, 50 µg of reagent was dissolved in 13 µL of DMSO to 
make a stock solution of 5 mmol/L as indicated in section 6.5. 
Potassium cyanide 
Potassium cyanide (KCN) stock solutions as indicated in section 6.5 were prepared 
fresh for each experiment in HPLC grade water. KCN is commonly used in studies 
to inhibit mitochondrial complex IV activity. It is an irreversible inhibitor that binds 
to the Haema3-CuB binuclear centre of complex IV (Way, 1984). 
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Sodium selenite 
Selenite stock solutions as indicated in section 6.5 were prepared fresh for each 
experiment in HPLC grade water. 
Minimal medium 
Minimal medium was prepared fresh every 4 weeks and consisted of 44 mmol/L 
sodium bicarbonate, 110 mmol/L sodium chloride, 1.8 mmol/L calcium chloride, 5.4 
mmol/L magnesium sulphate, 0.92 mmol/L sodium phosphate monobasic and 5 
mmol/L D-glucose prepared in sterile cell culture grade water adjusted to pH 7.4 
with CO2. Minimal medium was stored at +4°C when not in use and warmed to 
+37°C prior to cell culture. The pH was checked and, if necessary, re-adjusted to pH 
7.4 with CO2 with every use. Minimal medium was used to culture cells during 
experiments detailed in section 6.5. Minimal medium was used as a maintenance 
medium to keep the cells alive by providing essential components including glucose, 
and to reduce cell proliferation.  
6.4.3 Measurement of 5-MTHF 
5-MTHF was measured by HPLC as described in section 2.3. 
6.4.4 SH-SY5Y cell culture 
SH-SY5Y cells were cultured according to the protocols described in section 2.4. 
SH-SY5Y cells were used because this model system has been extensively used for 
neurological research. Undifferentiated cells were used owing to their ability to 
proliferate for long periods of time and are a good model for studying toxicity and 
oxidative stress (Cheung et al., 2009; Schneider et al., 2011). 
6.4.5 Measurement of mitochondrial respiratory chain enzyme activity in SH-
SY5Y cells 
Mitochondrial RCE assays were performed as described in section 2.5. 
Mitochondrial RCE activities were calculated as a ratio to citrate synthase, a 
mitochondrial marker enzyme, to compensate for mitochondrial enrichment of the 
muscle samples, and as expressed as nmol/min/mg of protein, to compensate for 
changes in cell number.  
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6.4.6 Total protein assay 
Total protein was measured as described in section 2.6. 
6.4.7 Flow cytometry 
Flow cytometric analysis was carried out as described in section 2.7. 
6.4.8 Data analysis 
Data analyses were carried out as described in section 2.9 and section 4.4.5.  
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6.5 Experimental protocol 
6.5.1 5-MTHF stability in extracellular minimal medium 
Cells were cultured as described in section 2.4. After a period of 24 hours of cell 
stabilisation and attachment, growth medium (DMEM/F-12 + 100 ml/L FBS + 5 
mmol/L L-glutamine) was removed and replaced with minimal medium containing 
5-MTHF. Minimal medium containing 5-MTHF was prepared by adding 100 µL or 
30 µL of 50 µmol/L 5-MTHF (final concentrations: 500 nmol/L or 150 nmol/L) 
made up in minimal medium (pH 7.4), to 9,900 µL or 9,970 µL of minimal medium 
(total volume: 10 ml). The minimal medium was mixed thoroughly. Control flasks 
were prepared in the absence of cells. Cell containing flasks and control flasks were 
incubated at +37°C in 5% CO2 for 30 minute timed intervals, from 0-150 minutes. 
At each 30 minute time interval, minimal media samples (120 µL) were immediately 
snap frozen in liquid nitrogen and stored at -80°C until analysis of 5-MTHF by 
HPLC as described in section 2.3. All subsequent experiments were compared to the 
stability of 5-MTHF in minimal medium in the presence of SH-SY5Y cells used as a 
control as described in section 6.6.1. 
6.5.2 5-MTHF stability in extracellular minimal medium of complex I inhibited 
SH-SY5Y cells in the absence and presence of AA 
Initially, complex I activity in rotenone treated cells was determined. Cells were 
cultured as described in section 2.4. After a period of 24 hours of cell stabilisation 
and attachment, growth medium was removed and replaced with rotenone containing 
growth medium. Rotenone containing growth medium was prepared by adding 5 µL 
or 10 µL of 100 µmol/L rotenone (final concentrations: 50 nmol/L or 100 nmol/L) 
made up in ethanol and 0.2 µm sterile filtered, to 9,995 µL or 9,990 µL of growth 
medium (total volume: 10 ml). An equivalent volume of 0.2 µm sterile filtered 
ethanol was added to an equivalent volume of growth medium (control). The growth 
media preparations were thoroughly mixed. Cells were left to incubate at +37°C in 
5% CO2 for 24 hours. Following incubation, cells were harvested as described in 
section 2.4. Complex I and citrate synthase activity were measured as described in 
section 2.5. Total protein was measured as described in section 2.6. A rotenone 
concentration of 100 nmol/L and cell incubation period of 24 hours were used for all 
subsequent experiments (see section 6.6.2). 
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Rotenone (100 nmol/L) containing growth medium was prepared and cells cultured 
and incubated as described in section 6.5.2 (above). After 24 hours cell incubation, 
rotenone containing growth medium or control growth medium was removed and 
replaced with either minimal medium containing 5-MTHF (as described in section 
6.5.1) or minimal medium containing 5-MTHF and AA. Minimal medium 
containing 5-MTHF and AA was prepared by adding 100 µL or 30 µL of 50 µmol/L 
5-MTHF (final concentrations: 500 nmol/L or 150 nmol/L) and 100 µL of 15 
mmol/L AA (final concentration: 150 µmol/L), made up in minimal medium (pH 
7.4), to 9,800 µL or 9,870 µL of minimal medium (total volume: 10 ml). The 
minimal medium was mixed thoroughly. Cells were incubated at +37°C in 5% CO2 
for 150 minutes (the conditions 5-MTHF is known to be stable for in CSF as 
determined by experiment 4.5.1). Following incubation, minimal media samples 
(120 µL) were immediately snap frozen in liquid nitrogen and stored at -80°C until 
analysis of 5-MTHF by HPLC as described in section 2.3. 
6.5.3 Measurement of mitochondrial superoxide generation in complex I 
inhibited SH-SY5Y cells 
Rotenone (100 nmol/L) containing growth medium was prepared, and cells cultured 
and incubated as described in section 6.5.2. After 24 hours cell incubation, rotenone 
containing growth medium and control growth medium were removed and replaced 
with minimal medium containing MitoSOX
TM
 Red or control minimal medium. 
Protected from light, minimal medium containing MitoSOX
TM
 Red was prepared by 
adding 10 µL of 5 mmol/L MitoSOX
TM
 Red (final concentration: 5 µmol/L) made 
up in DMSO, to 9990 µL of minimal medium (total volume: 10 ml). An equivalent 
volume of DMSO was added to an equivalent volume of control minimal medium. 
The minimal media preparations were thoroughly mixed. Cells were incubated in the 
dark, owing to the light sensitivity of the MitoSOX
TM
 Red stain, at +37°C in 5% 
CO2 for 30 minutes. Following incubation, cells were harvested as described in 
section 2.4 and immediately analysed by flow cytometry as described in section 2.7. 
6.5.4 5-MTHF stability in extracellular minimal medium of complex IV 
inhibited SH-SY5Y cells 
Initially, complex IV activity in KCN treated cells was determined. Cells were 
cultured as described in section 2.4. After a period of 24 hours of cell stabilisation 
and attachment, growth medium was removed and replaced with KCN containing 
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growth medium. KCN containing growth medium was prepared by adding 100 µL of 
100 mmol/L KCN (final concentration: 1 mmol/L) made up in ultrapure water and 
0.2 µm sterile filtered, to 9,900 µL of growth medium (total volume: 10 ml). An 
equivalent volume of 0.2 µm sterile filtered ultrapure water was added to an 
equivalent volume of growth medium (control). The minimal media preparations 
were thoroughly mixed. Cells were left to incubate at +37°C in 5% CO2 for 24 
hours. Following incubation, cells were harvested as described in section 2.4. 
Complex IV and citrate synthase were measured as described in section 2.5. Total 
protein was measured as described in section 2.6. A KCN concentration of 1 mmol/L 
and cell incubation period of 24 hours were used for all subsequent experiments (see 
section 6.6.4). 
KCN (1 mmol/L) containing growth medium was prepared, and cells cultured and 
incubated as described in section 6.5.4 (above). After 24 hours incubation, KCN 
containing growth medium and control growth medium were removed and replaced 
with minimal medium containing 5-MTHF as described in section 6.5.1. Cells were 
incubated at +37°C in 5% CO2 for 150 minutes (the conditions 5-MTHF is known to 
be stable for in CSF as determined by experiment 4.5.1). Following incubation, 
minimal media samples (120 µL) were immediately snap frozen in liquid nitrogen 
and stored at -80°C until analysis of 5-MTHF by HPLC as described in section 2.3. 
6.5.5 Measurment of mitochondrial superoxide generation in complex IV 
inhibited SH-SY5Y cells 
KCN (1 mmol/L) containing growth medium was prepared and cells cultured and 
incubated as described in section 6.5.4. After 24 hours cell incubation, KCN 
containing growth medium and control growth medium were removed and replaced 
with either minimal medium containing MitoSOX
TM
 Red or control minimal 
medium. Protected from light, minimal medium containing MitoSOX
TM
 Red and 
control minimal medium was prepared as described in section 6.5.3. Cells were 
incubated in the dark, owing to the light sensitivity of the MitoSOX
TM
 Red stain, at 
+37°C in 5% CO2 for 30 minutes. Following incubation, cells were harvested as 
described in section 2.4 and immediately analysed by flow cytometry as described in 
section 2.7. 
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6.5.6 5-MTHF stability in extracellular minimal medium of selenite treated SH-
SY5Y cells in the absence and presence of AA 
Cells were cultured as described in section 2.4. After a period of 24 hours of cell 
stabilisation and attachment, growth medium was removed and replaced with 
selenite containing growth medium. Selenite containing growth medium was 
prepared by adding 20 µL, 100µL or 200 µL of 1 mg/L selenite (final 
concentrations: 2 µg/L, 10 µg/L or 20 µg/L) made up in ultrapure water and 0.2 µm 
sterile filtered, to 9,980 µL, 9,900 µL or 9,800 µL of growth medium (total volume: 
10 ml). An equivalent volume of 0.2 µm sterile filtered ultrapure water was added to 
an equivalent volume of growth medium (control). The minimal media preparations 
were thoroughly mixed. Cells were left to incubate at +37°C in 5% CO2 for 1 hour. 
Following incubation, selenite containing growth medium and control growth 
medium were removed and replaced with either minimal medium containing 5-
MTHF or minimal medium containing 5-MTHF and AA as described in sections 
6.5.1 and 6.5.2, respectively. Cells were incubated at +37°C in 5% CO2 for 150 
minutes (the conditions 5-MTHF is known to be stable for in CSF as determined by 
experiment 4.5.1). Following incubation, minimal media samples (120 µL) were 
immediately snap frozen in liquid nitrogen and stored at -80°C until analysis of 5-
MTHF by HPLC as described in section 2.3. 
6.5.7 Complex I activity in selenite treated SH-SY5Y cells 
Selenite (2 µg/L, 10 µg/L and 20 µg/L) containing growth media was prepared and 
cells cultured and incubated as described in section 6.5.6. Following incubation, 
cells were harvested as described in section 2.4. Complex I and citrate synthase were 
measured as described in section 2.5. Total protein was measured as described in 
section 2.6. 
6.5.8 Mitochondrial superoxide generation in selenite treated SH-SY5Y cells 
Selenite (10 µg/L and 20 µg/L) containing growth media was prepared, and cells 
cultured and incubated as described in section 6.5.6. After 1 hour cell incubation, 
selenite containing growth medium and control growth medium were removed and 
replaced with either minimal medium containing MitoSOX
TM
 Red or control 
minimal medium. Protected from light, minimal medium containing MitoSOX
TM
 
Red and control minimal medium was prepared as described in section 6.5.3. Cells 
were incubated in the dark, owing to the light sensitivity of the MitoSOX
TM
 Red 
 230 
stain, at +37°C in 5% CO2 for 30 minutes. Following incubation, cells were 
harvested as described in section 2.4 and immediately analysed by flow cytometry as 
described in section 2.7. 
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6.6 Results 
6.6.1 5-MTHF is more stable in extracellular minimal medium than in minimal 
medium alone 
In view of the labile nature of 5-MTHF, as previously demonstrated in Chapter 4, the 
stability of 5-MTHF in minimal medium in the presence and absence of SH-SY5Y 
cells was initially determined. Stability was first determined in the presence of cells 
at an initial 5-MTHF concentration of 500 nmol/L, a concentration within the 
linearity of the 5-MTHF assay as shown in section 2.3 and comparable to 
concentrations used in previous studies (Opladen et al., 2006; Ormazabal et al., 
2006). A 5-MTHF concentration of 284.3 ± 2.1 nmol/L was recorded at 0 minute. 
Over time, 5-MTHF progressively decreased in concentration (Figure 55a). An 
overall significant loss of 21% was observed at 150 minutes, compared to 0 minute 
(p<0.05). The stability of 5-MTHF at an initial concentration of 500 nmol/L was also 
determined in the absence of cells. A 5-MTHF concentration of 285.3 ± 1.7 nmol/L 
5-MTHF was recorded at 0 minute. Over time, 5-MTHF progressively decreased in 
concentration (Figure 55a). An overall significant loss of 38% was observed at 150 
minutes, compared to 0 minute (p<0.001). The decay of 5-MTHF in minimal 
medium was found to obey first order kinetics over the 150 minute time period 
analysed (Table 14). 5-MTHF (500 nmol/L) degraded at a faster rate in the absence 
of cells than in the presence of cells (Table 14). 
Similar findings were observed when the stability of 5-MTHF in the presence of 
cells was determined at a more physiological CSF concentration of 150 nmol/L. This 
5-MTHF concentration is within the CSF reference range across all ages (72-305 
nmol/L [0-2 years], 52-178 nmol/L [2-5 years], 72-172 nmol/L [5-10 years], 46-160 
nmol/L [10 years-adult]).  A 5-MTHF concentration of 63.3 ± 3.7 nmol/L was 
recorded at 0 minute. Over time, 5-MTHF progressively decreased in concentration 
(Figure 55b). At 150 minutes, an overall loss of 24% was observed, compared to 0 
minute. The stability of 5-MTHF at an initial concentration of 150 nmol/L was also 
determined in the absence of cells. A 5-MTHF concentration of 64.0 ± 4.5 nmol/L 5-
MTHF was recorded at 0 minute. Over time, 5-MTHF progressively decreased in 
concentration (Figure 55b). An overall significant loss of 
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Figure 55 5-MTHF stability in minimal medium in the absence and presence of 
SH-SY5Y cells. a. 5-MTHF stability at an initial concentration of 500 nmol/L and 
b. at an initial concentration 150 nmol/L. Samples were incubated in air saturated 
conditions at 37˚C. All values are mean ± SEM of 4 independent experiments. 
*p<0.05, **p<0.01, ***p<0.001 difference in comparison to 0 minute determined 
by one-way ANOVA followed by Bonferroni’s multiple comparison test. #p<0.05, 
##p<0.01 difference in comparison to absence of cells at 150 minutes (in brackets) 
determined by Student’s t-test. 
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Table 14 Calculated first order rate constant for 5-MTHF degradation in minimal 
medium in the absence and presence of SH-SY5Y cells. All values are mean ± SEM 
of 4 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Conditions 
 
Rate (k/min) 
+ SH-SY5Y (5-MTHF 500 nmol/L) 
 
0.002 ± 0.0001 
- SH-SY5Y (5-MTHF 500 nmol/L) 
 
0.004 ± 0.0004  
+ SH-SY5Y (5-MTHF 150 nmol/L) 
 
0.006 ± 0.0001 
- SH-SY5Y (5-MTHF 150 nmol/L) 
 
0.009 ± 0.0002  
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63% was observed at 150 minutes, compared to 0 minute (p<0.01). The decay of 5-
MTHF in minimal medium was found to obey first order kinetics over the 150 
minute time period analysed (Table 14). 5-MTHF (150 nmol/L) degraded at a faster 
rate in the absence of cells than in the presence of cells (Table 14).  
The differences between the concentration of 5-MTHF remaining at 150 minutes in 
the presence and absence of cells at both initial concentrations of 500 nmol/L and 
150 nmol/L were statistically significant, (p<0.001, p<0.05) respectively (Figures 
55a and 55b).  
All subsequent experiments were compared to the stability of 5-MTHF in 
extracellular minimal medium in the presence of SH-SY5Y cells, used as a control. 
6.6.2 Rotenone mediated mitochondrial complex I inhibition in SH-SY5Y cells 
causes a significant loss of 5-MTHF from extracellular minimal medium 
which is prevented by AA 
As previously described in section 6.1, partial inhibition, to a degree insufficient to 
perturb oxidative phosphorylation, has been shown to increase ROS production 
(Jacobson et al., 2005). Threshold levels of complex I before major changes in rate 
of ATP synthesis or oxygen consumption, vary according to the in vitro model used. 
For example, in situ non-synaptic mitochondria have a complex I threshold of 
approximately 72% (Davey and Clark, 1996), whilst synaptic isolated nerve 
terminals have a complex I threshold of between 16% and 25% (Davey et al., 1998; 
Sipos et al., 2003). A rotenone concentration range of 50-100 nmol/L has previously 
been shown to inhibit complex I by approximately 50-60% in SH-SY5Y cells 
(Sherer et al., 2001). In addition, incubation of SH-SY5Y cells with 100 nmol/L 
rotenone for 24 hours, has previously been shown to increase ROS production 
(Xiong et al., 2013). Therefore, SH-SY5Y cells were incubated with 50 nmol/L or 
100 nmol/L rotenone for 24 hours and mitochondrial complex I activity measured. A 
decrease in complex I activity of 40% was observed in cells treated with 50 nmol/L 
rotenone which was not significant when compared to control. Whereas, a 
significant decrease in complex I activity of 58% (p<0.05) was observed following 
100 nmol/L rotenone treatment compared to control (Figure 56, Table 15). These 
effects were apparent when complex I activity was expressed as either a ratio to  
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Figure 56 Complex I activity in rotenone treated SH-SY5Y cells for 
24 hours. Complex I activity is expressed as a ratio to citrate synthase. 
Rotenone treatment (50 nmol/L and 100 nmol/L) led to a 40% and 58% 
reduction in complex I activity, respectively. All values are mean ± 
SEM of 4 independent experiments. *p<0.05 determined by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. 
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Table 15 Mitochondrial RCE activity in SH-SY5Y cells following rotenone or KCN 
treatment. Complex I activity (nmol/min/mg of protein), complex IV activity 
(nmol/min/mg of protein) and citrate synthase activity (nmol/min/mg of protein). 
Complex I % inhibition following rotenone treatment for 24 hours. Complex IV % 
inhibition following KCN treatment for 24 hours. All values are mean ± SEM of 4 
independent experiments. *p<0.05 compared to control determined by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. ***p<0.001 compared 
to control determined by Student’s t-test. 
 
 
 
Conditions 
 
Complex I (nmol/min/mg 
of protein) 
 
 
Complex IV 
(nmol/min/mg of 
protein) 
 
 
Citrate 
Synthase 
(nmol/min/mg 
of protein) 
 
Activity 
 
% 
inhibition 
 
Activity 
% 
inhibition 
Control (no rotenone) 
 
11.8 ± 2.1 - - - 125.0 ± 8.5 
Rotenone 50 nmol/L 
 
7.1 ± 2.4 40 - - 125.0 ± 17.0 
Rotenone  100 nmol/L 
 
* 
4.9 ± 0.3  
 
 
58 
- - 120.1 ± 4.9 
Control (no KCN) 
 
- - 0.7 ± 0.05 - 123.2 ± 1.6 
KCN 1 mmol/L 
 
- - *** 
0.1 ± 0.03 
 
 
86 
122.2 ± 1.9 
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citrate synthase or as nmol/min/mg of protein (Figure 56; Table 15). This level of 
complex I inhibition did not appear to cause cell morbidity under a light microscope. 
In view of the data documented in the literature regarding increased ROS generation 
following partial inhibition of complex I (Davey and Clark, 1996; Jacobson et al., 
2005) and statistical significance, a rotenone concentration of 100 nmol/L and cell 
incubation period of 24 hours were used for all subsequent experiments. 
Using these culture conditions, the stability of 5-MTHF in extracellular minimal 
medium of rotenone (100 nmol/L) treated cells for 150 minutes was evaluated. 
Stability was first determined at an initial 5-MTHF concentration of 500 nmol/L. A 
5-MTHF concentration of 257.6 ±9.3 nmol/L was recorded at 0 minute. A 
significant 5-MTHF loss of 25% from the extracellular minimal medium of rotenone 
treated cells was observed at 150 minutes, compared to control (p<0.001) (Figure 
57a). A similar finding was observed when the experiment was carried out at an 
initial 5-MTHF concentration of 150 nmol/L. A 5-MTHF concentration of 64.0 ± 5.2 
nmol/L was recorded at 0 minute. A significant 5-MTHF loss of 40% from the 
extracellular minimal medium of rotenone treated cells was observed at 150 minutes, 
compared to control (p<0.01) (Figure 57b).  
Since rotenone (100 nmol/L) treatment of cells led to a statistically significant 
reduction in 5-MTHF remaining in the extracellular minimal medium compared to 
control, the ability of AA to counteract 5-MTHF decay in this system was evaluated. 
At an initial 5-MTHF concentration of 500 nmol/L, co-incubation of 5-MTHF with a 
physiological CSF concentration of AA of 150 µmol/L (Brau et al., 1984) in 
minimal medium in the presence of rotenone (100 nmol/L) treated cells, led to a 
significantly greater amount of 5-MTHF remaining in the minimal medium at 150 
minutes of 18% (p<0.01) and 57% (p<0.001), when compared to control and 5-
MTHF incubated with rotenone treated cells only, respectively (Figure 57a). 
Similarly, at the 5-MTHF initial concentration 150 nmol/L, co-incubation of 5-
MTHF with AA (150 µmol/L) in minimal medium in the presence of rotenone 
treated cells, led to a significantly greater amount of 5-MTHF remaining in the 
minimal medium at 150 minutes of 30% (p<0.05) and 115% (p<0.001), when 
compared to control and 5-MTHF incubated with rotenone treated cells only (Figure 
57b).  
 238 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 57 5-MTHF stability in the extracellular minimal medium of SH-SY5Y 
cells pre-treated in the absence and presence of rotenone (100 nmol/L) for 24 
hours,  following a 150 minute incubation with or without AA (150 µmol/L). a. 
5-MTHF stability at an initial concentration of 500 nmol/L and b. at an initial 
concentration 150 nmol/L. All values are mean ± SEM of 4 independent 
experiments. *p<0.05, **p<0.01, ***p<0.001 determined by one-way ANOVA 
followed by Bonferroni’s Multiple comparison test. 
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6.6.3 Mitochondrial superoxide generation is significantly increased in rotenone 
treated SH-SY5Y cells 
To elucidate whether rotenone (100 nmol/L) treatment of SH-SY5Y cells led to an 
increase in mitochondrial superoxide production, the MitoSOX
TM
 Red assay system 
was utilised. A significant increase above basal levels in mitochondrial superoxide 
production of 23% was observed in rotenone (100 nmol/L) treated cells, compared to 
matched controls (p<0.05) (Figure 58). 
6.6.4 KCN mediated complex IV inhibition in SH-SY5Y cells has no effect on 5-
MTHF stability in extracellular minimal medium 
As previously described in section 6.1, partial inhibition, to a degree insufficient to 
perturb oxidative phosphorylation, has been shown to increase ROS production 
(Jacobson et al., 2005). Threshold levels of complex IV before major changes in rate 
of ATP synthesis or oxygen consumption, vary according to the in vitro model used. 
For example, in situ non-synaptic mitochondria have a complex IV threshold of 
approximately 60% (Davey and Clark, 1996), whilst synaptic isolated nerve 
terminals have a complex IV threshold of >70% (Davey et al., 1998; Sipos et al., 
2003). KCN at a concentration of 10 mmol/L for 24 hours has been shown to induce 
apoptosis in SH-SY5Y cells (Watabe and Nakaki, 2007). Therefore, a x10 lower 
concentration of KCN (1 mmol/L) was used to inhibit complex IV activity in SH-
SY5Y cells and cells were incubated for 24 hours. This concentration and incubation 
time has previously been shown to induce a sustained 50% inhibition of complex IV 
in astrocytes (Hargreaves et al., 2007). A significant decrease in complex IV activity 
of 86% was observed following KCN treatment, compared to control (p<0.001). 
This effect was apparent when complex IV activity was expressed as either a ratio to 
citrate synthase or as nmol/min/mg of protein (Figure 59; Table 15). This level of 
complex IV inhibition did not appear to cause cell morbidity under a light 
microscope.  In view of the complex IV respiratory thresholds (Davey and Clark, 
1996; Davey et al., 1998; Sipos et al., 2003) and statistical significance, a KCN 
concentration of 1 mmol/L and cell incubation period of 24 hours were used for all 
subsequent experiments. 
Using these culture conditions, the stability of 5-MTHF in the presence of KCN 
treated cells for 150 minutes was evaluated. Stability was first determined at an 
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Figure 58 Mitochondrial superoxide production in rotenone pre-
treated SH-SY5Y cells for 24 hours, following a 30 minute incubation 
with MitoSOX
TM
 Red. All values are mean ± SEM of 3 independent 
experiments. *p<0.05 determined by Student’s t-test. 
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Figure 59 Complex IV activity in KCN treated SH-SY5Y cells for 24 
hours. Complex IV activity is expressed as a ratio to citrate synthase. 
All values are mean ± SEM of 4 independent experiments. *** p<0.001 
determined by Student’s t-test. 
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initial 5-MTHF concentration of 500 nmol/L. A 5-MTHF concentration of 282.7 ± 
7.9 nmol/L was recorded at 0 minute. No significant loss of 5-MTHF from the 
minimal medium in the presence of KCN treated cells was observed at 150 minutes, 
compared to control (Figure 60a). A similar finding was observed when the 
experiment was carried out at an initial 5-MTHF concentration of 150 nmol/L. A 5-
MTHF concentration of 63.0 ± 2.7 nmol/L 5-MTHF was recorded at 0 minute. No 
significant loss of 5-MTHF from the minimal medium in the presence of KCN 
treated cells was observed at 150 minutes, compared to control (Figure 60b). 
6.6.5 KCN treatment of SH-SY5Y cells has no effect on mitochondrial 
superoxide generation  
To elucidate whether KCN treatment of SH-SY5Y cells led to an increase in 
mitochondrial superoxide production, the MitoSOX
TM
 Red assay system was 
utilised. There was no significant increase in mitochondrial superoxide production 
above basal levels observed in KCN treated cells compared to matched controls 
(Figure 61). 
6.6.6 Selenite treatment of SH-SY5Y cells causes a significant loss of 5-MTHF 
from extracellular minimal medium which is prevented by AA 
The stability of 5-MTHF in minimal medium in the presence of SH-SY5Y cells 
treated with various concentrations of selenite, was further determined. Similarly to 
SH-SY5Y cells, the neuroblastoma cell line SK-N-BE cells originated from a bone 
marrow biopsy in 1972 (Biedler et al., 1978). A previous study showed that 
treatment of SK-N-BE cells, with selenite concentrations >100 nmol/L (7.9 µg/L) for 
1 hour, led to an increase in ROS generation (Maraldi et al., 2011). Moreover, 
selenite has been shown to induce ROS production at very low concentrations, in the 
order of 8-80 µg/L (Vinceti et al., 2009). Therefore, cells were treated with either 2 
µg/L [a selenium concentration within the CSF reference range across all ages (1.8-
4.7 µg/L (1–30 days), 0.68-3.00 µg/L (1 month – 3 years) 0.73-2.13 µg/L (4 – 18 
years) (Tondo et al., 2010)], 10 µg/L or 20 µg/L selenite and incubated for 1 hour 
(Maraldi et al., 2011; Vinceti et al., 2009). 
Using these culture conditions, the stability of 5-MTHF in the extracellular minimal 
medium of selenite treated cells for 150 minutes was evaluated. Stability was first 
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Figure 60 5-MTHF stability in the extracellular minimal medium of SH-SY5Y 
cells pre-treated in the absence and presence of KCN (1 mmol/L), following a 150 
minute incubation. a. 5-MTHF stability at an initial concentration of 500 nmol/L 
and b. at an initial concentration 150 nmol/L. All values are mean ± SEM of 4 
independent experiments. In some cases the error bars were small owing to the 
tightness of the data.  
b. 
a. 
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Figure 61 Mitochondrial superoxide production in KCN pre-treated 
SH-SY5Y cells for 24 hours following a 30 minute incubation with 
MitoSOX
TM
 Red. All values are mean ± SEM of 3 independent 
experiments. 
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determined at an initial 5-MTHF concentration of 500 nmol/L. A 5-MTHF 
concentration of 267.9 ± 3.1 nmol/L was recorded at 0 minute. There was no 
significant difference in 5-MTHF concentration remaining in the minimal medium of 
2 µg/L selenite treated cells, compared to control (Figure 62a). In contrast, a 
significant 5-MTHF loss of 15% (p<0.01) and 18% (p<0.01) from the extracellular 
minimal medium of cells treated with 10 µg/L or 20 µg/L selenite at 150 minutes 
was observed, compared to control respectively (Figure 62b, Figure 62c). A similar 
finding was observed when the experiment was carried out at an initial 5-MTHF 
concentration of 150 nmol/L. A 5-MTHF concentration of 67.1 ± 1.3 nmol/L was 
recorded at 0 minute. There was no significant difference in 5-MTHF concentration 
remaining in the minimal medium of 2 µg/L selenite treated cells, compared to 
control (Figure 63a). In contrast, a significant 5-MTHF loss of 17% (p<0.05) and 
28% (p<0.01) from the extracellular minimal medium of cells treated with 10 µg/L 
or 20 µg/L selenite at 150 minutes was observed, compared to control respectively 
(Figure 63b, Figure 63c).  
Since treatment of cells with selenite (10 µg/L and 20 µg/L) led to a statistically 
significant reduction in 5-MTHF concentration remaining in the extracellular 
minimal medium compared to control at 150 minutes, the ability of AA to prevent 5-
MTHF decay in this system was evaluated. At an initial 5-MTHF concentration of 
500 nmol/L, co-incubation of 5-MTHF with AA (150 µmol/L), led to a significantly 
greater amount of 5-MTHF remaining in the extracellular minimal medium of 10 
µg/L selenite treated cells at 150 minutes of 26% (p<0.001), when compared to 5-
MTHF incubated with 10 µg/L selenite treated cells only (Figure 62b). Similarly, co-
incubation of 5-MTHF with AA (150 µmol/L), led to a significantly greater amount 
of 5-MTHF remaining in the extracellular minimal medium of 20 µg/L selenite 
treated cells at 150 minutes of 33% (p<0.001), when compared to 5-MTHF 
incubated with 20 µg/L selenite treated cells only (Figure 62c). At a 5-MTHF initial 
concentration 150 nmol/L, co-incubation of 5-MTHF with AA (150 µmol/L) led to a 
significantly greater amount of 5-MTHF remaining in the minimal medium at 150 
minutes of 24% (p<0.01), when compared to 5-MTHF incubated with 10 µg/L 
selenite treated cells only (Figure 63b). Similarly, a significant increase in 5-MTHF 
remaining in the minimal medium at 150 minutes following co-incubation 
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Figure 62 5-MTHF stability at an initial concentration of 500 nmol/L in the extracellular 
minimal medium of SH-SY5Y cells pre-treated in the absence and presence of selenite for 1 
hour, following a 150 minute incubation with or without AA (150 µmol/L). a. SH-SY5Y 
cells treated with 2 µg/L, b. 10 µg/L or c. 20 µg/L selenite. All values are mean ± SEM of 4 
independent experiments. **p<0.01, ***p<0.001 determined by one-way ANOVA followed 
by Bonferroni’s Multiple comparison test. 
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Figure 63 5-MTHF stability at an initial concentration of 150 nmol/L in the extracellular 
minimal medium of SH-SY5Y cells pre-treated in the absence  and presence of selenite for 1 
hour, following a 150 minute incubation with or without AA (150 µmol/L). a. SH-SY5Y 
cells treated with 2 µg/L, b. 10 µg/L or c. 20 µg/L selenite. All values are mean ± SEM of 4 
independent experiments. *p<0.01, **p<0.001 determined by one-way ANOVA followed by 
Bonferroni’s Multiple comparison test. 
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c. 
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with AA (150 µmol/L) of 27% (p<0.01), was observed when compared to 5-MTHF 
incubated with 20 µg/L selenite treated cells only (Figure 63c). 
6.6.7 Selenite treatment of SH-SY5Y cells has no effect on complex I activity 
Since mitochondrial superoxide generation was associated with rotenone treatment 
of SH-SY5Y cells potentially as a consequence of complex I inhibition (section 
6.6.3), elucidation of whether selenite treatment had any effect on mitochondrial 
complex I activity was determined. Complex I activity was measured in cells treated 
with either 2 µg/L, 10 µg/L or 20 µg/L selenite. There was no significant difference 
in complex I activity observed between selenite (2 µg/L, 10 µg/L or 20 µg/L) treated 
cells compared to control (Figure 64). This effect was apparent when complex I 
activity was expressed as either a ratio to citrate synthase or as nmol/min/mg of 
protein (Figure 64, Table 16). 
6.6.8 Selenite treatment has no effect on mitochondrial superoxide generation  
To elucidate whether treatment of cells with selenite (10 µg/L or 20 µg/L) led to an 
increase in mitochondrial superoxide production, the MitoSOX
TM
 Red assay system 
was utilised. There was no significant increase in mitochondrial superoxide 
production above basal levels observed in selenite (10 µg/L or 20 µg/L) treated cells 
compared to matched controls (Figure 65). 
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Figure 64 Complex I activity in selenite treated SH-SY5Y cells for 1 
hour. Complex I activity is expressed as a ratio to citrate synthase. All 
values are mean ± SEM of 4 independent experiments. 
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Table 16 Mitochondrial RCE activity in SH-SY5Y cells following selenite 
treatment for 1 hour. Complex I activity (nmol/min/mg of protein) and citrate 
synthase activity (nmol/min/mg of protein). Complex I % inhibition following 
selenite treatment for 1 hour. All values are mean ± SEM of 4 independent 
experiments. ND=not detectable. 
  
 
 
 
Conditions 
 
Complex I (nmol/min/mg of 
protein) 
 
 
 
Citrate Synthase 
(nmol/min/mg of protein) 
 
Activity 
 
% inhibition 
Control (selenite) 
 
12.5 ± 1.7 - 128.3 ± 5.8 
Selenite 2 µg/L 
 
13.6 ± 1.8 ND 121.7 ± 8.5 
Selenite 10 µg/L 
 
12.8 ± 1.4 ND 123.4 ± 1.6 
Selenite 20 µg/L 
 
12.4 ± 0.5 ND 122.2 ± 4.2 
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Figure 65 Mitochondrial superoxide production in selenite pre-
treated SH-SY5Y cells for 1 hour, following a 30 minute incubation 
with MitoSOX
TM
 Red. All values are mean ± SEM of 3 independent 
experiments. Se = selenite 
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6.7 Discussion 
An initial loss of 5-MTHF from the minimal medium was observed between sample 
preparation and 0 minute (see section 6.6.1) and in control samples (see sections 
6.6.2, 6.6.4, 6.6.6), owing to the susceptibility of 5-MTHF to autoxidation in the 
presence of molecular oxygen and the lack of antioxidants present. In addition, 
glucose, which is present in minimal medium, is susceptible to autoxidation yielding 
superoxide (Stewart et al., 2002; Wolff and Dean, 1987). Thus, the minimal medium 
may be a potential source of oxidising species, which additionally could contribute 
to the loss of 5-MTHF observed. The loss of 5-MTHF from the minimal medium 
between sample preparation and 0 minute observed is similar to that seen in 
potassium phosphate buffer in Chapter 4 (see section 4.7 for detailed discussion), 
and would be expected to occur prior to quantification of 5-MTHF at the initial time 
point, for the reasons dicussed above and in section 4.7. The degree of loss of 5-
MTHF from the minimal medium in the experiments described in this Chapter 
appears to be comparable and so 5-MTHF stability in the various experimental 
systems investigated is being tested against a relatively consistent background.   
5-MTHF decay in minimal medium at both initial 5-MTHF concentrations followed 
first order kinetics, as previously described in section 4.7. However, there was a 
greater concentration of 5-MTHF remaining in minimal medium in the presence of 
SH-SY5Y cells and the rate of 5-MTHF decay in this model was slower, compared 
with minimal medium alone. These results suggest that SH-SY5Y cells may secrete 
protective factors counteracting 5-MTHF decay. Neurones, astrocytes and glia have 
been shown to release factors into the extracellular space including antioxidants, and 
anti-inflammatory and trophic factors. For example, in co-cultures astrocytes 
facilitate glutathione trafficking and provide a source of cysteine in order to maintain 
neuronal glutathione content (Dringen et al., 1999; Sagara et al., 1993). Moreover, 
astrocytes and neurones additionally release ecSOD to prevent oxidation of 
extracellular glutathione, whilst the latter have also been shown to release GSH 
(Hirrlinger et al., 2002; Pope et al., 2008; Stewart et al., 2002; Stone et al., 1999; 
Strand and Marklund, 1992). Therefore, the increased preservation of 5-MTHF in 
minimal medium observed here in the presence of SH-SY5Y cells may indicate a 
similar phenomenon, demonstrating the potential neuroprotective capabilities of SH-
SY5Y cells. Further studies are required in order to fully elucidate this neurone-
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derived protective factor(s). All subsequent experiments were compared to the 
stability of 5-MTHF in extracellular minimal medium in the presence of SH-SY5Y 
cells, used as a control. 
The mitochondrial RC is considered to be an important source of ROS production 
and partial inhibition of the mitochondrial RC has been shown to lead to an increase 
in ROS production in the absence of ATP perturbation (Jacobson et al., 2005; Sipos 
et al., 2003). In view of this and the link between CFD and mitochondrial RCE 
defects as demonstrated in Chapter 3 and in the literature (Garcia-Cazorla et al., 
2008), complex I or complex IV was inhibited using either rotenone or KCN in SH-
SY5Y cells in order to ascertain whether a mechanistic link between compromised 
mitochondrial RCE activity and loss of 5-MTHF could be demonstrated. Complex I 
or complex IV inhibition were selected as model systems because these were the 
most frequently observed mitochondrial RCE defects in skeletal muscle of children 
with mitochondrial disease studied in Chapter 3. The effect of complex I inhibition 
on extracellular 5-MTHF stability in minimal medium was initially determined. 
Rotenone treatment (50 nmol/L) did not cause a significant decrease in complex I 
activity when expressed as a ratio to citrate synthase activity and as a proportion to 
cellular protein. However, following 100 nmol/L rotenone treatment, a significant 
decrease in complex I activity was observed when expressed both as a ratio to citrate 
synthase activity and as a proportion to cellular protein. Citrate synthase is 
commonly used as a mitochondrial marker and as a measure of mitochondrial 
enrichment (Almeida and Medina, 1998; Hargreaves et al., 1999). Citrate synthase 
activity was unaffected following cellular treatment with rotenone. This suggests 
that any change in complex I activity may not be the result of a change in 
mitochondrial number. Similarly, total protein was unaffected following cellular 
treatment with rotenone. This suggests that any change in complex I activity is not 
an artefact of change in cell number.  
Interestingly, following cellular rotenone treatment (100 nmol/L), a significantly 
greater loss of 5-MTHF was observed from the extracellular minimal medium 
compared to control at both initial 5-MTHF concentrations studied. However, co-
incubation of AA with 5-MTHF at both initial concentrations led to a significantly 
greater amount of 5-MTHF remaining in extracellular minimal medium compared to 
control and rotenone treated cells only. In view of the antioxidant role of AA 
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(Arrigoni and De Tullio, 2002; Regoli and Winston, 1999; Rice, 1999), this 
observation may indicate a role for an oxidative process whereby the significantly 
greater loss of 5-MTHF from the extracellular minimal medium of rotenone treated 
cells may be attributed to an increase in cellular production and release of ROS, 
which may outweigh the antioxidant capacity of the cells. This suggestion is 
supported by the significant increase in mitochondrial superoxide production above 
basal levels following inhibition of mitochondrial complex I with rotenone. The 
latter finding is also consistent with previous studies demonstrating increased ROS 
production in rotenone treated SH-SY5Y cells (Xiong et al., 2013).  
However, it is important to consider that other ROS may also be responsible for the 
observed loss of 5-MTHF from the extracellular minimal medium in these studies. It 
has been postulated that rotenone induced neurotoxicity in the extracellular 
environment may be a result of the conversion of superoxide into membrane 
permeable hydrogen peroxide by ecSOD and other ROS, including the hydroxyl 
radical, produced as a result of the Fenton reaction (Bienert et al., 2007; Okado-
Matsumoto and Fridovich, 2001). Furthermore, other factors, in addition to ROS 
generation, may contribute to the loss of 5-MTHF from extracellular medium of 
complex I inhibited SH-SY5Y cells, for example, alterations in cellular uptake of 5-
MTHF. Loss of mitochondrial RC activity per se does not appear to influence this 
process as evidenced by the lack of significant effect observed with the complex IV 
inhibited cells, as discussed below. Regarding AA, whilst its antioxidant ability may 
neutralise mitochondrial derived ROS, AA may also neutralise ROS produced by 5-
MTHF autoxidation and glucose autoxidation. 
The effect of complex IV inhibition on the stability of 5-MTHF in the extracellular 
minimal medium of KCN treated cells was also assessed. In cells treated with KCN, 
complex IV activity was significantly decreased when expressed as a ratio to citrate 
synthase activity and as a proportion to cellular protein. Citrate synthase activity and 
total protein were unaffected following KCN treatment, suggesting that the change 
in complex IV activity is not the result of a change in mitochondrial number or an 
artefact of change in cell number (Almeida and Medina, 1998; Hargreaves et al., 
1999). In contrast to complex I inhibited cells, inhibition of complex IV with KCN 
in cells did not affect 5-MTHF stability in extracellular minimal medium at both 
initial 5-MTHF concentrations. In addition, inhibition of complex IV was not 
 255 
associated with an increase in mitochondrial superoxide formation above basal levels 
in KCN treated SH-SY5Y cells. These findings suggest that oxidative stress may not 
be induced in this system. This may be attributed to the undifferentiated neuronal 
cell type used in these studies. For example, complex IV subunits are increased in 
differentiated SH-SY5Y cells compared to undifferentiated cells (Schneider et al., 
2011) and increased ROS production has been observed in other cell types following 
complex IV inhibition including cultured astrocytes (Jacobson et al., 2005). 
Additionally, there is on-going debate in the literature regarding the role of complex 
IV in ROS production. Complex IV has been implicated as a major source of 
mitochondrial ROS production in some studies (Jacobson et al., 2005; Zhao et al., 
2003), whilst in other studies mitochondrial ROS production at the level of complex 
IV has been reported to be negligible (Babcock and Wikström, 1992; Chen et al., 
2003; Wikström, 2004). 
Expanding upon the studies in Chapter 4, as detailed in section 6.1 of this Chapter, 
the effect of selenite treatment of SH-SY5Y cells on 5-MTHF stability in 
extracellular minimal medium was determined. Interestingly, a significantly greater 
loss of 5-MTHF at both initial concentrations was observed in cultures treated with 
selenite concentrations (10 µg/L and 20 µg/L) previously associated with induction 
of ROS production in the literature, compared to control (Maraldi et al., 2011). Co-
incubation of AA with 5-MTHF at both initial concentrations led to a significant 
increase in 5-MTHF concentration remaining in the extracellular minimal medium of 
selenite treated cells compared to selenite treated cells only. This observation may 
indicate a role for an oxidative process whereby the significantly greater loss of 5-
MTHF from the extracellular minimal medium of selenite treated cells may be 
attributed to an increase in cellular production and release of ROS, overwhelming 
the antioxidant capacity of the cells. This may occur via redox cycling of selenite 
with reduce thiols propagating ROS (Chen et al., 2007b; Tarze et al., 2007; Yan and 
Spallholz, 1993). The observed susceptibility of 5-MTHF to decay observed in this 
Chapter, in contrast to studies in CSF in Chapter 4, could be attributed to the 
presence of a cellular system facilitating the formation of selenium metabolites that 
more easily oxidise with intracellular and extracellular antioxidant systems (Yan and 
Spallholz, 1993). 
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Since the mitochondrial RC is considered to be a major site of ROS production 
(Boveris and Chance, 1973; Boveris et al., 1972; Loschen and Azzi, 1975), it was of 
interest to determine whether selenite treatment had any effect on mitochondrial 
function and mitochondrial-derived superoxide production. Regarding the former, in 
view of the observed mitochondrial superoxide generation following inhibition of 
mitochondrial complex I with rotenone, mitochondrial complex I activity was 
determined in selenite treated cells. There was no significant change in complex I 
activity in selenite treated cells when complex I activity was expressed as a ratio to 
citrate synthase activity and as a proportion to cellular protein. Citrate synthase 
activity and total protein were also unaffected following selenite treatment, 
suggesting that the unchanged complex I activity is not the result of a change in 
mitochondrial number or an artefact of change in cell number (Almeida and Medina, 
1998; Hargreaves et al., 1999). This, in turn, suggests that selenite treatment may not 
lead to inhibition of the mitochondrial RC at the level of complex I. In addition, 
selenite treatment in cells was not associated with an increase in mitochondrial 
superoxide formation above basal levels compared to control. However, this does 
not exclude the possibility that ROS may be produced at a cellular location other 
than the mitochondria. Measurement of cytoplasmic ROS to associate ROS 
production as a potential cause of 5-MTHF degradation observed in this system is 
required. 
6.8 Conclusion 
In conclusion, inhibition of the mitochondrial RC at the level of complex I led to 
significantly greater loss of 5-MTHF from the extracellular minimal medium which 
was counteracted following the addition of AA. This suggests a role for an oxidative 
process, which is supported by the observed increase in mitochondrial superoxide 
production in SH-SY5Y cell following rotenone treatment. In contrast, the stability 
of 5-MTHF was unaffected in the extracellular minimal medium of cells treated with 
KCN leading to complex IV inhibition. Mitochondrial superoxide production was 
not increased in this system. This may be attributed to the undifferentiated neuronal 
cell line used in these studies and the controversial role inhibition of complex IV 
plays in generating ROS (Babcock and Wikström, 1992; Jacobson et al., 2005; 
Schneider et al., 2011; Zhao et al., 2003). Selenite treatment of cells with 
concentrations known to be associated with increases in ROS production, led to a 
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significantly greater loss of 5-MTHF from the extracellular minimal medium, which 
was counteracted following the addition of AA. An oxidative process may occur in 
this system, however, selenite treatment of SH-SY5Y cell was not associated with 
abnormal mitochondrial complex I activity or an increase in mitochondrial 
superoxide generation. Cytoplasmic ROS may be propagated in this system via 
redox cycling of selenite with reduce thiols propagating ROS (Lu et al., 2009). 
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7. General discussion, conclusion and further work 
7.1 General discussion 
Decreased levels of 5-MTHF in the CSF compartment of the CNS is increasingly 
recognised to be associated with heterogeneous neurological disorders, including 
mitochondrial disorders (Garcia-Cazorla et al., 2008; Hyland et al., 2010; Ormazábal 
et al., 2011; Pérez-Dueñas et al., 2011; Pineda et al., 2006; Ramaekers et al., 2007c; 
Serrano et al., 2010). Whilst decreased CSF 5-MTHF concentration in patients with 
mitochondrial disease has previously been documented, from the available literature 
and current knowledge, no large-scale systematic analysis of CFD in this patient 
group has been performed. Additionally, whilst FOLR1 gene mutations and 
generation of auto-antibodies directed against the FRα can explain some causes of 
CFD (Cario et al., 2009; Frye et al., 2013; Pérez-Dueñas et al., 2010; Ramaekers et 
al., 2007a, 2005; Ramaekers et al., 2013b; Steinfeld et al., 2009), other mechanisms 
need to be identified to explain the low CSF 5-MTHF concentration that occurs in 
conditions such as mitochondrial disorders. Therefore, the main aims of this thesis 
were to evaluate the prevalence and significance of CFD in patients with a suspected 
or proven mitochondrial disease and to consider the potential role oxidative stress 
may play with regard to the development of a CSF deficiency of 5-MTHF. 
CFD and mitochondrial disease phenotypes have substantially overlapping clinical 
heterogeneity (Chi et al., 2010; Jackson et al., 1995; Nissenkorn et al., 1999; 
Ramaekers et al., 2002). Therefore, CFD may represent an under-recognised 
condition in patients with mitochondrial disease. Consequently, patients may be 
excluded from comprehensive diagnosis, and since CFD is a potentially treatable 
aspect of mitochondrial disease (Hansen and Blau, 2005; Moretti et al., 2005; Pérez-
Dueñas et al., 2011), patients may also be excluded from receiving effective 
treatment. The prevalence and significance of CFD in patients with a suspected or 
proven mitochondrial disease were evaluated in Chapter 3 of this thesis, and a 
number of key and novel findings addressing the above hypotheses were 
documented, as summarised in Table 17. 
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 Key findings Interpretation/recommendations 
1. The prevalence of CSF 5-MTHF deficiency in 
suspected mitochondrial disease patients and in 
those patients who had a biochemically 
confirmed skeletal muscle RCE defect, were 
both 15%, and the minimum population 
prevalence of mitochondrial disease with CFD 
is approximately one  in 30,000. 
CSF 5-MTHF deficiency is more common in 
patients with mitochondrial disease than is 
currently recognised. 
2. Patients with CSF 5-MTHF deficiency, 
including those with proven mitochondrial 
diseases share a heterogeneous clinical 
presentation and normal or non-specific MRI 
data. 
CSF 5-MTHF analysis should be carried out in all 
patients at risk of CFD, rather than relying on 
clinical manifestations. 
3. Severe CSF 5-MTHF (<10 nmol/L) deficiencies 
were seen in patients with KSS and FOLR1 or 
PCFT1 mutations.  A novel homozygous 
missense FOLR1 mutation in exon 5 
(c.335A>T; p.N112I) was identified. 
In the absence of a clinical diagnosis, FOLR1 
sequence analysis should be performed in all 
patients with CSF 5-MTHF values <10 nmol/L in 
the absence of peripheral folate deficiency. In the 
presence of a peripheral folate deficiency, PCFT1 
sequence analysis should be performed. 
4. Complex IV deficiency was the most common 
RCE defect in patients with CSF 5-MTHF 
deficiency in the cohort. One complex IV 
deficient patient had a severe CSF 5-MTHF 
(<10 nmol/L) deficiency and a homozygous 
FOLR1 mutation in exon 7 (c.610C>T; 
p.R204X). 
RCE defects in patients with low CSF 5-MTHF 
cannot be predicted from CSF 5-MTHF data and 
vice versa, highlighting the importance of 
performing both a skeletal muscle biopsy and 
lumbar puncture in patients with suspected 
mitochondrial disease.  This may be especially 
appropriate in patients with CSF 5-MTHF <10 
nmol/L who have suspected or confirmed FOLR1 
mutations. 
5. A lack of correlation between CSF 5-MTHF 
values and the degree of RCE deficiency 
measured in skeletal muscle was documented. 
Other mechanisms arising from loss of 
mitochondrial function may need to be considered, 
e.g oxidative stress leading to increased 5-MTHF 
catabolism. 
6. Genetically confirmed mitochondrial disease 
was associated with CSF 5-MTHF deficiency 
and normal RCE activities in two patients, one 
with KSS and one with POLG mutations. 
The former may be explained by the mtDNA 
deletion being heteroplasmic and there was 
enough wild type mtDNA to compensate. The 
latter had POLG mutations with a predominantly 
CNS phenotype and very low levels of multiple 
mtDNA deletions in skeletal muscle. 
7. No difference in CSF 5-MTHF concentration 
was observed between patients receiving and not 
receiving AEDs. 
Opladen et al. (2010) demonstrated decreased 
cellular 5-MTHF uptake owing to ROS generation 
with the use of AEDs. The data from the cohort 
reported in Chapter 3 do not necessarily support 
this work. The impact of specific AEDs on CSF 5-
MTHF availability was not determined owing to 
small sample size. 
8. Positive biochemical response to folinic acid 
treatment was documented in patients with KSS 
and FOLR1 mutations.  The onset of CSF 5-
MTHF deficiency may be associated with 
disease progression from Pearson syndrome to 
KSS. 
Specifically for KSS, empirical treatment with 
folinic acid to all paediatric patients with single 
large scale mtDNA deletions may be beneficial. 
Folinic acid treatment should be commenced in all 
other patients, including those with FOLR1 
mutations, as soon as low 5-MTHF levels have 
been documented in CSF. 
Table 17 Summary of the key findings and interpretation/recommendations discussed in Chapter 3. 
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5-MTHF, together with other reduced pterins, is a labile molecule and is known to 
be prone to oxidative catabolism (Blair et al., 1975; Heales et al., 1988; Lam and 
Heales, 2007). Consequently, increased generation of ROS and/or loss of 
antioxidants could have a deleterious effect upon 5-MTHF availability. As discussed 
in Chapter 1, high levels of selenium in CSF (Lu et al., 2009; Wallenberg et al., 
2010), low CSF AA concentration (Buettner and Jurkiewicz, 2010; Fisher and 
Naughton, 2003) and inhibition of mitochondrial RCE(s) may induce oxidative 
stress (Chen et al., 2007b; Jacobson et al., 2005; Liu et al., 2002), represented by an 
imbalance between ROS generation and antioxidant availability. With regard to 
mitochondrial disease, elevated CSF selenium concentrations have been reported in 
six patients with KSS and secondary CFD (Tondo et al., 2011), and low CSF AA 
concentration has been predicted in patients such as these (Spector and Johanson, 
2010). Furthermore, mitochondrial dysfunction and impaired RCE activity is 
associated with an increase in ROS production in the absence of ATP perturbation 
(Jacobson et al., 2005). As such, oxidative stress, induced under the aforementioned 
conditions, may represent a putative mechanism responsible for the development of 
a CSF deficiency of 5-MTHF, including in mitochondrial diseases. Studies were 
designed to evaluate this hypothesis in Chapters 4, 5 and 6 of this thesis and a 
summary diagram of the data documented in these Chapters is shown in Figure 66.  
In Chapter 4, the relative stability of 5-MTHF in CSF, in contrast to potassium 
phosphate buffer, suggests the presence of antioxidant molecules in CSF 
counteracting 5-MTHF degradation. AA is one of a number of antioxidants present 
in CSF (Barabás et al., 1995; Brau et al., 1984; Mandl et al., 2009) and as discussed 
above, has been purported to be low in patients with KSS and secondary CFD 
(Spector and Johanson, 2010). The potential importance of AA to convey protection 
towards 5-MTHF was illustrated in this Chapter by retardation of 5-MTHF 
catabolism observed in potassium phosphate buffer incubations carried out in the 
presence of AA at a concentration comparable to that seen in CSF. Introduction of a 
hydroxyl radical generating system to the CSF overcame the ability of AA to prevent 
5-MTHF catabolism. Comparable observations were documented in potassium 
phosphate buffer incubations. This observation implies that the antioxidant systems 
present in CSF can be overwhelmed by ROS generation leading to loss of 5-MTHF 
from the CSF.  
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Figure 66 Summary of results in Chapters 4, 5 and 6. 5-MTHF is susceptible to oxidative catabolism. However, the relative stability of CSF 5-MTHF may indicate the 
presence of antioxidants, for example AA. Such antioxidants may account for the stability of  5-MTHF in CSF only,  following the addition of Se or Se+GSH and the 
removal of antioxidants >10 kDa, for example  ecSOD.  Release of ecSOD and/or  GSH may account for the relative stability of  5-MTHF in extracellular medium of 
cultured SH-SY5Y cells. Inhibition of the mitochondrial RC, specifically complex I, leads to an increase in mitochondrial superoxide production which may degrade 5-
MTHF in the extracellular medium. High selenium (Se) concentration leads to 5-MTHF degradation from the extracellular medium owing  possibly to increased cytoplasmic 
ROS generation. AA protects against 5-MTHF degradation in the extracellular medium. Oxidative stress may represent a putative mechanism for secondary CFD observed in 
mitochondrial disease. O2 = oxygen, •OH = hydroxyl radical, CSF = cerebrospinal fluid, Se = selenium, GSH = glutathione (reduced), ecSOD = extracellular Cu/Zn 
superoxide dismutase, 5-MTHF = 5-methyltetrahydrofolate, AA = ascorbic acid, ROS = reactive oxygen species, RCE(s) = (mitochondrial) respiratory chain enzyme(s). 
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The apparent stability of 5-MTHF in CSF following the addition of selenite alone, 
selenite plus GSH and selenite plus GSH at a ratio of 40:1, could be attributed to the 
presence of AA, in addition to other antioxidant systems likely to be present in CSF 
that could also convey protection towards 5-MTHF (although other explanations 
may also be possible (see section 4.7)) (Alho et al., 1998; Kolmakova et al., 2010). 
These could include enzymes such as the extracellular form of superoxide dismutase 
(ecSOD) (Stewart et al., 2002; Strand and Marklund, 1992), as well as other 
antioxidant molecules with a molecular mass >10 kDa (see section 4.7) (Montecinos 
et al., 2007). However, CSF filtration through 10 kDa pore size filters still conveyed 
5-MTHF protection indicating a possible protective role for smaller antioxidant 
molecules with regard to 5-MTHF (see section 4.7). AA is present in filtered CSF, as 
shown in Chapter 5 (see section 5.4.3.9), which adds further credence to this 
suggestion. 
CSF AA availability has previously been proposed, but not evaluated, to play a role 
in the development of CFD (Spector and Johanson, 2010). In Chapter 5, a method 
for the determination of CSF AA was developed (see section 5.4.3), an age-
independent CSF AA reference range was established (see sections 5.5.1 and 5.5.2) 
and a significant positive correlation between AA and 5-MTHF in CSF was 
demonstrated. Such a correlation may be a reflection that both AA and 5-MTHF 
status are dependent upon dietary intake and active transport into the CSF 
compartment (Grapp et al., 2013; Liang et al., 2001; Verlinde et al., 2008). However, 
this correlation could also indicate an antioxidant protective role of AA towards 5-
MTHF. This suggestion is supported by the observation of enhanced serum 5-MTHF 
in individuals also taking AA (Verlinde et al., 2008). 
Whilst a significant positive correlation, when looking at all the data, could be 
demonstrated between CSF 5-MTHF and AA in Chapter 5, closer inspection 
revealed 38% of individuals with a demonstrable deficiency of CSF 5-MTHF had 
CSF AA deficiency. Although this was not a clinical evaluation study and only 
minimal clinical details were available, the clinical data reflect the known diversity 
of patients presenting with a CSF 5-MTHF deficiency. It is also of interest to note 
that the patient with a FOLR1 mutation (patient 17) did not have an associated AA 
deficiency. This is in contrast to the finding for the patient with reported folate 
malabsorption (patient 6) where both CSF AA and 5-MTHF deficiency could be 
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demonstrated. Whilst AA deficiency was not universal amongst the 5-MTHF 
deficient patients studied, this finding may indicate that for a significant sub-set of 
individuals with a CSF 5-MTHF deficiency, the biochemical interaction between 
these two vitamins deserves further evaluation. 
In accordance with previous studies (Surtees et al., 1994; Verbeek et al., 2008), a 
positive correlation between CSF 5-MTHF and CSF 5-HIAA was also documented 
in Chapter 5. Whilst this relationship could not readily be explained, possible 
hypotheses have been suggested. For example, the role of 5-MTHF in 
tetrahydrobiopterin regeneration may link 5-MTHF to serotonin synthesis and 
subsequently 5-HIAA metabolite production (Kaufman, 1991; Matthews and 
Kaufman, 1980). Conversely, decreased 5-MTHF levels may disturb de novo purine 
and thymidylate synthesis, which may lead to mitochondrial dysfunction. 
Subsequently, decreased ATP production could impair neurotransmitter vesicular 
loading and release (Serrano et al., 2010; Surtees et al., 1994). 
The mitochondrial RC is considered to be an important source of ROS production 
(Jacobson et al., 2005). In view of this and the link between CFD and mitochondrial 
RCE defects as demonstrated in Chapter 3 and in the literature (Garcia-Cazorla et al., 
2008; Serrano et al., 2010), a neuronal cell line model of complex I or IV inhibition 
was utilised in Chapter 6 in order to ascertain whether a mechanistic link between 
compromised mitochondrial RCE activity and loss of 5-MTHF could be 
demonstrated. Complex I or complex IV inhibition were selected as model systems 
because these are the most frequently observed mitochondrial RCE defects in 
skeletal muscle of children with mitochondrial disease identified in Chapter 3 and at 
Great Ormond Street Hospital, London, UK. Loss of 5-MTHF from the minimal 
medium utilised was expected to occur in all cases owing to the lack of antioxidants. 
However, the presence of cells slowed this loss of 5-MTHF from the extracellular 
medium, suggesting cellular release of protective factors. Such protective factors 
could include ecSOD and GSH, which have previously been demonstrated to be 
released into the medium of cultured primary rat neurons (Hirrlinger et al., 2002; 
Stewart et al., 2002; Strand and Marklund, 1992; Tulpule et al., 2013), although 
further work would need to be carried out in order to confirm this. 
For complex I inhibited cells, a significantly greater loss of 5-MTHF from the 
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extracellular medium was noted. The finding that AA could significantly limit this 
loss may indicate a role for an oxidative process in the development of CFD, a 
suggestion supported by the finding that superoxide generation is significantly 
increased in rotenone treated cells. This latter finding is also consistent with previous 
observations relating to ROS production following complex I inhibition in these cells 
(Xiong et al., 2013). Inhibition of complex IV was not associated with an increase in 
superoxide formation and it is of note that, under the conditions employed, there was 
no significant increase in the disappearance of 5-MTHF from the extracellular 
medium. Interestingly, in Chapter 3 all patients with a confirmed mitochondrial RCE 
defects and low CSF 5-MTHF were complex IV deficient. However, as discussed 
above, a significant loss of 5-MTHF from the extracellular medium was associated 
with inhibition of complex I, but not complex IV. This may be attributed to the 
neuronal cell type (SH-SY5Y neuroblastoma cells) used in the studies of Chapter 6, 
since complex IV inhibition has previously been associated with an increase in ROS 
production in cultured astrocytes (see section 6.7) (Hargreaves et al., 2007; Jacobson 
et al., 2005). Further work could be directed towards determining the stability of 5-
MTHF in the extracellular medium of complex IV inhibited astrocytes in culture, for 
example using the 1321N1 astrocytoma cell line. 
Similarly to pharmacological inhibition of complex I in neuronal cells, treatment of 
cells with selenite led to a significantly greater loss of 5-MTHF from the 
extracellular medium which was counteracted following the addition of AA. These 
findings may indicate an oxidative process in the development of CFD where 
selenium levels are elevated. However, selenite treatment was not associated with 
abnormal complex I activity or increased mitochondrial superoxide formation, 
suggesting that any oxidative process taking place may be independent of the 
mitochondrial RC within the cell. For example, intracellular and extracellular redox 
cycling of selenite with reduced thiols, including GSH, which is present in CSF, has 
been shown to generate ROS (Lu et al., 2009; Wallenberg et al., 2010; Yan and 
Spallholz, 1993). 
It is important to consider that a number of factors, in addition to ROS generation, 
may contribute to the degradation/disappearance of 5-MTHF from extracellular 
medium, for example, alterations in cellular uptake of 5-MTHF. Loss of 
mitochondrial RCE activity per se does not appear to influence this process as 
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evidenced by the lack of significant effect observed with the KCN treated complex 
IV inhibited cells. However, further work is required to measure cytosolic ROS in 
order to associate ROS as potential cause of 5-MTHF degradation from the 
extracellular minimal medium of selenite treated cells. 
7.2 Conclusion 
In conclusion, the data presented in this thesis indicate that 5-MTHF is susceptible to 
oxidative catabolism. The extracellular environment, including CSF, may convey 
protection to 5-MTHF owing to the presence of antioxidants such as AA. However, 
under conditions of increased ROS generation and/or loss of antioxidants, for 
example, high selenium concentration, low AA concentration and mitochondrial 
RCE inhibition, which may occur in some mitochondrial disorders, this protective 
capacity could be exceeded leading to CFD. The data presented here further raise the 
possibility that co-supplementation of AA together with appropriate folate 
replacement therapy may be beneficial for all patients in order to increase 5-MTHF 
bioavailability. 
7.3 Further work 
The data presented in Chapter 3 suggest it may be plausible that CFD could also 
complicate more common neurodegenerative disorders known to be associated with 
secondary mitochondrial dysfunction, including Parkinson’s disease and 
Alzheimer’s disease (dos Santos et al., 2009; Duan et al., 2002; Shea, 2006). A 
decrease in neuronal function owing to mitochondrial dysfunction could, 
theoretically at least, lead to concomitant deficiency of CSF 5-MTHF, which in turn 
could exacerbate the clinical phenotype. Initiation of folinic acid supplementation in 
those presenting with CFD, could result in significant biochemical improvements 
and represent a wider therapeutic application of folinic acid supplementation in the 
clinic. Additionally, the potential antioxidant role of AA to convey protection 
towards 5-MTHF may also complicate the biochemical presentation of these patients 
and AA supplementation may also be a therapeutic benefit. Further work to initially 
address this hypothesis could be carried out by: 
 Combined determination of CSF 5-MTHF and AA values in patients with 
Parkinson’s disease and Alzheimer’s disease. 
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In this thesis, HPLC coupled to a fluorescence detector was used to quantify 5-
MTHF in human CSF samples for both diagnostic and research purposes. However, 
the concentration of other folate species could be of diagnostic use and pose 
additional research questions. This work could be extended by: 
 Developing and utilising a method of measuring all the folate species 
comprising the one-carbon metabolism pathway using a mass spectrometry 
method (Hannisdal et al., 2009) and generating metabolic profiles. 
 Developing and utilising a method of measuring the 5-MTHF oxidation 
products 5-methyl-5,6-dihydrofolate and 4a-hydroxy-5-methyltetrahydrofolate 
in the extracellular medium (Blair et al., 1975), using a mass spectrometry 
method (Hannisdal et al., 2009). 
 
CSF AA was shown to be positively correlated with CSF 5-MTHF. This could 
indicate an antioxidant protective role of AA towards 5-MTHF. Further evaluation of 
this relationship could be investigated by: 
 Measuring CSF AA and 5-MTHF, and peripheral AA and 5-MTHF, in paired 
CSF and serum samples. 
 Monitoring CSF AA status in patients with low CSF 5-MTHF to determine 
whether CSF AA levels may be of concern with regard to CSF 5-MTHF 
bioavailability. The method to quantify CSF AA developed in Chapter 5 is now 
established in the Neurometabolic Unit at the National Hospital for Neurology 
and Neurosurgery, London, UK. 
 
CSF 5-MTHF, AA and HVA were measured in individual patient samples in 
Chapter 5. Whilst no correlation was observed between CSF 5-MTHF and HVA in 
this thesis, increased HVA has previously been reported in patients with low CSF 5-
MTHF (Tondo et al., 2011). Based on the findings presented in Chapter 5 and of 
Tondo et al. (2011), the following testable hypothesis could be formulated. AA is a 
cofactor required for the enzymatic conversion of noradrenaline to dopamine 
catalysed by dopamine-β-hydroxylase (Menniti et al., 1986; Rebouche, 1991). It 
could be hypothesised that in patients with CFD associated with AA deficiency, 
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dopamine conversion could be impaired. This could lead to increased dopamine 
turnover, providing a putative explanation for the elevated HVA levels observed in 
these patients. Further work measuring CSF AA and HVA in patients with low CSF 
5-MTHF concentration and carrying out statistical analyses on the data, could be 
performed to evaluate this hypothesis. 
The SH-SY5Y cell line was used as a neuronal model to investigate mitochondrial 
RCE inhibition and the effect of high physiological selenite concentrations on 5-
MTHF stability in the extracellular medium, since RCE inhibition and high selenite 
concentrations are associated with ROS generation. This work could be extended by: 
 Repeating these experiments in other cell models for example, keratin forming 
Henrietta Lacks (HeLa) cells (KB cells), which express the FRα (Sadasivan and 
Rothenberg, 1989) and which could be used as a model of the choroid plexus 
(Opladen et al., 2010), and primary neurons. 
 Investigating the effect of inducing oxidative stress on intracellular 5-MTHF 
levels. 
 
Selenium has previously been reported to be elevated in CSF of patients with KSS 
(Tondo et al., 2011). In this thesis, to investigate the effect of selenium on 5-MTHF 
stability, the selenium compound selenite was used, since selenite is routinely used 
throughout the literature to study thiol-mediated redox cycling of selenium (Selenius 
et al., 2008; Wallenberg et al., 2010). This work could be extended by: 
 Developing and utilising an inductively coupled plasma mass spectrometry 
(ICP-MS) method to measure selenium species and other trace elements in 
human CSF (Mandal et al., 2012). 
 Utilising the above developed method to measure intracellular selenium species 
in selenite treated cells in order to generate metabolic profiles. 
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